



/5R-10

Best Available Copy

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/495, 31/50	(11) International Publication Number: WO 98/25617
(43) International Publication Date: 18 June 1998 (18.06.98)	

(21) International Application Number: PCT/US97/22769	(22) International Filing Date: 12 December 1997 (12.12.97)
(30) Priority Date: 6/00/95, 6/85 13 December 1996 (13.12.96) US 20 December 1996 (20.12.96) US	

(71) Applicant (for all designated States, except US): MERCK & CO, INC. (US/US); 126 East Lincoln Avenue, Rahway, NJ 07065 (US).


(72) Inventors; and
Inventors/applicants (for US only): MILLS, Sander, G. (US/US); 126 East Lincoln Avenue, Rahway, NJ 07065 (US). SPERNOER, Martin, S. (US/US); 126 East Lincoln Avenue, Rahway, NJ 07065 (US). MacCOSSE, Malcolm (GB/US); 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(74) Common Representative: MERCK & CO, INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(64) Title: SUBSTITUTED ARYL PIPERAZINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

(57) Abstract

The present invention is directed to aryl piperazines of formula (I) (wherein Ar, R₁, R₂ and R₃ are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-3B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.



Published

With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendment.

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

FOR THE PURPOSES OF INFORMATION ONLY

AL	RS	ES	LT	LE	SI	SV
Albania	Spain	Finland	Lithuania	Slovenia	Slovenia	
AM	FI	France	LTU	SK	SR	
Armenia	Greece	Latvia	Lithuania	Slovakia	Serbia	
AT	GB	United Kingdom	LV	SZ	Serbia	
Austria	Georgia	MC	Malta	TD	Swaziland	
AZ	GE	MD	Republic of Moldova	TC	Chad	
Azerbaijan	Ghana	MG	Madagascar	TJ	Togo	
BA	GR	MK	The former Yugoslav	TM	Tajikistan	
Bosnia and Herzegovina	Guinea	GR	Republic of Macedonia	TR	Turkmenistan	
BB	Guinea-Bissau	GR	Malta	TT	Turkey	
BE	Burkina Faso	GR	Hungary	TT	Trinidad and Tobago	
BE	Burundi	HU	Hungary	TT	Ukraine	
BG	Bulgaria	IE	ICELAND	UA	Ukraine	
BR	Burma	IL	Iceland	UG	Uganda	
BY	Brunei	IS	Iceland	US	United States of America	
CA	Belarus	IT	Italy	UZ	Uzbekistan	
CG	Central African Republic	JP	Japan	VN	Viet Nam	
CO	Cameroon	KR	Kenya	YU	Yugoslavia	
CH	Switzerland	KG	Kyrgyzstan	ZW	Zimbabwe	
CI	Cote d'Ivoire	KP	Democratic People's			
CM	Cameroon	KR	Republic of Korea			
CN	China	KZ	Kazakhstan			
CU	Cuba	LA	Saint Lucia			
CZ	Czech Republic	LC	Liechtenstein			
DE	Germany	LA	Lithuania			
DK	Denmark	LK	Sri Lanka			
ER	Eritrea	LB	Liberia			

TITLE OF THE INVENTION
SUBSTITUTED ARYL PIPERAZINES AS MODULATORS OF
CHEMOKINE RECEPTOR ACTIVITY

5 BACKGROUND OF THE INVENTION

Chemokines are chemotactic cytokines that are released by a wide variety of cells to attract macrophages, T cells, eosinophils,

basophils and neutrophils to sites of inflammation (reviewed in Schall, Cytokine, **3**, 165-189 (1991) and Murphy, Rev. Immun., **22**, 599-633 (1994)).

There are two classes of chemokines, C-X-C (α) and C-C (β), depending on whether the first two cysteines are separated by a single amino acid (C-X-C) or are adjacent (C-C). The α-chemokines, such as interleukin-8 (IL-8), neutrophil-activating protein-2 (NAP-2) and melanoma growth stimulatory activity protein (MGSA) are chemotactic primarily for neutrophils, whereas β-chemokines, such as RANTES, MIP-1 α , MIP-1 β , monocyte chemoattractant protein-1 (MCP-1), MCP-2, MCP-3 and eotaxin (Deng, et al., Nature, **381**, 661-666 (1996)).

The chemokines bind specific cell-surface receptors belonging to the family of G-protein-coupled seven-transmembrane-domain proteins (reviewed in Horuk, Trends Pharm. Sci., **15**, 159-165 (1994)) which are termed "chemokine receptors." On binding their cognate ligands, chemokine receptors transduce an intracellular signal through the associated trimeric G protein, resulting in a rapid increase in intracellular calcium concentration. There are at least seven human chemokine receptors that bind or respond to β-chemokines with the following characteristic pattern: CCR-1 (or "CKR-1" or "CC-CKR-1") [MIP-1 α , MIP-1 β , MCP-3, RANTES] (Ben-Baruch, et al., J. Biol. Chem., **270**, 22128-22128 (1995); Beote, et al., Cell, **72**, 415-425 (1993)); CCR-2A and CCR-2B (or "CKR-2A"/"CKR-2A" or "CC-CKR-2A"/"CC-CKR-2A") [MCP-1, MCP-3, MCP-4]; CCR-3 (or "CKR-3" or "CC-CKR-3") [eotaxin, RANTES, MCP-3] (Combalie, et al., J. Biol. Chem., **270**, 16491-16494 (1995); CCR-4 (or "CKR-4" or "CC-CKR-4") [MIP-1 α , RANTES, MCP-1] (Power, et al., J. Biol. Chem., **270**, 19495-19500 (1995)); CCR-5 (or "CKR-5" or "CC-CKR-5") [MIP-1 α , RANTES, MIP-1 β]

(Sansom, et al., Biochemistry, **35**, 3362-3367 (1996)); and the Duffy blood-group antigen (RANTES, MCP-11 (Chaudhuri, et al., J. Biol. Chem., **269**, 7835-7838 (1994)). The β-chemokines include eotaxin, MIP ("macrophage inflammatory protein"), MCP ("monocyte chemoattractant protein") and RANTES ("regulation-upon-activation, normal T expressed and secreted").

Chemokine receptors, such as CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, CXCR-4, have been implicated as being important mediators of inflammatory and immunoregulatory disorders and diseases, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. For example, the chemokine receptor CCR-3 plays a pivotal role in attracting eosinophils to sites of allergic inflammation. Accordingly, agents which modulate chemokine receptors would be useful in such disorders and diseases.

A retrovirus designated human immunodeficiency virus (HIV-1) is the etiological agent of the complex disease that includes progressive destruction of the immune system (acquired immune deficiency syndrome; AIDS) and degeneration of the central and peripheral nervous system. This virus was previously known as LAV, HTLV-III, or ARV.

Certain compounds have been demonstrated to inhibit the replication of HIV, including soluble CD4 protein and synthetic derivatives (Smith, et al., Science, **238**, 1704-1707 (1987)), dextran sulfate, the dyes Direct Yellow 50, Evans Blue, and certain azo dyes (U.S. Patent No. 5,468,469). Some of these antiviral agents have been shown to act by blocking the binding of gp120, the coat protein of HIV, to its target, the CD4 glycoprotein of the cell.

Entry of HIV-1 into a target cell requires cell-surface CD4 and additional host cell cofactors. Fusin has been identified as a cofactor required for infection with virus adapted for growth in transformed T cells, however, fusin does not promote entry of macrophagotropic viruses which are believed to be the key pathogenic strains of HIV in vivo. It has recently been recognized that for efficient entry into target cells, human immunodeficiency viruses require the chemokine

receptors CCR-5 and CXCR-4, as well as the primary receptor CD4 (Levy, N. Engl. J. Med., 325(20), 1528-1530 (Nov. 14 1996). The principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CCR5, a receptor for the β -chemokines RANTES, MIP-1 α and MIP-1 β (Deng, et al., *Nature*, 381, 661-666 (1996)). HIV attaches to the CD4 molecule on cells through a region of its envelope protein, gp120. It is believed that the CD-4 binding site on the gp120 of HIV interacts with the CD4 molecule on the cell surface, and undergoes conformational changes which allow it to bind to another cell-surface receptor, such as CCR5 and/or CXCR-4. This brings the viral envelope closer to the cell surface and allows interaction between gp41 on the viral envelope and a fusion domain on the cell surface, fusion with the cell membrane, and entry of the viral core into the cell. Macrophage-tropic HIV and SV40 envelope proteins have been shown to induce a signal through CCR-5 on CD4+ cells resulting in chemotaxis of T cells which may enhance the replication of the virus (Weissman, et al., *Nature*, 389, 981-985 (1997)). It has been shown that β -chemokine ligands prevent HIV-1 from fusing with the cell (Dragic, et al., *Nature*, 381, 667-673 (1996)). It has further been demonstrated that a complex of gp120 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands MIP-1 α and MIP-1 β (Wu, et al., *Nature*, 384, 179-183 (1996); Trkola, et al., *Nature*, 384, 184-187 (1996)).

Humans who are homozygous for mutant CCR-5 receptors which do not serve as co-receptors for HIV-1 in vitro appear to be unusually resistant to HIV-1 infection and are not immunocompromised by the presence of this genetic variant (Nature, 382, 722-725 (1996)). Similarly, an alteration in the CCR-2 gene, CCR2-641, can prevent the onset of full-blown AIDS (Smith, et al., *Science*, 271, 958-965 (1997)). Absence of CCR-5 appears to confer protection from HIV-1 infection (Nature, 382, 668-669 (1996)). An inherited mutation in the gene for CCR5, Delta 32, has been shown to abolish functional expression of the gene and individuals homozygous for the mutation are apparently not susceptible to HIV infection. Other chemokine receptors may be used by some strains of HIV-1 or may be favored by non-sexual routes of


as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

The present invention is further concerned with compounds which inhibit the entry of human immunodeficiency virus (HIV) into target cells and are of value in the prevention of infection by HIV, the treatment of infection by HIV and the prevention and/or treatment of the resulting acquired immune deficiency syndrome (AIDS). The present invention also relates to pharmaceutical compositions containing the compounds and to a method of use of the present compounds and other agents for the prevention and treatment of AIDS and viral infection by HIV.

The present invention is directed to compounds of

DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to compounds of

Formula I:



20

wherein the nitrogen attached to R₁ shown above is optionally

quaternized with C₁-4alkyl or phenylC₁-4alkyl or is optionally present as the N-oxide (N⁺O⁻), and wherein:

R₁ is selected from a group consisting of:

linear or branched C₁-8 alkyl, linear or branched C₂-8 alkenyl, wherein the C₁-8 alkyl or C₂-8 alkenyl is optionally

25 mono, di, tri or tetra substituted, the substituents independently selected from:

- (a) hydroxy,
- (b) o xo,
- (c) cyano,
- (d) halogen which is defined to include Br, Cl, I, and F,
- (e) trifluoromethyl,
- (f) phenyl or mono, di or tri-substituted phenyl, the substituents independently selected from
 - (1) phenyl,
 - (2) hydroxy,
 - (3) C₁-3alkyl,
 - (4) cyano,
 - (5) halogen,
 - (6) trifluoromethyl,
 - (7) -NR₆COR₇,
 - (8) -NR₆CO₂R₇,
 - (9) -NR₆CONHR₇,
 - (10) -NR₆Si(O_j)R₇, wherein j is 1 or 2,
 - (11) -CONR₆R₇,
 - (12) -COR₆,
 - (13) -CO₂R₆,
 - (14) -OR₆,
 - (15) -S(O)_kR₆, wherein k is 0, 1 or 2,
 - (g) -NR₆R₇,
 - (h) -NR₆COR₇,
 - (i) -NR₆CO₂R₇,
 - (j) -NR₆CONHR₇,
 - (k) -NR₆Si(O_j)R₇,
 - (l) -CONR₆R₇,
 - (m) -COR₆,
 - (n) -CO₂R₆,
 - (o) -OR₆,
 - (p) -S(O)_kR₆,
 - (q) -NR₆CO-heteroaryl,

(r) -NR₆S(O)-heteraryl, and

(s) heteraryl, wherein heteraryl is selected from the

group consisting of:

- (1') benzimidazolyl,
- (2') benzofuranyl,
- (3') benzoxazolyl,
- (4') furanyl,
- (5') imidazolyl,
- (6') indolyl,
- (7') isoxazolyl,
- (8') isothiazolyl,
- (9') oxadiazolyl,
- (10') oxazolyl,
- (11') pyrazinyl,
- (12') pyrazolyl,
- (13') pyridyl,
- (14') pyrimidyl,
- (15') pyrrolyl,
- (16') quinolyl,
- (17') quinolyl,
- (18') thiadiazolyl,
- (19') thiazolyl,
- (20') thienyl, and
- (21') triazolyl,

wherein the heteraryl is unsubstituted or mono di or tri-substituted, the substituents independently selected from:

- (a'') phenyl,
- (b'') hydroxy,
- (c'') oxo,
- (d'') cyano,
- (e'') halogen, and
- (f'') trifluoromethyl;

Ar is selected from the group consisting of:

- (1) phenyl,
- (2) pyridyl,
- (3) pyrimidyl,
- (4) naphthyl,
- (5) furyl,
- (6) pyrryl,
- (7) thienyl,
- (8) isothiazolyl,
- (9) imidazolyl,
- (10) benzimidazolyl,
- (11) tetrazolyl,
- (12) pyrazinyl,
- (13) quinolyl,
- (14) isoquinolyl,
- (15) benzofuryl,
- (16) isobenzofuryl,
- (17) benzothienyl,
- (18) pyrazolyl,
- (19) indolyl,
- (20) isoindolyl,
- (21) purinyl,
- (22) isoxazolyl,
- (23) thiazolyl,
- (24) oxazolyl,
- (25) triazinyl, and
- (26) benzthiazolyl,
- (27) benzoxazolyl,
- (28) imidazopyrazinyl,
- (29) triazolopyrazinyl,
- (30) naphthyridinyl,
- (31) furopyridinyl,
- (32) thiopyranopyrimidyl and the 5-oxide and 5-dioxide thereof,
- (33) pyridazinyl,
- (34) quinazolinyl,

25

wherein the heteraryl is unsubstituted or mono di or tri-substituted, the substituents independently selected from:

- (a'') phenyl,
- (b'') hydroxy,
- (c'') oxo,
- (d'') cyano,
- (e'') halogen, and
- (f'') trifluoromethyl;

25

wherein the heteraryl is unsubstituted or mono di or tri-substituted, the substituents independently selected from:

- (a'') phenyl,
- (b'') hydroxy,
- (c'') oxo,
- (d'') cyano,
- (e'') halogen, and
- (f'') trifluoromethyl;

wherein the heteraryl is unsubstituted or mono di or tri-substituted, the substituents independently selected from:

- (a'') phenyl,
- (b'') hydroxy,
- (c'') oxo,
- (d'') cyano,
- (e'') halogen, and
- (f'') trifluoromethyl;

30

wherein the heteraryl is unsubstituted or mono di or tri-substituted, the substituents independently selected from:

- (a'') phenyl,
- (b'') hydroxy,
- (c'') oxo,
- (d'') cyano,
- (e'') halogen, and
- (f'') trifluoromethyl;

35

wherein the heteraryl is unsubstituted or mono di or tri-substituted, the substituents independently selected from:

- (a'') phenyl,
- (b'') hydroxy,
- (c'') oxo,
- (d'') cyano,
- (e'') halogen, and
- (f'') trifluoromethyl;

5 (35) pteridinyl,
 (36) triazolopyrimidyl,
 (37) triazolopyrazinyl,
 (38) thiapurinyl,
 (39) oxapurinyl, and
 (40) deazapurinyl,
 wherein Ar items (1) to (40) are optionally mono or di-substituted, said substituents being independently selected from:

10 (a) C1-3 alkyl, unsubstituted or substituted with
 (1') oxo,
 (2') hydroxy,
 (3') OR₆,
 (4') halogen,
 (5') trifluoromethyl,
 (6') phenyl or mono, di or tri-substituted phenyl,
 the substituents independently selected from
 (b) hydroxy, cyano, halogen, and trifluoromethyl,
 -(CH₂)_nSO₂-(C1-6 alkyl), wherein n is 0, 1 or 2,
 (c) -(CH₂)_nSO₂-(C1-6 alkyl),
 (d) -(CH₂)_nSO₂-NH₂,
 (e) -(CH₂)_nSO₂-NHR₆,
 (f) -(CH₂)_nSO₂-NR₆-(C1-6 alkyl),
 (g) -(CH₂)_nCONH₂,
 (h) -(CH₂)_nCONH-(C1-6 alkyl),
 (i) -(CH₂)_nCONHR₆,
 (j) -(CH₂)_nCONR₆-(C1-6 alkyl),
 (k) -(CH₂)_nCO₂H,
 (l) -(CH₂)_nCO₂-(C1-6 alkyl),
 (m) -(CH₂)_nNR₆R₇,
 (n) -(CH₂)_nNH-C(O)-C1-6alkyl,
 (o) -(CH₂)_nNH-C(O)NH₂,
 (p) -(CH₂)_nNH-C(O)NH-C1-6alkyl,
 (q) -(CH₂)_nNH-C(O)N-(diC1-6 alkyl),
 (r) -(CH₂)_nNH-S(O)k-C1-6alkyl,
 (s) -(CH₂)_nN(C1-3alkyl)-C(O)-N(diC1-6 alkyl),

15 (1') benzimidazolyl,
 (2') benzofuranyl,
 (3') benzoxazolyl,
 (4') furanyl,
 (5') imidazolyl,
 (6') indolyl,
 (7') isooxazolyl,
 (8) isothiazolyl,
 (9') oxadiazolyl,
 (10') oxazolyl,
 (11') pyrazinyl,
 (12') pyrazolyl,
 (13') pyridyl or oxypyridyl,
 (14') pyrimidyl,
 (15') pyrrolyl,
 (16') quinolyl,
 (17') tetrazolyl,
 (18') thiadiazolyl,
 (19') thiazolyl,
 (20') thiaryl, and
 (21') triazolyl,
 wherein the heteroaryl group of items (1') to (21') is
 20 unsubstituted, mono, di or tri substituted, the
 substituents selected from:
 (a') hydrogen,
 (b') C1-6 alkyl, branched or unbranched,
 unsubstituted or mono or di-substituted,
 the substituents being selected from
 hydrogen and hydroxy,
 (c') hydroxy,
 (d') oxo,

25

30

35

(e') -OR₆,
(f') halogen,
(g') trifluoromethyl,

(h') nitro,
(i') cyano,
(j') -NHR₆,

(k') -NR₆R₇,
(l') -NHCOR₆,

(m') -NR₆COR₇,
(n') -NHCO₂R₆,

(o') -NR₆CO₂R₇,
(p') -NHS(O)jR₆,

(q') -NR₆SO(O)jR₇,
(r') -CONR₆R₇,

(s') -COR₆,
(t') -CO₂R₆, and
(u') -S(O)jR₆;

(e) trifluoromethyl;

(f) trifluoromethyl,

(g) trifluoromethyl, C1-3alkyloxy,

(h) hydroxy, C1-3alkyl,

(i) cyano, C1-3alkyl,

(j) halogen, C1-3alkyl,

(k) trifluoromethyl, C1-3alkyloxy,

(l) hydroxy, C1-3alkyloxy,

(m) oxo, C1-3alkyloxy,

(n) cyano, C1-3alkyloxy,

(o) halogen, C1-3alkyloxy,

(p) trifluoromethyl, phenyl or mono di or tri-substituted phenyl, the substituents independently selected from:

(a) hydroxy, C1-3alkyl,

(b) cyano, C1-3alkyl,

(c) halogen, C1-3alkyl,

(d) trifluoromethyl, C1-3alkyl,

(e) trifluoromethyl, naphthyl or mono di or tri-substituted naphthyl, the substituents independently selected from:

(a) hydroxy, C1-3alkyl,

(b) cyano, C1-3alkyl,

(c) halogen, C1-3alkyl,

(d) trifluoromethyl, C1-3alkyloxy;

35 or R₆ and R₇ are joined together to form a 5-, 6-, or 7-

(e) trifluoromethyl;

(f) trifluoromethyl,

(g) trifluoromethyl, C1-3alkyloxy,

(h) hydroxy, C1-3alkyl,

(i) cyano, C1-3alkyl,

(j) halogen, C1-3alkyl,

(k) trifluoromethyl, C1-3alkyloxy,

(l) hydroxy, C1-3alkyloxy,

(m) oxo, C1-3alkyloxy,

(n) cyano, C1-3alkyloxy,

(o) halogen, C1-3alkyloxy,

(p) trifluoromethyl, phenyl or mono di or tri-substituted phenyl, the substituents independently selected from:

(a) hydroxy, C1-3alkyl,

(b) cyano, C1-3alkyl,

(c) halogen, C1-3alkyl,

(d) trifluoromethyl, C1-3alkyl,

(e) trifluoromethyl, naphthyl or mono di or tri-substituted naphthyl, the substituents independently selected from:

(a) hydroxy, C1-3alkyl,

(b) cyano, C1-3alkyl,

(c) halogen, C1-3alkyl,

(d) trifluoromethyl, C1-3alkyloxy;

35 or R₆ and R₇ are joined together to form a 5-, 6-, or 7-

membered monocyclic saturated ring containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and in which the ring is unsubstituted or mono or di-substituted, the substituents independently selected from:

(1) hydroxy,

(2) oxo,

(3) cyano,

(4) halogen,

10 (5) trifluoromethyl,


R8 and R9 are each independently hydrogen or substituted C1-alkyl wherein the substituent is selected from the group consisting of

15 (1) hydroxy,
(2) hydrogen,
(3) cyano,
(4) halogen,
(5) trifluoromethyl,
(6) C1-alkyloxy,

20 provided that when Ar is phenyl, pyridyl or pyrimidyl, then Ar is mono di or tri-substituted; and further provided that when Ar is mono substituted phenyl, then the substituent is other than halo, hydroxy, -OC1-4alkyl, CF3 or C1-4alkyl;

25 and further provided that when Ar is di- or tri-substituted, at least one of the substituents is other than halo, hydroxy, -OC1-4alkyl, CF3 or C1-4alkyl; and pharmaceutically acceptable salts thereof.

30 Preferred compounds for use in the present invention include those of Formula Ia:



Ia

5 wherein:
R1 is selected from a group consisting of:

C3, C4, C5, C6, C7, C8 linear or branched alkyl, unsubstituted or mono, di or tri-substituted, the substituents independently selected from:

10 (a) hydroxy,
(b) Cl or F,
(c) phenyl or mono, di or tri-substituted phenyl, the substituents independently selected from:

15 (1') phenyl,
(2') hydroxy,
(3') C1-3alkyl,
(4') cyano,
(5') halogen,

(6') trifluoromethyl,
(d) -NR6CO-R7, wherein R6 is hydrogen or C1-3 alkyl and R7 is phenyl optionally substituted with Cl, F, CF3 or C1-3alkyl,

20 (e) -COR6,
(f) -OR6,
(g) -NR6S(O)j-R7, where j is 1 or 2,
(h) -NR6S(O)j-heteroaryl, wherein heteroaryl is selected from the group consisting of:

25 (1') benzimidazolyl,
(2) benzofuranyl,
(3) benzoxazolyl,

(4') furanyl,
(5') imidazolyl,
(6') indolyl,
(7') isooxazolyl,
(8') isothiazolyl,
(9') oxadiazolyl,
(10') oxazolyl,
(11') pyrazinyl,
(12') pyrazolyl,
(13') pyridyl,
(14') pyrimidyl,
(15') pyrrolyl,
(16') quinolyl,
(17') tetrazolyl,
(18') thiadiazolyl,
(19') thiazolyl,
(20') thiaryl, and
(21') triazolyl,

wherein the heteroaryl is unsubstituted or mono di or tri-substituted, the substituents independently selected from:

(a') phenyl,
(b') hydroxy,
(c') oxo,
(d') cyano,
(e') halogen, and
(f') trifluoromethyl;

Ar is selected from the group consisting of:

(1) phenyl,
(2) pyrazinyl,
(3) pyrazolyl,
(4) pyridyl,
(5) pyrimidyl, and
(6) thiaryl,

wherein the Ar is unsubstituted or mono or di-substituted, and substituents are independently selected from:

(a) C1-3 alkyl, unsubstituted or substituted with
(1') oxo,
(2') hydroxy,
(3') OR₆,
(4') halogen, and
(5') trifluoromethyl,
(b) CONR₆-C(1-2 alkyl),
(c) CO₂H,
(d) CO₂(C1-2 alkyl),
(e) CH₂NR₆-C(1-2 alkyl),
(f) CH₂NH-C(O)-C(1-3 alkyl),
(h) CH₂NH-C(O)NH₂,
(i) CH₂NH-C(O)NH-C(1-3 alkyl),
(j) CH₂NH-C(O)N-dIC(1-3 alkyl),
(k) CH₂NH-S(O)j-C(1-3 alkyl),
(l) CH₂-heteroaryl, with the heteroaryl is selected from the group consisting of:

(1') imidazolyl,
(2') oxazolyl,
(3') pyridyl,
(4') tetrazolyl,
(5') triazolyl,

and the heteroaryl is unsubstituted, mono, di or tri-substituted, where the substituents selected from:

(a') hydrogen,
(b') C1-6 alkyl, branched or unbranched, unsubstituted or mono or di-substituted, the substituents being selected from hydrogen and hydroxy;

and pharmaceutically acceptable salts thereof.

Preferred compounds for use in the present invention include those of Formula I wherein:

R1 is selected from a group consisting of:

5 C4, C5, C6, C7 or C8 linear or branched alkyl, which is mono, di- or tri-substituted, where the substituents are independently selected from:

- (a) hydroxy,
- (b) Cl or F,
- (c) phenyl or mono or di-substituted phenyl, where the substituents are independently selected from:

- (1') hydroxy,
- (2') methyl or ethyl,
- (3') Cl or F,
- (4') trifluoromethyl,
- (d) -NR6COR7, wherein R6 is methyl and R7 is phenyl optionally substituted with halo, CF3, C1-3alkyl or C1-3alkoxy, and
- (e) -NR6S(O)jR7, where j is 1 or 2;

20

and pharmaceutically acceptable salts thereof.

Preferred compounds for use in the present invention include those of Formula I wherein:

25

Ar is mono substituted or di-substituted phenyl,

wherein the substituents are selected from the group consisting of:

- (a) C1-3 alkyl, unsubstituted or substituted with

30

- (1) oxo,
- (2) hydroxy, or
- (3) OR6, wherein R6 is hydrogen or C1-3 alkyl,

- (b) -CH2NR6(C1-2 alkyl),
- (c) -CH2NH-C(=O)-C1-3alkyl,
- (d) -CH2NH-C(=O)NH2,

- (i) -CH2NH-C(=O)NHC1-3alkyl,
- (j) -CH2NH-C(=O)N-diC1-3 alkyl,
- (k) -CH2NH-S(=O)j-C1-3alkyl,
- (l) -CH2-heteroaryl, where heteroaryl is selected from the group consisting of:

- (1') imidazolyl,
- (2') oxazolyl,
- (3') pyridyl,
- (4') tetrazolyl,
- (5') triazolyl,

and where heteroaryl is unsubstituted, mono, di or tri substituted, where the substituents are independently selected from:

- (a') hydrogen,
- (b') C1-6 alkyl, branched or unbranched,


unsubstituted or mono or disubstituted, where the substituents are selected from: hydrogen and hydroxy;

20 and pharmaceutically acceptable salts thereof.

Preferred compounds for use in the present invention include those of Formula Ia.

25





Preferred compounds for use in the present invention include those of Formula Ia.





Ia

25
wherein:







R1 is




Another embodiment of compounds which are useful in the present invention is directed to compounds of Formula I wherein Ar is selected from the group consisting of:




Exemplifying the present invention is the use of a compound selected from the group consisting of:






5



5






- 26 -




-27-

5




-28-

5





-29-




-30-

Specific compounds of use in the present invention include compounds of the formula:



81

wherein:



As appreciated by those of skill in the art, ~~help~~ as used

5 herein are intended to include chloro, fluoro, bromo and iodo. Similarly, C1-6, as in C1-6alkyl is defined to identify the group as having 1, 2, 3, 4, 5,


propyl, butyl, pentyl or hexyl

Examining the invention is the use of the compounds disclosed in the Examples and herein.

3,5-diCF₃

-31-

•32•



(n) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl)-(methylamino)butyl)-4-(2-(1'-2(1H)-pyridone)methyl-phenyl)piperazine;

(o) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(2-amino-7,8-dihydro-6H-thiopyran-3,2-d)pyrimid-4-yl)piperazine-5-oxide;

(p) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(2-methyl-7,8-dihydro-6H-thiopyran-3,2-d)pyrimid-4-yl)piperazine-5-oxide;

(q) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(9-(2-fluoroethyl)-2-methoxy-purin-6-yl)piperazine;

(r) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(9-(2-methoxyethyl)-2-methoxy-purin-6-yl)piperazine;

(s) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(9-methyl-purin-6-yl)piperazine;

(t) 1-(3-((S)-4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(9-methyl-purin-6-yl)piperazine;

(u) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(9-methyl-imidazo(1,2-a)pyrazin-1-yl)piperazine;

(v) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(1,7-naphthyridin-8-yl)piperazine;

(w) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(1,2,4-triazolo(1,5-a)pyrazin-8-yl)piperazine;

(x) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(5-methyl-pyrid-2-yl)piperazine;

(y) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(2-amino-pyrazin-4-yl)piperazine;

(z) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(fluor(2,3-c)pyrid-4-yl)piperazine;

(aa) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(2-amino-7,8-dihydro-6H-thiopyran-3,2-d)pyrimid-4-yl)piperazine;

(ab) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(2-methyl-7,8-dihydro-6H-thiopyran-3,2-d)pyrimid-4-yl)piperazine;

(ac) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(1,2,4-triazolo(1,5-a)pyrazin-8-yl)piperazine; and

(ad) 1-(3-((S)-4-Chlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(1,2,4-triazolo(1,5-a)pyrazin-8-yl)piperazine;

and pharmaceutically acceptable salts thereof.

The subject compounds are useful in a method of modulating chemokine receptor activity in a patient in need of such modulation comprising the administration of an effective amount of the compound.

The present invention is directed to the use of the foregoing spiro-substituted azacycles as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors, including CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.

With respect to activity as modulators of the chemokine receptor CCR-5 it is preferred that in the subject compound^g R₁ is alkyl which bears a substituent -NR₆SO₂OR₇, where R₆, R₇ and j are defined above.

The present invention is further directed to the use of compounds of this general structure which are disclosed as being antagonists of neurokinin receptors. Such compounds are disclosed, for example, in: U.S. Patent No. 5,317,020; U.S. Patent No. 5,534,525; U.S. Patent No. 5,350,852; U.S. Patent No. 5,411,971; U.S. Patent No. 5,446,052; U.S. Patent No. 5,560,700; EP 0 559 538, Sep. 8, 1993; EP 0 591 040, Apr. 6, 1994; EP 0 698 601, Feb. 28, 1996; EP 0 625 609, Nov. 23, 1994; EP 0 630 887, Dec. 28, 1994; EP 0 680 962, Nov. 8, 1995; EP 0 709 375, May 1, 1996; EP 0 709 376, May 1, 1996; EP 0 723 969, Jul. 31, 1996; EP 0 739 891, WO

94/10146, May 11, 1994; WO 94/17045, Aug. 4, 1994; WO 94/26795, Nov. 24, 1994; WO 94/29809, Dec. 22, 1994; WO 95/05377, Feb. 28, 1995; WO 95/12577, May 11, 1995; WO 95/15961, Jun. 15, 1995; WO 95/16682, Jun. 22, 1995; WO 95/21187; WO 95/26335, Oct. 5, 1995; WO 95/26338, Oct. 5, 1995; WO 95/35279; WO 96/06094, Feb. 29, 1996; WO 96/10568, Apr. 11, 1996; WO 96/23787, Aug. 8, 1996; WO 96/24582, Aug. 15, 1996; WO 96/28441; and WO 96/32385. Accordingly, the present invention embraces the use of a compound disclosed in these publications as a modulator of chemokine receptor activity.

10 The utility of the compounds in accordance with the present invention as modulators of chemokine receptor activity may be demonstrated by methodology known in the art, such as the assay for CCR-1 and/or CCR-5 binding as disclosed by Van Riper, et al., *J. Exp. Med.*, **177**, 851-856 (1993), and the assay for CCR-2 and/or CCR-3 binding as disclosed by Daugherty, et al., *J. Exp. Med.*, **183**, 2349-2354 (1996). Cell lines for expressing the receptor of interest include those naturally expressing the receptor, such as EOL-3 or THP-1, or a cell engineered to express a recombinant receptor, such as CHO, RBL-2H3, HEK-293. For example, a CCR3 transfected AML14.3D10 cell line has been placed on restricted deposit with American Type Culture Collection in Rockville, Maryland as ATCC No. CRL-12079, on April 5, 1996. The utility of the compounds in accordance with the present invention as inhibitors of the spread of HIV infection in cells may be demonstrated by methodology known in the art, such as the HIV quantitation assay disclosed by Nurnberg, et al., *J. Virology*, **65** (9), 4887-4892 (1991).

15 In particular, the compounds of the following examples had activity in binding to either the CCR-5 receptor or the CCR-3 receptor in the aforementioned assays. Such a result is indicative of the intrinsic activity of the compounds in use as modulators of chemokine receptor activity.

20

25

30

35

40

45

50

55

60

65

70

75

80

85

90

95

100

105

110

115

120

125

130

135

140

145

150

155

160

165

170

175

180

185

190

195

200

205

210

215

220

225

230

235

240

245

250

255

260

265

270

275

280

285

290

295

300

305

310

315

320

325

330

335

340

345

350

355

360

365

370

375

380

385

390

395

400

405

410

415

420

425

430

435

440

445

450

455

460

465

470

475

480

485

490

495

500

505

510

515

520

525

530

535

540

545

550

555

560

565

570

575

580

585

590

595

600

605

610

615

620

625

630

635

640

645

650

655

660

665

670

675

680

685

690

695

700

705

710

715

720

725

730

735

740

745

750

755

760

765

770

775

780

785

790

795

800

805

810

815

820

825

830

835

840

845

850

855

860

865

870

875

880

885

890

895

900

905

910

915

920

925

930

935

940

945

950

955

960

965

970

975

980

985

990

995

1000

1005

1010

1015

1020

1025

1030

1035

1040

1045

1050

1055

1060

1065

1070

1075

1080

1085

1090

1095

1100

1105

1110

1115

1120

1125

1130

1135

1140

1145

1150

1155

1160

1165

1170

1175

1180

1185

1190

1195

1200

1205

1210

1215

1220

1225

1230

1235

1240

1245

1250

1255

1260

1265

1270

1275

1280

1285

1290

1295

1300

1305

1310

1315

1320

1325

1330

1335

1340

1345

1350

1355

1360

1365

1370

1375

1380

1385

1390

1395

1400

1405

1410

1415

1420

1425

1430

1435

1440

1445

1450

1455

1460

1465

1470

1475

1480

1485

1490

1495

1500

1505

1510

1515

1520

1525

1530

1535

1540

1545

1550

1555

1560

1565

1570

1575

1580

1585

1590

1595

1600

1605

1610

1615

1620

1625

1630

1635

1640

1645

1650

1655

1660

1665

1670

1675

1680

1685

1690

1695

1700

1705

1710

1715

1720

1725

1730

1735

1740

1745

1750

1755

1760

1765

1770

1775

1780

1785

1790

1795

1800

1805

1810

1815

1820

1825

1830

1835

1840

1845

1850

1855

1860

1865

1870

1875

1880

1885

1890

1895

1900

1905

1910

1915

1920

1925

1930

1935

1940

1945

1950

1955

1960

1965

1970

1975

1980

1985

1990

1995

2000

2005

2010

2015

2020

2025

2030

2035

2040

2045

2050

2055

2060

2065

2070

2075

2080

2085

2090

2095

2100

2105

2110

2115

2120

2125

2130

2135

2140

2145

2150

2155

2160

2165

2170

2175

2180

2185

2190

2195

2200

2205

2210

2215

2220

2225

2230

2235

2240

2245

2250

2255

2260

2265

2270

2275

2280

2285

2290

2295

2300

2305

2310

2315

2320

2325

2330

2335

2340

2345

2350

2355

2360

2365

2370

2375

2380

2385

2390

2395

2400

2405

2410

2415

2420

2425

2430

2435

2440

2445

2450

2455

2460

2465

2470

2475

2480

2485

2490

2495

2500

2505

2510

2515

2520

2525

2530

2535

2540

2545

2550

2555

2560

2565

2570

2575

2580

2585

2590

2595

2600

2605

2610

2615

2620

2625

2630

2635

2640

2645

2650

2655

2660

2665

2670

2675

2680

2685

2690

2695

2700

2705

2710

2715

2720

2725

2730

2735

2740

2745

2750

2755

2760

2765

2770

2775

2780

2785

2790

2795

2800

2805

2810

2815

2820

2825

2830

2835

2840

2845

2850

2855

2860

2865

2870

2875

2880

2885

2890

2895

2900

2905

2910

2915

2920

2925

2930

2935

2940

2945

2950

2955

2960

2965

2970

2975

2980

2985

2990

2995

3000

3005

3010

3015

3020

3025

3030

3035

3040

3045

3050

3055

3060

3065

3070

3075

3080

3085

3090

3095

3100

3105

3110

3115

3120

3125

3130

3135

3140

3145

3150

3155

3160

3165

3170

3175

3180

3185

3190

3195

3200

3205

3210

3215

3220

3225

3230

3235

3240

3245

3250

3255

3260

3265

3270

3275

3280

3285

3290

3295

3300

3305

3310

3315

3320

3325

3330

3335

3340

3345

3350

3355

3360

3365

3370

3375

3380

3385

3390

3395

3400

3405

3410

3415

3420

3425

3430

3435

3440

3445

3450

3455

3460

3465

3470

3475

3480

3485

3490

3495

3500

3505

3510

3515

3520

3525

3530

3535

3540

3545

3550

3555

3560

3565

3570

3575

3580

3585

3590

3595

3600

3605

3610

3615

3620

3625

3630

3635

3640

3645

3650

3655

3660

3665

3670

3675

3680

3685

3690

3695

3700

3705

3710

3715

3720

3725

3730

3735

3740

3745

3750

3755

3760

3765

3770

3775

3780

3785

3790

3795

3800

3805

3810

3815

3820

3825

3830

3835

3840

3845

3850

3855

3860

3865

3870

3875

3880

3885

3890

3895

3900

3905

3910

3915

3920

3925

3930

3935

3940

3945

3950

3955

3960

3965

3970

3975

3980

3985

3990

3995

4000

4005

4010

4015

4020

4025

4030

4035

4040

4045

4050

4055

4060

4065

4070

4075

4080

4085

4090

4095

4100

4105

4110

4115

4120

4125

4130

4135

4140

4145

4150

4155

4160

4165

4170

4175

4180

4185

4190

4195

4200

4205

4210

4215

4220

4225

4230

4235

4240

4245

4250

4255

4260

4265

4270

4275

4280

4285

4290

4295

4300

4305

4310

4315

4320

4325

4330

4335

4340

4345

4350

4355

4360

4365

4370

4375

4380

4385

4390

4395

4400

4405

4410

4415

4420

4425

4430

4435

4440

4445

4450

4455

4460

4465

4470

4475

4480

4485

4490

4495

4500

4505

4510

4515

4520

4525

4530

4535

4540

4545

4550

4555

4560

4565

4570

4575

4580

4585

4590

4595

4600

4605

4610

4615

4620

4625

4630

4635

4640

4645

4650

4655

4660

4665

4670

4675

4680

4685

4690

4695

4700

4705

4710

4715

4720

4725

4730

4735

4740

4745

4750

4755

4760

4765

4770

4775

4780

4785

4790

4795

4800

4805

4810

4815

4820

4825

4830

4835

4840

4845

4850

4855

4860

4865

4870

4875

4880

4885

4890

4895

4900

4905

4910

4915

4920

4925

4930

4935

4940

4945

4950

4955

4960

4965

4970

4975

4980

4985

4990

4995

5000

5005

5010

5015

5020

5025

5030

5035

5040

5045

5050

5055

5060

5065

5070

5075

5080

5085

5090

5095

5100

5105

5110

5115

5120

5125

5130

5135

5140

5145

5150

5155

5160

5165

5170

5175

5180

5185

5190

5195

5200

5205

5210

5215

5220

5225

5230

5235

5240

5245

5250

5255

5260

5265

5270

5275

5280

5285

5290

5295

5300

5305

5310

5315

5320

5325

5330

5335

5340

5345

5350

5355

5360

5365

5370

5375

5380

5385

5390

5395

5400

5405

5410

5415

5420

5425

5430

5435

5440

5445

5450

5455

5460

5465

5470

5475

5480

5485

5490

5495

5500

5505

5510

5515

5520

5525

5530

5535

5540

5545

5550

5555

5560

5565

5570

5575

5580

5585

5590

5595

5600

5605

5610

5615

5620

5625

5630

5635

5640

5645

5650

5655

5660

5665

5670

5675

5680

5685

5690

5695

5700

5705

5710

5715

5720

5725

5730

5735

5740

5745

5750

5755

5760

5765

5770

5775

5780

5785

5790

5795

5800

5805

5810

5815

5820

5825

5830

5835

5840

5845

5850

5855

5860

5865

but are not limited to: inflammatory or allergic diseases and conditions, including respiratory allergic diseases such as asthma, allergic rhinitis, hypersensitivity lung diseases, hypersensitivity pneumonitis, eosinophilic pneumonias (e.g., Loeffler's syndrome, chronic 5 eosinophilic pneumonia), delayed-type hypersensitivity, interstitial lung diseases (ILD) (e.g., idiopathic pulmonary fibrosis, or ILD associated with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, systemic sclerosis, Sjogren's syndrome, polymyositis or dermatomyositis); systemic anaphylaxis or hypersensitivity responses, 10 drug allergies (e.g., to penicillin, cephalosporins), insect sting allergies; autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, juvenile onset diabetes; glomerulonephritis, autoimmune thyroiditis, Behcet's disease; graft rejection (e.g., in transplantation), including 15 allograft rejection or graft-versus-host disease; inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis; spondyloarthropathies; scleroderma; psoriasis (including T-cell mediated psoriasis) and inflammatory dermatoses such as dermatitis, 20 eczema, atopic dermatitis, allergic contact dermatitis, urticaria; vasculitis (e.g., necrotizing, cutaneous, and hypersensitivity vasculitis); eosinophilic myositis, eosinophilic fascitis; cancers with leukocyte infiltration of the skin or organs. Other diseases or conditions in which undesirable inflammatory responses are to be inhibited can be treated, including, but not limited to, reperfusion injury, atherosclerosis, certain 25 hematologic malignancies, cytokine-induced toxicity (e.g., septic shock, endotoxic shock), polymyositis, dermatomyositis.

Diseases or conditions of humans or other species which can be treated with promoters of chemokine receptor function, include, but are not limited to: immunosuppression, such as that in individuals 30 with immunodeficiency syndromes such as AIDS, individuals undergoing radiation therapy, chemotherapy, therapy for autoimmune disease or other drug therapy (e.g., corticosteroid therapy), which causes immunosuppression; immunosuppression due congenital deficiency in receptor function or other causes; and infectious diseases, such as parasitic diseases, including, but not limited to helminth 35

infections, such as nematodes (round worms) (Trichuriasis, Enterobiasis, Ascariasis, Hookworm, Strongyloidiasis, Trichinosis, filariasis); trematodes (flukes) (Schistosomiasis, Clonorchiasis), cestodes (tape worms) (Echinococcosis, Taeniasis saginata, 5 Cysticercosis); visceral worms, visceral larva migrans (e.g., Toxocara), eosinophilic gastroenteritis (e.g., Anisakis spp., *Phocanemus* spp.), cutaneous larva migrans (*Ancylostoma braziliense*, *Ancylostoma caninum*).

The compounds of the present invention are accordingly useful in the prevention and treatment of a wide variety of inflammatory and immunoregulatory disorders and diseases.

In another aspect, the instant invention may be used to evaluate putative specific agonists or antagonists of chemokine receptors, including CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, 15 CCR-5, CXCR-3, and CXCR-4. Accordingly, the present invention is directed to the use of these compounds in the preparation and execution of screening assays for compounds which modulate the activity of chemokine receptors. For example, the compounds of this invention are useful for isolating receptor mutants, which are excellent screening tools for more potent compounds. Furthermore, the compounds of this invention are useful in establishing or determining the binding site of other compounds to chemokine receptors, e.g., by competitive inhibition. The compounds of the instant invention are also useful for the evaluation of putative specific modulators of the chemokine receptors, 20 including CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and CXCR-4. As appreciated in the art, thorough evaluation of specific agonists and antagonists of the above chemokine receptors has been hampered by the lack of availability of non-peptidyl (metabolically 25 resistant) compounds with high binding affinity for these receptors. Thus the compounds of this invention are commercial products to be sold for these purposes.

The present invention is further directed to a method for the manufacture of a medicament for modulating chemokine receptor activity in humans and animals comprising combining a compound of 30 the present invention with a pharmaceutical carrier or diluent.

The present invention is further directed to the use of these compounds in the prevention or treatment of infection by a retrovirus, in particular, the human immunodeficiency virus (HTV) and the treatment of, and delaying of the onset of consequent pathological conditions such as AIDS. Treating AIDS or preventing or treating infection by HTV is defined as including, but not limited to, treating a wide range of states of HIV infection: AIDS, ARC (AIDS related complex), both symptomatic and asymptomatic, and actual or potential exposure to HTV. For example, the compounds of this invention are useful in treating infection by HTV after suspected past exposure to HTV by, e.g., blood transfusion, organ transplant, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery. In addition, a compound of the present invention may be used for the prevention of infection by HTV and the prevention of AIDS, such as in post-coital prophylaxis or in the prevention of maternal transmission of the HIV virus to a fetus or a child upon birth.

In a preferred aspect of the present invention, a subject compound may be used in a method of inhibiting the binding of a human immunodeficiency virus to a chemokine receptor, such as CCR-5 and/or CXCR-4, of a target cell, which comprises contacting the target cell with an amount of the compound which is effective at inhibiting the binding of the virus to the chemokine receptor.

The subject treated in the methods above is a mammal, preferably a human being, male or female, in whom modulation of chemokine receptor activity is desired. "Modulation" as used herein is intended to encompass antagonism, agonism, partial antagonism and/or partial agonism. The term "therapeutically effective amount" means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.

The term "composition" as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified

amounts. By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

The terms "administration of" and or "administering a" compound should be understood to mean providing a compound of the invention or a prodrug of a compound of the invention to the individual in need of treatment.

Combined therapy to modulate chemokine receptor activity and thereby prevent and treat inflammatory and immunoregulatory disorders and diseases, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis, and those pathologies noted above is illustrated by the combination of the compounds of this invention and other compounds which are known for such utilities.

For example, in the treatment or prevention of inflammation, the present compounds may be used in conjunction with an antiinflammatory or analgesic agent such as an opiate agonist, a lipoxygenase inhibitor, such as an inhibitor of 5-lipoxygenase, a cyclooxygenase inhibitor, such as a cyclooxygenase-2 inhibitor, an interleukin inhibitor, such as an interleukin-1 inhibitor, an NMDA antagonist, an inhibitor of nitric oxide or an inhibitor of the synthesis of nitric oxide, a non-steroidal antiinflammatory agent, or a cytokine-suppressing antiinflammatory agent, for example with a compound such as acetaminophen, aspirin, codiene, fentanyl, ibuprofen, indomethacin, ketorolac, morphine, naproxen, phenacetin, piroxicam, a steroid analgesic, sufentanyl, sunlindac, tenidap, and the like. Similarly, the instant compounds may be administered with a pain reliever, a potentiator such as caffeine, an H₂-antagonist, simethicone, aluminum or magnesium hydroxide; a decongestant such as phenylephrine, phenylpropanolamine, pseudoephedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine; an antitussive such as codeine, hydrocodone, caramiphen, carbetapentane, or dextromethorphan; a diuretic; and a sedating or non-sedating antihistamine. Likewise, compounds of the present invention may be used in combination with other drugs that are

used in the treatment/prevention/suppression or amelioration of the diseases or conditions for which compounds of the present invention are useful. Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of the present invention. When a compound of the present invention is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound of the present invention is preferred.

Accordingly, the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients, in addition to a compound of the present invention. Examples of other active ingredients that may be combined with a compound of the present

15 invention, either administered separately or in the same pharmaceutical compositions, include, but are not limited to: (a) VLA-4 antagonists such as those described in US 5,510,332, WO 97/03094,

WO9702289, WO95140781, WO9622966, WO9620216, WO961644, WO96106108, WO9515973 and WO96131206; (b) steroids such as beclomethasone, methylprednisolone, betamethasone, prednisone,

dexamethasone, and hydrocortisone; (c) immunosuppressants such as cyclosporin, tacrolimus, rapamycin and other FK-506 type immunosuppressants; (d) antihistamines (H1-histamine antagonists).

tripelennamine, hydroxyzine, methdilazine, promethazine, trimoprazine, azatadine, cyproheptadine, antazoline, pheniramine pyrilamine, astemizole, terfepradine, loratadine, cetirizine

sexofenadine, descarboethoxyloratadine, and the like; (e) non-steroidal anti-asthmatics such as β_2 -agonists (terbutaline, metaproterenol).

pobilukast, SKB-106-203), leukotriene biosynthesis inhibitors (zileuton, BAY-1005); (f) non-steroidal antiinflammatory agents (NSAIDs) such as

propionic acid derivatives (alminoprofen, benoxaprofen, bucoxic acid, carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen, ibuprofen,

• 43 •

35 pranoprofen, suprofen, tiaprofenic acid, and tioxaprofen), acetic acid derivatives (indometacin, acemetacin, alclofenac, clidanac, diclofenac, fenclofenac, fencloxic acid, fentiazac, furofenac, ibufenac, isoxepac, oxipinac, sulindac, tiopinac, tolmetin, zidometacin, and zomepirac), fenamic acid derivatives (flufenamic acid, mectofenamic acid, mefenamic acid, niflumic acid and tolfenamic acid), biphenylcarboxylic acid derivatives (diflunisal and flufenisal), oxicanes (isoxicam, piroxicam, sodoxicam and tenoxicam), salicylates (acetyl salicylic acid, sulfasalazine) and the pyrazolones (apazone, beziperylon, feprazon, mofebutazone, oxyphenbutazone, phenylbutazone); (g) cyclooxygenase-2 (COX-2) inhibitors; (h) inhibitors of phosphodiesterase type IV (PDE-IV); (i) other antagonists of the chemokine receptors, especially CCR-1, CCR-2, CCR-3 and CCR-5; (j) cholesterol lowering agents such as HMG-CoA reductase inhibitors (lovastatin, simvastatin and pravastatin, fluvastatin, atorvastatin, and other statins) sequestrants (gemfibrozil, clofibrate, fenofibrate and bezafibrate), and probucol; (k) anti-diabetic agents such as insulin, sulfonylureas, biguanides (metformin), α -glucosidase inhibitors (acarbose) and glitazones (troglitazone and pioglitazone); (l) preparations of interferon beta (interferon beta-1a, interferon beta-1B); (m) other compounds such as 5-aminosalicylic acid and prodrugs thereof, antimetabolites such as azathioprine and 6-mercaptopurine, and cytotoxic cancer chemotherapeutic agents. The weight ratio of the compound of the compound of the present invention to the second active ingredient may be varied and will depend upon the effective dose of each ingredient.

25 Generally, an effective dose of each will be used. Thus, for example, when a compound of the present invention is combined with an NSAID the weight ratio of the compound of the present invention to the NSAID will generally range from about 1000:1 to about 1:1000, preferably about 200:1 to about 1:200. Combinations of a compound of the present invention and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.

30

35

六

The present invention is further directed to combinations of the present compounds with one or more agents useful in the prevention or treatment of AIDS. For example, the compounds of this invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of the AIDS antivirals, immunomodulators, anti-infectives, or vaccines known to those of ordinary skill in the art.

ANTIVIRALS

Cidofovir	Gilead Science	CMV retinitis, herpes, papillomavirus	El10	Elan Corp, PLC (Gainesville, GA)	HIV infection
Curdlan sulfate	AJI Pharma USA	HTV infection	Famciclovir	Smith Kline	herpes zoster, herpes simplex
Cytomegalovirus	MedImmune	CMV retinitis			HTV infection, AIDS, ARC
immune globin	Syntax	sight threatening CMV	FTC	Emory University	(reverse transcriptase inhibitor)
Cytovene		peripheral CMV retinitis			HIV infection, AIDS, ARC
Ganciclovir		HTV infection, AIDS, ARC	GS 840	Gilead	(reverse transcriptase inhibitor)
Delavirdine	Pharmacia-Upjohn	(RT inhibitor) AIDS, ARC, HIV positive asymptomatic	GW 141	Glaxo Welcome	HIV infection, AIDS, ARC
Dextran Sulfate	Ueno Fine Chem. Ind. Ltd. (Osaka, Japan)	HIV infection, AIDS, ARC	GW 1592	Glaxo Welcome	(reverse transcriptase inhibitor)
ddC	Hoffman-La Roche	HIV infection, AIDS, ARC			HIV infection, AIDS, ARC
Dideoxycytidine	Bristol-Myers Squibb	HIV infection, AIDS, ARC; combination with AZT/d4T			(protease inhibitor)
ddI	DuPont-Merck Pharmaceuticals	HIV infection, AIDS, ARC (non-nucleoside reverse transcriptase inhibitor)	HBY097	Hoechst Marion Roussel	HIV infection, AIDS, ARC
DMP-266					(non-nucleoside reverse transcriptase inhibitor)
DMP-450	AVID (Camden, NJ)	Hypericin	VIMRx Pharm.	HIV infection, AIDS, ARC	HIV infection, AIDS, AIDS, Kaposi's sarcoma, ARC
Efavirenz	DuPont Merck (DMP 266)	Recombinant Human Interferon Beta Interferon alfa-n3 Indinavir	Triton Biosciences (Alameda, CA) Interferon Sciences Merck		ARC, AIDS HIV infection, AIDS, ARC, asymptomatic HIV positive, also in combination with AZT/ddI/ddC

ISIS 2922	ISIS Pharmaceuticals	CMV retinitis	Saquinavir	Hoffmann-La Roche	HIV infection, AIDS, ARC
KNI-272	Nat'l Cancer Institute	HIV-assoc. diseases			(protease inhibitor)
Lamivudine, 3TC	Glaxo Wellcome	HIV infection, AIDS, ARC (reverse transcriptase inhibitor); also with AZT	Stavudine; d4T	Bristol-Myers Squibb	HIV infection, AIDS, ARC
			Didehydrodeoxy-thymidine		
Lobutacavir	Bristol-Myers Squibb	CMV infection	Valaciclovir	Glaxo Wellcome	genital HSV & CMV infections
Nelfinavir	Agouron Pharmaceuticals	HIV infection, AIDS, ARC (protease inhibitor)	Virazole	Viratek/ICN (Costa Mesa, CA)	asymptomatic HIV positive, LAS, ARC
			Ribavirin	Vertex	HIV infection, AIDS, ARC
Nevirapine	Boehringer Ingelheim	HIV infection, AIDS, ARC (RT inhibitor)	Zalcitabine	Hoffmann-La Roche	HIV infection, AIDS, ARC, with AZT
			Zidovudine; AZT	Glaxo Wellcome	HIV infection, AIDS, ARC, Kaposi's sarcoma, in combination with other therapies
Peptide T	Novaferon Labs, Inc. (Akron, OH)				
Octapeptide Sequence	Peninsula Labs (Belmont, CA)	AIDS			
Trisodium Phosphonoformate	Astra Pharm. Products, Inc.	CMV retinitis, HIV infection, other CMV infections			
PNU-140690	Pharmacia Upjohn	HIV infection, AIDS, ARC (protease inhibitor)	Drug Name	Manufacturer	Indication
		HIV infection, AIDS, ARC	AS-101	Wyeth-Ayerst	AIDS
Probucol RBC-CD4	Vyrex	HIV infection, AIDS, ARC	Bropirimine	Pharmacia Upjohn	advanced AIDS
	Sheffield Med. Tech (Houston TX)	HIV infection, AIDS, ARC	Acemannan	Carrington Labs, Inc. (Irving, TX)	AIDS, ARC
Ritonavir	Abbott	HIV infection, AIDS, ARC (protease inhibitor)	CL246,738	American Cyanamid Lederle Labs	AIDS, Kaposi's sarcoma
			EL10	Elan Corp, PLC	HIV infection
			FP-21399	Fuki ImmunoPharm (Gainesville, GA)	blocks HIV fusion with CD4+ cells

Gamma Interferon	Genentech	ARC, in combination w/TNF (tumor necrosis factor)	Methionine-Enkephalin	TNI Pharmaceutical (Chicago, IL)	AIDS, ARC
Granulocyte Macrophage Colony Stimulating Factor	Genetics Institute Sandoz	AIDS	MTP-PE	Ciba-Geigy Corp.	Kaposi's sarcoma
Granulocyte Macrophage Colony Stimulating Factor	Hoescht-Roussel	AIDS	Muramyl-Tripeptide	Amgen	AIDS, in combination w/AZT
Granulocyte Macrophage Colony Stimulating Factor	Immunex	AIDS	Granulocyte Colony Stimulating Factor	Remune	Immune Response immunotherapeutic
Granulocyte Macrophage Colony Stimulating Factor	Schering-Plough	AIDS, combination w/AZT	rCD4 Recombinant Soluble Human CD4	Immune Response Corp.	AIDS, ARC
HIV Core Particle Immunostimulant	Rorer	seropositive HIV	rCD4-IgG hybrids	Genentech	AIDS, ARC
IL-2	Cetus	AIDS, in combination w/AZT	Recombinant Soluble Human CD4	Biogen	AIDS, ARC
Interleukin-2	Hoffman-La Roche	AIDS, ARC, HIV, in combination w/AZT	Interferon Alfa 2a	Hoffman-La Roche	Kaposi's sarcoma
IL-2	Immunex	AIDS, increase in CD4 cell counts	SK&F106528	Smith Kline	AIDS, ARC, in combination w/AZT
Interleukin-2	Chiron		Soluble T4		HTV infection
Interleukin-2 (aldeslukin)	Cutter Biological (Berkeley, CA)	pediatric AIDS, in combination w/AZT	Thymopentin	Research Institute (Annandale, NJ)	HIV infection
Intravenous (human) IMREG-1	Imreg (New Orleans, LA)	AIDS, Kaposi's sarcoma, ARC, PGL	Tumor Necrosis Factor; TNF	Genentech	ARC, in combination w/gamma Interferon
IMREG-2					ANTI-INJECTIVES
Imuthiol Diethyl Dithio Carbamate	(New Orleans, LA) Merieux Institute	AIDS, Kaposi's sarcoma, ARC, PGL	Drug Name	Manufacturer	Indication
Alpha-2 Interferon	Schering Plough	Kaposi's sarcoma w/AZT, AIDS	Clindamycin with Primaquine	Pharmacia Upjohn	PCP

Fluconazole	Pfizer	cryptococcal meningitis, candidiasis prevention of oral candidiasis	Megestrol Acetate	Bristol-Myers Squibb	treatment of anorexia assoc. w/AIDS
Pastille	Squibb Corp.		Testosterone	Alza, Smith Kline	AIDS-related wasting
Nystatin Pastille			Total Enteral	Norwich Eaton	diarrhea and malabsorption
Ornidyl	Merrell Dow		Nutrition	Pharmaceuticals	related to AIDS
Enormithine					
Pentamidine	LyphoMed	PCP treatment			
Isethionate (IM & IV) (Rosemont, IL)					
Trimethoprim		antibacterial			
Trimethoprim/sulfa		antibacterial			
Piritrexim	Burroughs Wellcome	PCP treatment			
Pentamidine isethionate for inhalation	Fisons Corporation	PCP prophylaxis			
Spiramycin	Rhone-Poulenc	cryptosporidial diarrhea			
Intraconazole- R5121	Janssen Pharm.	histoplasmosis; cryptococcal meningitis			
Trineterpate	Warner-Lambert	PCP			
OTHER					
Drug Name	Manufacturer	Indication			
Daunorubicin	NeXstar, Sequus	Kaposi's sarcoma			
Recombinant Human Erythropoietin	Ortho Pharm. Corp.	severe anemia assoc. with AZT therapy			
Recombinant Human Growth Hormone	Serono	ADS-related wasting, cachexia			
5					
Preferred combinations are simultaneous or alternating treatments of with a compound of the present invention and an inhibitor of HIV protease and/or a non-nucleoside inhibitor of HIV reverse transcriptase. An optional fourth component in the combination is a nucleoside inhibitor of HIV reverse transcriptase, such as AZT, 3TC, ddC or ddI. A preferred inhibitor of HIV protease is indinavir, which is the sulfate salt of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridyl-methyl))2(S)-N ^t -(t-buty)carboxamido)-piperazinyl)-pentaneamide ethanolate, and is synthesized according to U.S. 5,413,999. Indinavir is generally administered at a dosage of 800 mg three times a day. Other preferred protease inhibitors are nelfinavir and ritonavir. Another preferred inhibitor of HIV protease is saquinavir which is administered in a dosage of 600 or 1200 mg tid. Preferred non-nucleoside inhibitors of HIV reverse transcriptase include efavirenz. The preparation of ddC, ddI and AZT are also described in EPO 0,484,071. These combinations may have unexpected effects on limiting the spread and degree of infection of HIV. Preferred combinations include those with the following (1) indinavir with etavirenz, and, 25 optionally, AZT and/or 3TC and/or ddI and/or ddC; (2) indinavir, and, and AZT and 3TC; (3) stavudine and 3TC and/or zidovudine; (4)					

zidovudine and lamivudine and 141W94 and 1592U89; (5) zidovudine and lamivudine.

In such combinations the compound of the present invention and other active agents may be administered separately or in conjunction. In addition, the administration of one element may be prior to, concurrent to, or subsequent to the administration of other agent(s).

The compounds of the present invention may be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV, intracisternal injection or infusion, subcutaneous injection, or implant), by inhalation spray, nasal, vaginal, rectal, sublingual, or topical routes of administration and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, monkeys, etc., the compounds of the invention are effective for use in humans.

The pharmaceutical compositions for the administration of the compounds of this invention may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. In the pharmaceutical composition the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases. As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Patents 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-

propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example 5 polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethoxyacetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

10 Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The

15 oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation

20 of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening,

25 flavoring and coloring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or

30 gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example 5 polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.

35 The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

40 The compounds of the present invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of the present invention are employed. (For purposes of this application, topical application shall include mouth washes and gargles.)

The pharmaceutical composition and method of the present invention may further comprise other therapeutically active compounds as noted herein which are usually applied in the treatment of the above mentioned pathological conditions.

5 In the treatment or prevention of conditions which require chemokine receptor modulation an appropriate dosage level will

generally be about 0.001 to 100 mg per kg patient body weight per day which can be administered in single or multiple doses. Preferably, the dosage level will be about 0.01 to about 25 mg/kg per day; more preferably about 0.05 to about 10 mg/kg per day. A suitable dosage level may be

10 about 0.01 to 25 mg/kg per day, about 0.05 to 10 mg/kg per day, or about 0.1 to 5 mg/kg per day. Within this range the dosage may be 0.005 to 0.05, 0.05 to 0.5 or 0.5 to 5.0 mg/kg per day. For oral administration, the compositions are preferably provided in the form of tablets containing 1.0

15 to 1000 milligrams of the active ingredient, particularly 1.0, 5.0, 10.0, 15.0, 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 milligrams of the active ingredient

for the symptomatic adjustment of the dosage to the patient to be treated. The compounds may be administered on a regimen of 1 to 4 times per

20 day, preferably once or twice per day.

It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.

Several methods for preparing the compounds of this invention are illustrated in the following Schemes and Examples.

Starting materials are made from known procedures or as illustrated. Substituted purines may be prepared as disclosed in US 5,057,517;

imidazo[1,2-a]pyrazinyl, as disclosed in US 4,242,344; (1,2,4)-triazolo[1,5-a]pyrazinyl as disclosed in *J. Org. Chem.*, 1974, 39, 2143 and *J.C.S. Perkin I*, 1980, 506; 1,7-naphthyridinyl as disclosed in *J. Org. Chem.*, 1963, 28, 1753; furo(3,2-c)pyridinyl as disclosed in *J. Heterocyclic Chem.*,

1982, 19, 1207; and substituted 6-H-7,8-dihydro-thiopyranos[3,2-d]pyrimidyl as disclosed in *Arch. Int. Pharmacodyn.* 1986, 280, pp302-313. As appreciated by those of skill in the art, compounds bearing the substituents R8 and R9 may be prepared essentially as described in the Schemes.

The compounds of the present invention are prepared by

alkylating piperazine 1 (R1 = H) under appropriate conditions (Scheme 1). In one method illustrated by Example 1, Step E, piperazine 1 (R1 = H) is combined with the appropriate aldehyde and the intermediate imine is reduced to the amine chemically (e.g. using sodium cyanoborohydride) or catalytically (e.g. using hydrogen and palladium on carbon or Raney nickel catalyst) (Scheme 1). The aldehyde needed for this reaction can be prepared by methods generally known in the chemical literature; for the

purposes of the present invention the preparation of a representative aldehyde is described in Examples 1 Step A by Hale, J.J.; Finke, P.E.; MacCoss, M. *Bioorganic and Medicinal Chemistry Letters* 1993 3, 319-322.



In an alternative embodiment of the present invention, piperazine 1 (R1 = H) can be alkylated with an alkyl halide or alkyl sulfonate ester (with or without an added base to neutralize the mineral acid or sulfonic acid by-product) to give the desired compound (Scheme 1). The alkyl halide or alkyl sulfonate needed for this reaction can be prepared by methods generally known in the chemical literature; for the purposes of the present invention an aldehyde, prepared as described above, can be reduced to an alcohol with sodium borohydride, diisobutylaluminum hydride or lithium aluminum hydride, and the product alcohol converted to either the alkyl halide using methods described in March J., *Advanced Organic Chemistry*, 3rd ed., John Wiley & Sons, New York, pp. 382-384 (1985) or alkyl sulfonate ester using methods described in March J., *Advanced Organic Chemistry*, 3rd ed., John Wiley & Sons, New York, p. 444 (1985).

In an alternative embodiment of the present invention, 1 (R1 = H) can be acylated to give the tertiary amide and subsequent reduction with a strong reducing agent (e.g. diborane including borane dimethylsulfide; and, lithium aluminum hydride) will give the desired

compound (Scheme 1). The acylating agent needed for this reaction can be prepared by methods generally known in the chemical literature; for the purposes of the present invention an aldehyde, prepared as described above, can be oxidized using such commonly used reagents as

5 permanganate in acid or silver oxide, and the resulting acid activated as an acid chloride or mixed anhydride which can be used to acylate I. The

product amide can be reduced with a strong reducing agent, such as diborane or lithium aluminum hydride, to give the tertiary amine.



After reductive amination, the t-butoxycarbonyl group is removed by treatment with a strong acid such as trifluoroacetic acid, formic acid or hydrochloric acid and the resulting amine may be acylated to provide other analogs.

The piperazine starting materials used in the coupling reaction are prepared using methods described in the literature; more specifically as described in Meurer, US 5,057,517, US 4,242,344; *J. Org. Chem.*, 1974, 39, 2143 and *J.C.S. Perkin I*, 1980, 506; *J. Org. Chem.* 1963, 28, 1753; *J. Heterocyclic Chem.*, 1982, 19, 1207; *Arch. Int. Pharmacodyn.* 1986, 280, pp302-313; Meurer, L. C. et al., *J. Med. Chem.*, 1992, 35, 3845.

3867. Alternatively, the piperazine substrates can be prepared as illustrated in Schemes 2-4.

Substituted 4-arylpiperazines can be prepared from appropriate fluorobenzene derivative as shown in Scheme 2. Thus,

reaction of 2-fluorobenzonitrile with 1-t-butoxycarbonylpiperazine in the presence of a base such as K_2CO_3 gives 1-t-butoxycarbonyl-4-(2-

cyanophenyl)-piperazine. Reduction of the cyano group by


hydrogenation in the presence of Raney nickel or by other known

methods gives a benzyl amine which can be acylated (Example 1, Step

D). The t-butoxycarbonyl protecting group is removed by treatment with trifluoroacetic acid or anhydrous HCl to give a piperazine which can be used in the reductive amination step (Example 1, Step E). Similar reactions using 2-chloro-nitrobenzene in the place of 2-fluorobenzonitrile

20 can provide compounds containing a substituted aniline. Analogs containing a benzoic acid or its derivatives can be prepared by


substituting 2-fluorobenzonic acid in this sequence.




Arylpiperazine derivatives containing heterocyclic substituents can be synthesized as shown in Scheme 3. Reaction

between 2-fluorobenzaldehyde and 1-t-butoxycarbonyl-4-(2-formylphenyl)-piperazine as described above gives 1-t-butoxycarbonyl-4-(2-formylphenyl)-piperazine (Example 9, Step A). Reduction of the aldehyde and treatment of the resulting alcohol with methanesulfonyl chloride gives a mesylate, while treatment of the alcohol with triphenylphosphine and carbon tetrabromide gives the bromide. Displacement of the mesylate by a base and removal of the t-butoxycarbonyl protecting group furnishes piperazine which is used in the coupling reactions described in Scheme I.

SCHEME 3



SCHEME 4



Preparation of hydroxymethyl derivatives of the target compounds is outlined in Scheme 5. The oxazolidinone imide is made from the indicated acid, by formation of the corresponding acid chloride (by treatment with oxalyl chloride or thionyl chloride) and addition of N-lithio 2(S)-benzyl oxazolidinone. The enolate oxidation can be

accomplished by a variety of methods, such as the procedure of Evans, D. A.; et. al. *J. Am. Chem. Soc.* 1990, 112, 4011-4030. Reduction of the oxazolidinone moiety can be carried out by a variety of metal hydride reagents (e.g. LiBH4/MeOH, LiAlH4, etc.). The azide is then reduced by treatment with PPh3/H2O or NaBH4. Formation of the cyclic carbamate is accomplished by literature methods; i.e. phosgene, triphosgene or carbonyl diimidazole. The target compounds are prepared by oxidative cleavage of the olefin to the aldehyde followed by reductive amination with an amine salt as described for Scheme 1. In one method illustrated by Example 48, the aldehyde is reductively aminated with a heteroaryl substituted aryl piperazine to afford the target precursors. Hydrolysis of the cyclic carbamate under basic conditions (for example, potassium hydroxide in ethanol at elevated temperature) followed by selective amide formation at 0°C by combining with an active acylating agent derived from an aryl carboxylic acid (for example, an aryl chloride) gives the *α*-hydroxy-methyl amides.


5 Preparation of piperazines containing a heteroaryl substituent is outlined in Scheme 4. Reaction of 1-t-butoxycarbonyl-piperazine with a chloro substituted heteroaromatic compound such as 8-chloro-1,7-naphthyridine (Example 22, Step A) or 8-chloro-(1,2,4)-triazolo(1,5-a)pyrazine (Example 23, Step A) gives a protected piperazine.

10 Removal of the t-butoxycarbonyl protecting group by treatment with acid provides the piperazine substrate for use in the coupling step.

15 Preparation of hydroxymethyl derivatives of the target compounds is outlined in Scheme 5. The oxazolidinone imide is made from the indicated acid, by formation of the corresponding acid chloride (by treatment with oxalyl chloride or thionyl chloride) and addition of N-lithio 2(S)-benzyl oxazolidinone. The enolate oxidation can be

20 accomplished by a variety of methods, such as the procedure of Evans, D. A.; et. al. *J. Am. Chem. Soc.* 1990, 112, 4011-4030. Reduction of the oxazolidinone moiety can be carried out by a variety of metal hydride reagents (e.g. LiBH4/MeOH, LiAlH4, etc.). The azide is then reduced by treatment with PPh3/H2O or NaBH4. Formation of the cyclic carbamate is accomplished by literature methods; i.e. phosgene, triphosgene or carbonyl diimidazole. The target compounds are prepared by oxidative cleavage of the olefin to the aldehyde followed by reductive amination with an amine salt as described for Scheme 1. In one method illustrated by Example 48, the aldehyde is reductively aminated with a heteroaryl substituted aryl piperazine to afford the target precursors. Hydrolysis of the cyclic carbamate under basic conditions (for example, potassium hydroxide in ethanol at elevated temperature) followed by selective amide formation at 0°C by combining with an active acylating agent derived from an aryl carboxylic acid (for example, an aryl chloride) gives the *α*-hydroxy-methyl amides.

SCHEME 5



Preparation of piperazines containing a heteroaryl substituent on a branched side chain is outlined in Scheme 6. Reaction of the 2-piperazinyl-benzaldehyde derivative whose synthesis is described in Scheme 3 with a carbon nucleophile such as a Grignard reagent, for example methyl magnesium bromide, provides the corresponding benzyl alcohol. Conversion to the benzylic amine can be carried out by treatment of the alcohol with potassium phthalimide in the presence of diethyl azodicarboxylate and triphenyl phosphine, to provide the benzyl N-phthalimido derivative. Heating with hydrazine hydrate then gives the free primary amine. Conversion to the corresponding benzylic amine can also be carried out by activation of the hydroxyl group with a alkyl- or arylsulfonyl chloride, such as p-toluenesulfonyl chloride, to give a benzylic sulfonate ester. The sulfonate ester is then displaced with ammonia or a primary or secondary amine. Alternatively, the sulfonate ester can be displaced with a suitable salt of the azide anion, such as sodium azide, zinc azide, or tetrabutylammonium azide, and the resulting alkyl azide can be reduced to the primary amine with hydrogen gas in the presence of a suitable catalyst, such as 5% palladium on carbon. Alternatively, the alkyl azide can be reduced by treatment with triphenyl phosphine followed by hydrolysis to provide the primary amine.

The benzylic amine can then be derivatized with a number of electrophilic reagents, such as alkyl or aryl sulfonyl chlorides, carboxylic acid chlorides, carboxylic acid anhydrides, alkyl chloroformates, carbamyl chlorides or alkyl or aryl isocyanates to provide sulfonamides, carboxamides, ureas, or carbamates. These intermediates can then be deprotected under acidic conditions to remove the Boc group to provide the free piperazines for use in the coupling reactions described in Scheme 1.

1) IM KOH , EtOH , 85°C

2) $\text{Ar}'\text{COCl}$, Et_3N , CH_2Cl_2 , 0°C

5


10

15


20

25

SCHEME 6



EXAMPLE 1



10 1-(3-((S)-(3,4-Dichlorophenyl))-4-(3,5-dimethylbenzyl)-(methylamino)butyl)-4-(2-acetylaminomethylphenyl)piperazine

Step A: 3-(S)-(3,4-Dichlorophenyl)-4-((3,5-dimethylbenzyl)methylamino)-butanal

To a suspension of 4.81 g (32 mmol) of 3,5-dimethyl-benzoic acid in 30 mL of CH₂Cl₂ and 7 drops of DMF was added 3.3 mL (38 mmol) of oxalyl chloride. After stirring for 1 h all the solids were dissolved and gas evolution had stopped. The solution was concentrated and the residual acid chloride was dissolved in 20 mL of CH₂Cl₂. This


solution was added to a solution of 7.2 g (29 mmol) of 3-(S)-(3,4-dichlorophenyl)-4-methylamino-1-pentene (prepared as described by J. Hale *et al.*, *Bioorganic and Medicinal Chemistry Letters*, 1993, 3, 319-322) in 50 mL of CH₂Cl₂ and 5.3 mL (38 mmol) of triethylamine (Et₃N) with cooling in an ice bath. The ice bath was removed after 5 min and stirring was continued for 1 h. The reaction mixture was diluted with

CH₂Cl₂ and washed with water, 1.2 N HCl, saturated NaHCO₃ and brine. The solution was dried over Na₂SO₄ and concentrated to give 11.98 g of residual oil. 1H NMR (CDCl₃, p.p.m. ranges are given because of amide rotamers and line broadening) 2.26 (s, 6 H), 2.1-3.9 (m, 8 H), 4.9-5.1 (m, 2 H), 5.4-5.7 (m, 1 H), 6.5-7.4 (m, 6 H).

30 The residue was dissolved in 45 mL of acetone, 15 mL of t-butanol and 15 mL of water. To this solution 0.75 mL of osmium tetroxide (4% solution in water) and 3.63 g (31 mmol) of 4-methylmorpholine N-oxide were added. After stirring for 18 h, the reaction was quenched with approximately 30 mL of 10% aqueous Na₂SO₃ and concentrated to 25% of the original volume. The residue

In some cases the order of carrying out the foregoing reaction schemes may be varied to facilitate the reaction or to avoid unwanted reaction products.

The following examples are provided for the purpose of further illustration only and are not intended to be limitations on the disclosed invention.



where X = -SO₂-, -CO-, -OC(O)-, -CONH-, or -CONR₂

was partitioned between water and 1:1 ether (Et₂O), ethyl acetate (EtOAc), the layers were separated and the aqueous layer was reextracted with Et₂O:EtOAc. Each organic layer was washed with water, brine and dried by filtering through Na₂SO₄. The combined

5 filtrate was concentrated to afford the crude diol.

A solution of the diol in 60 mL of tetrahydrofuran (THF) and 20 mL of water was treated with 6.63 g (31 mmol) of sodium periodate. After stirring for 2 h, the reaction was diluted with Et₂O:EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄) and the filtrate was concentrated. The residue was purified by prep LC

10 using 30% EtOAc/hexane to furnish 7.86 g (72% yield for three steps) of the title compound as a light yellow solid. ¹H NMR (CDCl₃, ppm ranges are given because of amide rotamers and line broadening) δ 2.27 (s, 6 H), 2.6-3.9 (m, 8 H), 6.5-7.5 (m, 6 H), 9.73 (s, 1 H).

15 Step B: 1-t-Butoxycarbonyl-4-(2-cyanophenyl)piperazine

To a 30mL DMF solution of t-butyloxycarbonyl-piperazine 10g (53.7mmol) and o-fluorobenzonitrile 4.34g (35.8mmol) were added

20 potassium carbonate 22.26 g (161 mmol) and copper powder 230mg (3.6mmol). The reaction mixture was stirred at 150 °C in an oil bath overnight. After cooling to rt, the reaction mixture was concentrated reduced pressure. The residual material was suspended in EtOAc and

was filtered through a pad of celite. The filtrate was washed with sat NH₄Cl aq. solution, dried over anhydrous Na₂SO₄, filtered, concentrated, chromatographed on silica gel column eluting with

25 Hexanes : EtOAc = 10:1 to 7:1 to give 7.84g of the title compound. ¹H-NMR (400MHz CDCl₃) δ 1.46(9H,s), 3.13(4H, m), 3.61(4H, m), 6.99-7.04(2H, s), 7.46-7.58(2H,s).

30 Step C: 1-t-Butoxycarbonyl-4-(2-aminomethyl)phenyl-piperazine

1-t-Butoxycarbonyl-4-(2-cyano)phenyl-piperazine 3g (10.4mmol) was dissolved in EtOH (65mL) and liq. NH₃ (13mL), and was hydrogenated in a bomb (H₂ 1000psi, 80° C, 36h). The solvent was then

removed under reduced pressure to give the title compound. This material was used in step D below without further purification.

Step D: 4-(2-(Acetylaminomethyl)phenyl)piperazine

5 A solution of 0.258 g (0.89 mmol) of 4-(2-aminomethyl)-CH₂Cl₂ was treated with 0.076 mL (1.06 mmol) of acetyl chloride and 0.15 mL (1.07 mmol) of Et₃N. After stirring for 20 min the reaction mixture was diluted with CH₂Cl₂ and washed with water, saturated NaHCO₃,

10 brine and dried over Na₂SO₄. The filtrate was concentrated and the residue was treated with 10 drops of anisole and 2 mL of cold TFA. The solution was stirred in an ice bath for 1 hr, then concentrated. The residue was partitioned between CH₂Cl₂ and dilute NaOH. The organic layer was washed with brine, dried and the filtrate was concentrated to furnish 0.198 g (96%) of the title compound which was used in the next step without purification. ¹H NMR (CDCl₃) δ 2.0 (s, 3 H), 2.90 (m, 4 H), 3.02 (m, 4 H), 4.52 (AB, 2 H), 6.55 (br s, 1 H), 6.85-7.4 (m, 4 H).

Step E: 1-(3-((S)-3,4-Dichlorophenyl)-4-(N-3,5-dimethylbenzoyl)-(methyl-amino)butyl)-4-(2-(acetylaminomethyl)phenyl)piperazine

To a solution of 0.12 g (0.32 mmol) of 3-((S)-3,4-dichlorophenyl)-4-((3,5-dimethylbenzoyl)methylamino)butanal (Step A)

25 in 1 mL of MeOH were added 0.099 g (0.42 mmol) of 4-(2-acetylaminomethyl)phenyl-piperazine (Step D), 0.3 g of powdered 4 Å molecular sieves and 20 μ L of acetic acid. After stirring the mixture for 1.5 h a solution of 0.063 g (1 mmol) of NaCNBH₃ in 3 mL of THF was added. Some gas evolution was observed. After 1 h when the reaction was complete by TLC the mixture was filtered through a pad of celite, the reaction flask and the pad were rinsed with MeOH. The filtrate was concentrated to approximately 2 mL and the residue was diluted with Et₂O:EtOAc. The Et₂O:EtOAc solution was washed with water, brine and dried over Na₂SO₄. The filtrate was concentrated and the residue was purified by prep TLC using 88:10:2 EtOAc:MeOH:Et₃N to isolate

0.163 g (86%) of the title compound as a white foam. ^1H NMR (CDCl_3 , ppm ranges are given because of amide rotamers and line broadening) 8.98 (s, 3 H), 1.5-3.9 (m, 18 H), 2.27 (s, 6 H), 4.48 (AB, 2 H), 6.3-6.5 (br, 1 H), 6.6-7.5 (m, 10 H).

5

EXAMPLE 2

1-((S)-3,4-Dichlorophenyl)-4-(N-3,5-dichlorobenzoyl)-(methylaminobutyl)butyl-4-(2-(acetamidomethylphenyl)-piperazine

10 **Step A:** 3-((S)-3,4-Dichlorophenyl)-4-(3,5-dichlorobenzoyl)methyl-
amino-butanal

The title compound was prepared following the procedures described in Example 1, Step A, but using 3,5-chlorobenzoyl chloride in the place of freshly prepared 3,5-dimethylbenzoyl chloride.

15 ^1H NMR (CDCl_3 , ppm ranges are given because of amide rotamers and line broadening) 8.2-6.3-9 (m, 8 H), 6.7-7.5 (m, 6 H), 9.7 (s, 1 H).

Step B: 1-((S)-3,4-Dichlorophenyl)-4-(N-3,5-

dichlorobenzoyl)-(methylamino)butyl-4-(2-

acetamidomethylphenyl)-piperazine

The title compound was prepared by the procedure described in Example 1, Step E by substituting 3-((S)-3,4-

dichlorophenyl)-4-(3,5-dichlorobenzoyl)methylamino)butanal as the aldehyde component. Mass Spectrum (Cl) 637 ($37\text{Cl} + 35\text{Cl}$ isotope), 635 ($35\text{Cl} + 35\text{Cl}$ isotope).

20

EXAMPLE 6

1-((S)-3,4-Dichlorophenyl)-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl-4-(2-methylaminocarbonylamino)methylphenyl)-piperazine

15

Mass Spectrum (Cl) 633 ($37\text{Cl} + 35\text{Cl}$ isotope), 631 ($35\text{Cl} + 35\text{Cl}$ isotope).

EXAMPLE 7

The compounds in Examples 3-8 were prepared by reacting the requisite piperazine with either 3-((S)-3,4-dichlorophenyl)-4-(3,5-dimethylbenzyl)methylamino)butanal (Example 1, Step A) or 3-((S)-3,4-dichlorophenyl)-4-(3,5-dichlorophenyl)-4-(3,5-dichlorobenzoyl)methylamino)butanal (Example 2, Step A) according to the procedure of Example 1, Step E. The piperazine substrates were synthesized by the method of Example 1, Step D by substituting the appropriate acylation reagent.

35

EXAMPLE 3

- 73 -

1-((S)-3,4-Dichlorophenyl)-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl-4-(2-dimethylaminocarbonylamino)methylphenyl)-piperazine

20

Mass Spectrum (Cl) 668 ($37\text{Cl} + 35\text{Cl}$ isotope), 666 ($35\text{Cl} + 35\text{Cl}$ isotope).

EXAMPLE 8

1-((S)-3,4-Dichlorophenyl)-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl-4-(2-dimethylaminocarbonylamino)methylphenyl)-piperazine

25

Mass Spectrum (Cl) 668 ($37\text{Cl} + 35\text{Cl}$ isotope), 666 ($35\text{Cl} + 35\text{Cl}$ isotope).

- 74 -

1-(3-((S)-3,4-Dichlorophenyl)-4-(N-3,5-dichlorobenzoyl)-(methylaminobutyl)-4-(2-methanesulfonylaminoethyl)phenyl)-piperazine
Mass Spectrum (Cl) 675 (37Cl + 35Cl isotope), 673 (35Cl + 35Cl isotope).

5 EXaMPLe 9

1-(3-((S)-3,4-Dichlorophenyl)-4-(N-3,5-dimethylbenzoyl)-(methylaminobutyl)-4-(2-methoxybenzoyl)-piperazine
Mass Spectrum (Cl) 675 (37Cl + 35Cl isotope), 673 (35Cl + 35Cl isotope).

5

Step C: 1-t-Butoxycarbonyl-4-(2-((1'-imidazolyl)methyl)phenyl)-piperazine
To 0.2 g (0.68 mmol) of 1-t-butoxycarbonyl-4-(2-hydroxy-methylphenyl)piperazine in 2 mL of CH₂Cl₂ were added 0.064 mL (0.82 mmol) of methanesulfonyl chloride and 0.11 mL (0.82 mmol) of Et₃N.

After stirring for 30 min the reaction was partitioned between water and CH₂Cl₂. The CH₂Cl₂ layer was washed with brine, dried and concentrated and the residue was dissolved in 1 mL of DMF. This

10 solution was added to a mixture of 51 mg (0.75 mmol) of imidazole in 1 mL of DMF and 18 mg (0.75 mmol) of NaH which had been stirred for 30 min. After heating the reaction mixture for 18 h at 60 °C, it was cooled and partitioned between water and EtOAc. The organic layer was washed with water, brine, dried and the filtrate was concentrated. The residue was chromatographed using 5% MeOH-CH₂Cl₂ to isolate 0.096 g (41%) of 1-t-butoxycarbonyl-4-(2-((1'-imidazolyl)methyl)-phenyl)-piperazine. ¹H NMR (CDCl₃) δ 1.46 (s, 9 H), 2.74 (m, 4 H), 3.53 (m, 4 H), 5.2 (s, 2 H) 6.89 (s, 1 H), 7.0-7.4 (m, 5 H), 7.54 (s, 1 H).

15

Step D: 4-(2-((1'-imidazolyl)methyl)phenyl)piperazine
Cold TFA (1 mL) and 0.1 mL of anisole were added to 0.096 g (0.28 mmol) of 1-t-butoxycarbonyl-4-(2-((1'-imidazolyl)-methyl)phenyl)-piperazine. The bath was removed and the mixture stirred for 1 h while it was warmed to room temperature. The reaction mixture was concentrated and the residue was partitioned between CH₂Cl₂ and dilute NaOH. The CH₂Cl₂ layer was washed with brine, dried and concentrated to give 0.047 g (69%) of the title compound which was used without purification. ¹H NMR (CDCl₃) δ 2.78 (m, 4 H), 3.02 (m, 4 H), 5.2 (s, 2 H), 6.89-7.4 (m, 6 H), 7.54 (s, 1 H).

20

Step E: 1-(3-((S)-3,4-Dichlorophenyl)-4-(N-3,5-dimethylbenzoyl)-(methylaminobutyl)-4-(2-((1'-imidazolyl)methyl)phenyl)piperazine
The reaction between 47 mg (0.19 mmol) of 4-(2-((1'-imidazolyl)methyl)phenyl)piperazine and 92 mg (0.24 mmol) of 3-((S)-

25 (3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)methylamino)-butanal
A solution of 1.15 g (3.96 mmol) of 1-t-butoxycarbonyl-4-(2-formyl-phenyl)-piperazine in 10 mL of MeOH was treated with 0.15 g (3.96 mmol) of NaBH₄. After 2 h the reaction was quenched by adding 1.2 N HCl and the mixture was extracted with EtOAc. The EtOAc solution was washed with water, brine and dried. The filtrate was concentrated to yield 1.1 g (85%) of 1-t-butoxycarbonyl-4-(2-hydroxymethyl-phenyl)-piperazine as a white foam which was used without purification. ¹H NMR (CDCl₃) δ 1.24 (s, 9 H), 2.92 (m, 4 H), 3.59 (m, 4 H), 4.84 (s, 2 H), 7.0-7.4 (m, 4 H).

30

Step E: 1-(3-((S)-3,4-Dichlorophenyl)-4-(N-3,5-dimethylbenzoyl)-(methylaminobutyl)-4-(2-((1'-imidazolyl)methyl)phenyl)piperazine
The reaction between 47 mg (0.19 mmol) of 4-(2-((1'-imidazolyl)methyl)phenyl)piperazine and 92 mg (0.24 mmol) of 3-((S)-

35

(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)methylamino)-butanal

according to the method of Example 1. Step E furnished 55 mg (47%) of the title compound. ¹H NMR (CDCl₃, ppm ranges are given because of amide rotamers and line broadening) δ 1.5-3.9 (m, 18 H), 2.27 (s, 6 H),

5.14 (s, 2 H), 6.6-7.6 (m, 13 H). Mass Spectrum (CI) 606 (37Cl + 35Cl isotope), 604 (35Cl + 35Cl isotope).

The compounds in Examples 10-14 were prepared by the procedure of Example 9 substituting the requisite heterocycle for imidazole in Step C and carrying out Step E with either 3-((S)-3,4-

10 dichlorophenyl)-4-((3,5-dimethylbenzoyl)methyl-amino)-butanal (from Example 1, Step A) or 3-((S)-3,4-dichlorophenyl)-4-((3,5-

dichlorobenzoyl)methyl-amino)-butanal (from Example 2, Step A).

EXAMPLE 10

1-3-((S)-3,4-Dichlorophenyl)-4-(N-3,5-dichlorobenzoyl)-(methyl-

amino)butyl)-4-(2-(1'-1',2',4'-triazoledimethylphenyl)-piperazine

Mass Spectrum (CI) 647 (37Cl + 35Cl isotope), 645 (35Cl + 35Cl isotope).

EXAMPLE 11

1-3-((S)-3,4-Dichlorophenyl)-4-(N-3,5-dimethylbenzoyl)-(methyl-

amino)butyl)-4-(2-(1'-1',2',4'-triazoledimethylphenyl)-piperazine

Mass Spectrum (CI) 607 (37Cl + 35Cl isotope), 605 (35Cl + 35Cl isotope).

EXAMPLE 12

1-3-((S)-3,4-Dichlorophenyl)-4-(N-3,5-dimethylbenzoyl)-(methyl-

amino)butyl)-4-(2-(1'-1',2',3',4'-tetraazolidimethylphenyl)-piperazine

Mass Spectrum (CI) 608 (37Cl + 35Cl isotope), 606 (35Cl + 35Cl isotope).

EXAMPLE 13

1-3-((S)-3,4-Dichlorophenyl)-4-(N-3,5-dimethylbenzoyl)-(methyl-

amino)butyl)-4-(2-(3-pyridyloxy)methylphenyl)-piperazine

The title compound was synthesized by the method of

Example 9 by substituting 3-hydroxypyridine for imidazole in Step C. Mass Spectrum (CI) 633 (37Cl + 35Cl isotope), 631 (35Cl + 35Cl isotope).

EXAMPLE 14

5 1-3-((S)-3,4-Dichlorophenyl)-4-(2-(1'-1',2',4'-triazoledimethylphenyl)-piperazine

The title compound was prepared according to Example 9 and using 2-hydroxypyridine in Step C. Mass Spectrum (CI) 633 (37Cl + 35Cl isotope), 631 (35Cl + 35Cl isotope).

EXAMPLE 15

1-3-((S)-3,4-Dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)-(methyl-

amino)butyl)-4-(2-methylphenyl)piperazine

15 Step A: 3-(S)-3,4-Dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)-methylamino)butanol

To a solution of 3-((S)-3,4-dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)methylamino)butanol (2.5 g) from Example 1, Step A) in 35 mL of methanol at 0°C was added portionwise over 5 min sodium

20 borohydride (400 mg). After stirring for 1 h at r.t., the reaction was slowly quenched with 2 N HCl and extracted twice with ethyl acetate. The organic layers were washed with brine, dried (Na₂SO₄), combined and evaporated to give 2.5 g (100%) of a crude oil. Residual water and methanol were removed by concentration from a portion of isopropyl acetate.

Step B:

4-Bromo-2-(S)-3,4-dichlorophenyl)-1-(N-(3,5-dimethyl-

benzoylmethylamino)butane

To a solution of crude 3-(S)-3,4-dichlorophenyl)-4-(N-(3,5-dimethylbenzoylmethylamino)butanol (2.5 gm) from Step A in 30 mL of acetonitrile was added 3.5 g (8.25 mmol) of triphenylphosphine dibromide.

The reaction was stirred at r.t. for 16 h and was then partitioned between ethyl ether and water. The organic layer was washed with brine, dried (Na₂SO₄) and concentrated. The residue was flash chromatographed with a solvent gradient of 25-40% EtOAc/Hexanes to give 2.6 g (89% from

Step A) of oil which solidified on standing. Mass Spectrum (ESI 80/20 MCuNH_2O , 0.01% TFA) $\text{M}+\text{H} = 441, 443, 445(35,37\text{Cl}, 79\text{Br}, 81\text{Br}$ -isotope).

Step C: $(3-((S)-3,4-\text{Dichlorophenyl}))\text{-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(2-methylphenyl)piperazine}$

A solution of 4-bromo-2-(S)-(3,4-dichlorophenyl)-1-(N-(3,5-dimethylbenzoyl)methylamino)butane prepared in Step B (50 mg), N,N-diisopropylethylamine (40 μl) and 1-(2-methylphenyl)-piperazine (40 mg) in 0.5 mL of acetonitrile was heated in a tightly capped vial at 50°C for four days. The solvent was evaporated and the residue was purified on a 1000 μm silica gel prep plate (4% MeOH/CH₂Cl₂) to furnish 30 mg (50%) of the title compound as a white foam.

Mass Spectrum (CluNH_3) $\text{M}+\text{H} = 537, 539$ (35,37Cl-isotope).

15 EXAMPLE 16

$1-((S)-(3,4-\text{Dichlorophenyl}))\text{-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(phenyl)piperazine}$

Following essentially the same procedure as in Example 15 but substituting 1-phenylpiperazine (35 mg), 30 mg (61%) of the title compound was prepared.

Mass Spectrum (CluNH_3) $\text{M}+\text{H} = 523, 525$ (35,37Cl-isotope).

15 EXAMPLE 17

$1-((S)-(3,4-\text{Dichlorophenyl}))\text{-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(9-(2-methoxymethyl)-2-methoxy-purin-6-yl)piperazine}$

The starting piperazine was prepared according to D.B. Johnston, M. MacCoss, S. Marburg, L. Meurer, and R. L. Tolman; U.S. Patent # 5,057,517. Mass Spectrum (CluNH_3) $\text{M}+\text{H} = 640, 642$ (35,37Cl-isotope).

20 EXAMPLE 19

$1-((S)-(3,4-\text{Dichlorophenyl}))\text{-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(9-methoxy-purin-6-yl)piperazine}$

The starting piperazine was prepared according to D.B. Johnston, M. MacCoss, S. Marburg, L. Meurer, and R. L. Tolman; U.S. Patent # 5,057,517. Mass Spectrum (CluNH_3) $\text{M}+\text{H} = 580, 582$ (35,37Cl-isotope).

25 EXAMPLE 20

$1-((S)-(3,4-\text{Dichlorophenyl}))\text{-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(9-methyl-purin-6-yl)piperazine}$

A mixture of 4-bromo-2-(S)-(3,4-dichlorophenyl)-1-(N-(3,5-dimethylbenzoyl)methylamino)butane prepared in Example 15, Step B above (43.5 mg), N,N-diisopropylethylamine (68 μl) and 9-(2-fluoroethyl)-2-methoxy-6-(1-piperazinyl)purine dihydrochloride (69 mg; prepared according to D.B. Johnston, M. MacCoss, S. Marburg, L. Meurer, and R. L. Tolman; U.S. Patent # 5,057,517) in 0.5 mL of acetonitrile was heated in a tightly capped vial at 50°C for four days. The solvent was evaporated and the residue was purified on a 1000 μm silica gel prep

plate (93:5:2 ethyl acetate:methanol:triethylamine) to furnish 32.5 mg of the title compound as a white foam.

Mass Spectrum (CluNH_3) $\text{M}+\text{H} = 642, 644$ (35,37Cl-isotope).

The compounds in Examples 18-30 were (unless otherwise stated) prepared from 4-bromo-2-(S)-(3,4-dichlorophenyl)-1-(N-(3,5-dimethylbenzoyl)methylamino)butane (prepared in Example 15, Step B) and the appropriate piperazine derivatives by essentially the same procedure as in Example 17.

10 EXAMPLE 18

$1-((S)-(3,4-\text{Dichlorophenyl}))\text{-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(9-(2-methoxymethyl)-2-methoxy-purin-6-yl)piperazine}$

The starting piperazine was prepared according to D.B. Johnston, M. MacCoss, S. Marburg, L. Meurer, and R. L. Tolman; U.S. Patent # 5,057,517. Mass Spectrum (CluNH_3) $\text{M}+\text{H} = 640, 642$ (35,37Cl-isotope).

15 EXAMPLE 19

$1-((S)-(3,4-\text{Dichlorophenyl}))\text{-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(9-methoxy-purin-6-yl)piperazine}$

The starting piperazine was prepared according to D.B. Johnston, M. MacCoss, S. Marburg, L. Meurer, and R. L. Tolman; U.S. Patent # 5,057,517. Mass Spectrum (CluNH_3) $\text{M}+\text{H} = 580, 582$ (35,37Cl-isotope).

20 EXAMPLE 20

$1-((S)-(3,4-\text{Dichlorophenyl}))\text{-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(9-methyl-purin-6-yl)piperazine}$

The starting piperazine was prepared according to D.B. Johnston, M. MacCoss, S. Marburg, L. Meurer, and R. L. Tolman; U.S. Patent # 5,057,517. Mass Spectrum (CluNH_3) $\text{M}+\text{H} = 580, 582$ (35,37Cl-isotope).

by analogy to 4-bromo-2-(S)-(3,4-dichlorophenyl)-1-(N-(3,5-dimethylbenzoyl)methylamino)butane in Example 15, Steps A and B) and the requisite piperazine, which was prepared according to D.B. Johnston, M. MacCoss, S. Marburg, L. Meurer, and R. L. Tolman; U.S. Patent # 5,057,517. Mass Spectrum (C₁₇NH₃) M+H = 546,548 (35,37/Cl-isotope).

5 **EXAMPLE 21**

10 1-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(6-methyl-1-imidazol-1,2-a)pyrazin-1-yl)piperazine
The starting piperazine was prepared according to L.C. Meurer, R.L. Tolman, E.W. Chapin, R. Saperstein, P.P. Vicario, M.F. Zrada and M. MacCoss, *J. Med. Chem.* 1992, 35, 3845-3857.

15 Mass Spectrum (C₁₇NH₃) M+H = 579, 581 (85,37/Cl-isotope).

10 **EXAMPLE 22**

20 1-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(1,7-naphthyridin-8-yl)piperazine
Step A: 8-(1-t-Butyloxycarbonyl)piperazine.

25 To a solution of 1.56 g (9.48 mmol) of 8-chloro-1,7-naphthyridine (J. Org. Chem. 1963, 28, 1753) in 100 mL of isoamyl alcohol was added 1-(t-butyloxycarbonyl)piperazine (6.36g, 34.15mmol). This solution was heated under reflux, under nitrogen for 2hr and then dissolved in CH₂Cl₂ (100mL), and 10% aq. Na₂CO₃ (100mL). After shaking, the layers were separated and the aqueous layer was washed with CH₂Cl₂ (2 x 100mL) and the pooled organic layers were dried (over MgSO₄), filtered, and evaporated to dryness. This oily residue was dissolved in a little CH₂Cl₂, absorbed onto silica gel 60, and chromatographed on a dry-packed silica gel 60 column (3.5 x 20.5 cm) developed with EtOAc : hexanes (1 : 3). Fractions containing the desired product were pooled and evaporated to dryness to give a thick yellow

15 syrup which crystallized on standing. Yield 2.78g (8.84mmol, 93% yield). Mass Spec. showed M⁺ at m/e 311, 313, 315, 317, 319, 321, 323, 325, 327, 329, 331, 333, 335, 337, 339, 341, 343, 345, 347, 349, 351, 353, 355, 357, 359, 361, 363, 365, 367, 369, 371, 373, 375, 377, 379, 381, 383, 385, 387, 389, 391, 393, 395, 397, 399, 401, 403, 405, 407, 409, 411, 413, 415, 417, 419, 421, 423, 425, 427, 429, 431, 433, 435, 437, 439, 441, 443, 445, 447, 449, 451, 453, 455, 457, 459, 461, 463, 465, 467, 469, 471, 473, 475, 477, 479, 481, 483, 485, 487, 489, 491, 493, 495, 497, 499, 501, 503, 505, 507, 509, 511, 513, 515, 517, 519, 521, 523, 525, 527, 529, 531, 533, 535, 537, 539, 541, 543, 545, 547, 549, 551, 553, 555, 557, 559, 561, 563, 565, 567, 569, 571, 573, 575, 577, 579, 581, 583, 585, 587, 589, 591, 593, 595, 597, 599, 601, 603, 605, 607, 609, 611, 613, 615, 617, 619, 621, 623, 625, 627, 629, 631, 633, 635, 637, 639, 641, 643, 645, 647, 649, 651, 653, 655, 657, 659, 661, 663, 665, 667, 669, 671, 673, 675, 677, 679, 681, 683, 685, 687, 689, 691, 693, 695, 697, 699, 701, 703, 705, 707, 709, 711, 713, 715, 717, 719, 721, 723, 725, 727, 729, 731, 733, 735, 737, 739, 741, 743, 745, 747, 749, 751, 753, 755, 757, 759, 761, 763, 765, 767, 769, 771, 773, 775, 777, 779, 781, 783, 785, 787, 789, 791, 793, 795, 797, 799, 801, 803, 805, 807, 809, 811, 813, 815, 817, 819, 821, 823, 825, 827, 829, 831, 833, 835, 837, 839, 841, 843, 845, 847, 849, 851, 853, 855, 857, 859, 861, 863, 865, 867, 869, 871, 873, 875, 877, 879, 881, 883, 885, 887, 889, 891, 893, 895, 897, 899, 901, 903, 905, 907, 909, 911, 913, 915, 917, 919, 921, 923, 925, 927, 929, 931, 933, 935, 937, 939, 941, 943, 945, 947, 949, 951, 953, 955, 957, 959, 961, 963, 965, 967, 969, 971, 973, 975, 977, 979, 981, 983, 985, 987, 989, 991, 993, 995, 997, 999, 1001, 1003, 1005, 1007, 1009, 1011, 1013, 1015, 1017, 1019, 1021, 1023, 1025, 1027, 1029, 1031, 1033, 1035, 1037, 1039, 1041, 1043, 1045, 1047, 1049, 1051, 1053, 1055, 1057, 1059, 1061, 1063, 1065, 1067, 1069, 1071, 1073, 1075, 1077, 1079, 1081, 1083, 1085, 1087, 1089, 1091, 1093, 1095, 1097, 1099, 1101, 1103, 1105, 1107, 1109, 1111, 1113, 1115, 1117, 1119, 1121, 1123, 1125, 1127, 1129, 1131, 1133, 1135, 1137, 1139, 1141, 1143, 1145, 1147, 1149, 1151, 1153, 1155, 1157, 1159, 1161, 1163, 1165, 1167, 1169, 1171, 1173, 1175, 1177, 1179, 1181, 1183, 1185, 1187, 1189, 1191, 1193, 1195, 1197, 1199, 1201, 1203, 1205, 1207, 1209, 1211, 1213, 1215, 1217, 1219, 1221, 1223, 1225, 1227, 1229, 1231, 1233, 1235, 1237, 1239, 1241, 1243, 1245, 1247, 1249, 1251, 1253, 1255, 1257, 1259, 1261, 1263, 1265, 1267, 1269, 1271, 1273, 1275, 1277, 1279, 1281, 1283, 1285, 1287, 1289, 1291, 1293, 1295, 1297, 1299, 1301, 1303, 1305, 1307, 1309, 1311, 1313, 1315, 1317, 1319, 1321, 1323, 1325, 1327, 1329, 1331, 1333, 1335, 1337, 1339, 1341, 1343, 1345, 1347, 1349, 1351, 1353, 1355, 1357, 1359, 1361, 1363, 1365, 1367, 1369, 1371, 1373, 1375, 1377, 1379, 1381, 1383, 1385, 1387, 1389, 1391, 1393, 1395, 1397, 1399, 1401, 1403, 1405, 1407, 1409, 1411, 1413, 1415, 1417, 1419, 1421, 1423, 1425, 1427, 1429, 1431, 1433, 1435, 1437, 1439, 1441, 1443, 1445, 1447, 1449, 1451, 1453, 1455, 1457, 1459, 1461, 1463, 1465, 1467, 1469, 1471, 1473, 1475, 1477, 1479, 1481, 1483, 1485, 1487, 1489, 1491, 1493, 1495, 1497, 1499, 1501, 1503, 1505, 1507, 1509, 1511, 1513, 1515, 1517, 1519, 1521, 1523, 1525, 1527, 1529, 1531, 1533, 1535, 1537, 1539, 1541, 1543, 1545, 1547, 1549, 1551, 1553, 1555, 1557, 1559, 1561, 1563, 1565, 1567, 1569, 1571, 1573, 1575, 1577, 1579, 1581, 1583, 1585, 1587, 1589, 1591, 1593, 1595, 1597, 1599, 1601, 1603, 1605, 1607, 1609, 1611, 1613, 1615, 1617, 1619, 1621, 1623, 1625, 1627, 1629, 1631, 1633, 1635, 1637, 1639, 1641, 1643, 1645, 1647, 1649, 1651, 1653, 1655, 1657, 1659, 1661, 1663, 1665, 1667, 1669, 1671, 1673, 1675, 1677, 1679, 1681, 1683, 1685, 1687, 1689, 1691, 1693, 1695, 1697, 1699, 1701, 1703, 1705, 1707, 1709, 1711, 1713, 1715, 1717, 1719, 1721, 1723, 1725, 1727, 1729, 1731, 1733, 1735, 1737, 1739, 1741, 1743, 1745, 1747, 1749, 1751, 1753, 1755, 1757, 1759, 1761, 1763, 1765, 1767, 1769, 1771, 1773, 1775, 1777, 1779, 1781, 1783, 1785, 1787, 1789, 1791, 1793, 1795, 1797, 1799, 1801, 1803, 1805, 1807, 1809, 1811, 1813, 1815, 1817, 1819, 1821, 1823, 1825, 1827, 1829, 1831, 1833, 1835, 1837, 1839, 1841, 1843, 1845, 1847, 1849, 1851, 1853, 1855, 1857, 1859, 1861, 1863, 1865, 1867, 1869, 1871, 1873, 1875, 1877, 1879, 1881, 1883, 1885, 1887, 1889, 1891, 1893, 1895, 1897, 1899, 1901, 1903, 1905, 1907, 1909, 1911, 1913, 1915, 1917, 1919, 1921, 1923, 1925, 1927, 1929, 1931, 1933, 1935, 1937, 1939, 1941, 1943, 1945, 1947, 1949, 1951, 1953, 1955, 1957, 1959, 1961, 1963, 1965, 1967, 1969, 1971, 1973, 1975, 1977, 1979, 1981, 1983, 1985, 1987, 1989, 1991, 1993, 1995, 1997, 1999, 2001, 2003, 2005, 2007, 2009, 2011, 2013, 2015, 2017, 2019, 2021, 2023, 2025, 2027, 2029, 2031, 2033, 2035, 2037, 2039, 2041, 2043, 2045, 2047, 2049, 2051, 2053, 2055, 2057, 2059, 2061, 2063, 2065, 2067, 2069, 2071, 2073, 2075, 2077, 2079, 2081, 2083, 2085, 2087, 2089, 2091, 2093, 2095, 2097, 2099, 2101, 2103, 2105, 2107, 2109, 2111, 2113, 2115, 2117, 2119, 2121, 2123, 2125, 2127, 2129, 2131, 2133, 2135, 2137, 2139, 2141, 2143, 2145, 2147, 2149, 2151, 2153, 2155, 2157, 2159, 2161, 2163, 2165, 2167, 2169, 2171, 2173, 2175, 2177, 2179, 2181, 2183, 2185, 2187, 2189, 2191, 2193, 2195, 2197, 2199, 2201, 2203, 2205, 2207, 2209, 2211, 2213, 2215, 2217, 2219, 2221, 2223, 2225, 2227, 2229, 2231, 2233, 2235, 2237, 2239, 2241, 2243, 2245, 2247, 2249, 2251, 2253, 2255, 2257, 2259, 2261, 2263, 2265, 2267, 2269, 2271, 2273, 2275, 2277, 2279, 2281, 2283, 2285, 2287, 2289, 2291, 2293, 2295, 2297, 2299, 2301, 2303, 2305, 2307, 2309, 2311, 2313, 2315, 2317, 2319, 2321, 2323, 2325, 2327, 2329, 2331, 2333, 2335, 2337, 2339, 2341, 2343, 2345, 2347, 2349, 2351, 2353, 2355, 2357, 2359, 2361, 2363, 2365, 2367, 2369, 2371, 2373, 2375, 2377, 2379, 2381, 2383, 2385, 2387, 2389, 2391, 2393, 2395, 2397, 2399, 2401, 2403, 2405, 2407, 2409, 2411, 2413, 2415, 2417, 2419, 2421, 2423, 2425, 2427, 2429, 2431, 2433, 2435, 2437, 2439, 2441, 2443, 2445, 2447, 2449, 2451, 2453, 2455, 2457, 2459, 2461, 2463, 2465, 2467, 2469, 2471, 2473, 2475, 2477, 2479, 2481, 2483, 2485, 2487, 2489, 2491, 2493, 2495, 2497, 2499, 2501, 2503, 2505, 2507, 2509, 2511, 2513, 2515, 2517, 2519, 2521, 2523, 2525, 2527, 2529, 2531, 2533, 2535, 2537, 2539, 2541, 2543, 2545, 2547, 2549, 2551, 2553, 2555, 2557, 2559, 2561, 2563, 2565, 2567, 2569, 2571, 2573, 2575, 2577, 2579, 2581, 2583, 2585, 2587, 2589, 2591, 2593, 2595, 2597, 2599, 2601, 2603, 2605, 2607, 2609, 2611, 2613, 2615, 2617, 2619, 2621, 2623, 2625, 2627, 2629, 2631, 2633, 2635, 2637, 2639, 2641, 2643, 2645, 2647, 2649, 2651, 2653, 2655, 2657, 2659, 2661, 2663, 2665, 2667, 2669, 2671, 2673, 2675, 2677, 2679, 2681, 2683, 2685, 2687, 2689, 2691, 2693, 2695, 2697, 2699, 2701, 2703, 2705, 2707, 2709, 2711, 2713, 2715, 2717, 2719, 2721, 2723, 2725, 2727, 2729, 2731, 2733, 2735, 2737, 2739, 2741, 2743, 2745, 2747, 2749, 2751, 2753, 2755, 2757, 2759, 2761, 2763, 2765, 2767, 2769, 2771, 2773, 2775, 2777, 2779, 2781, 2783, 2785, 2787, 2789, 2791, 2793, 2795, 2797, 2799, 2801, 2803, 2805, 2807, 2809, 2811, 2813, 2815, 2817, 2819, 2821, 2823, 2825, 2827, 2829, 2831, 2833, 2835, 2837, 2839, 2841, 2843, 2845, 2847, 2849, 2851, 2853, 2855, 2857, 2859, 2861, 2863, 2865, 2867, 2869, 2871, 2873, 2875, 2877, 2879, 2881, 2883, 2885, 2887, 2889, 2891, 2893, 2895, 2897, 2899, 2901, 2903, 2905, 2907, 2909, 2911, 2913, 2915, 2917, 2919, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, 2969, 2971, 2973, 2975, 2977, 2979, 2981, 2983, 2985, 2987, 2989, 2991, 2993, 2995, 2997, 2999, 3001, 3003, 3005, 3007, 3009, 3011, 3013, 3015, 3017, 3019, 3021, 3023, 3025, 3027, 3029, 3031, 3033, 3035, 3037, 3039, 3041, 3043, 3045, 3047, 3049, 3051, 3053, 3055, 3057, 3059, 3061, 3063, 3065, 3067, 3069, 3071, 3073, 3075, 3077, 3079, 3081, 3083, 3085, 3087, 3089, 3091, 3093, 3095, 3097, 3099, 3101, 3103, 3105, 3107, 3109, 3111, 3113, 3115, 3117, 3119, 3121, 3123, 3125, 3127, 3129, 3131, 3133, 3135, 3137, 3139, 3141, 3143, 3145, 3147, 3149, 3151, 3153, 3155, 3157, 3159, 3161, 3163, 3165, 3167, 3169, 3171, 3173, 3175, 3177, 3179, 3181, 3183, 3185, 3187, 3189, 3191, 3193, 3195, 3197, 3199, 3201, 3203, 3205, 3207, 3209, 3211, 3213, 3215, 3217, 3219, 3221, 3223, 3225, 3227, 3229, 3231, 3233, 3235, 3237, 3239, 3241, 3243, 3245, 3247, 3249, 3251, 3253, 3255, 3257, 3259, 3261, 3263, 3265, 3267, 3269, 3271, 3273, 3275, 3277, 3279, 3281, 3283, 3285, 3287, 3289, 3291, 3293, 3295, 3297, 3299, 3301, 3303, 3305, 3307, 3309, 3311, 3313, 3315, 3317, 3319, 3321, 3323, 3325, 3327, 3329, 3331, 3333, 3335, 3337, 3339, 3341, 3343, 3345, 3347, 3349, 3351, 3353, 3355, 3357, 3359, 3361, 3363, 3365, 3367, 3369, 3371, 3373, 3375, 3377, 3379, 3381, 3383, 3385, 3387, 3389, 3391, 3393, 3395, 3397, 3399, 3401, 3403, 3405, 3407, 3409, 3411, 3413, 3415, 3417, 3419, 3421, 3423, 3425, 3427, 3429, 3431, 3433, 3435, 3437, 3439, 3441, 3443, 3445, 3447, 3449, 3451, 3453, 3455, 3457, 3459, 3461, 3463, 3465, 3467, 3469, 3471, 3473, 3475, 3477, 3479, 3481, 3483, 3485, 3487, 3489, 3491, 3493, 3495, 3497, 3499, 3501, 3503, 3505, 3507, 3509, 3511, 3513, 3515, 3517, 3519, 3521, 3523, 3525, 3527, 3529, 3531, 3533, 3535, 3537, 3539, 3541, 3543, 3545, 3547, 3549, 3551, 3553, 3555, 3557, 3559, 3561, 3563, 3565, 3567, 3569, 3571, 3573, 3575, 3577, 3579, 3581, 3583, 3585, 3587, 3589, 3591, 3593, 3595, 3597, 3599, 3601, 3603, 3605, 3607, 3609, 3611, 3613, 3615, 3617, 3619, 3621, 3623, 3625, 3627, 3629, 3631, 3633, 3635, 3637, 3639, 3641, 3643, 3645, 3647, 3649, 3651, 3653, 3655, 3657, 3659, 3661, 3663, 3665, 3667, 3669, 3671, 3673, 3675, 3677, 3679, 3681, 3683, 3685, 3687, 3689, 3691, 3693, 3695, 3697, 3699, 3701, 3703, 3705, 3707, 3709, 3711, 3713, 3715, 3717, 3719, 3721, 3723, 3725, 3727, 3729, 3731, 3733, 3735, 3737, 3739, 3741, 3743, 3745, 3747, 3749, 3751, 3753, 3755, 3757, 3759, 3761, 3763, 3765, 3767, 3769, 3771, 3773, 3775, 3777, 3779, 3781, 3783, 3785, 3787, 3789, 3791, 3793, 3795, 3797, 3799, 3801, 3803, 3805, 3807, 3809, 3811, 3813, 3815, 3817, 3819, 3821, 3823, 3825, 3827, 3829, 3831,

This solution was heated under reflux, under nitrogen, for 2hr and then the mixture was evaporated to dryness under reduced pressure and the residue was dissolved in i-pentyl alcohol (76mL) and the reflux continued for 4hr. The reaction mixture was cooled and evaporated to dryness to give a yellow syrupy residue that was dissolved in CH_2Cl_2 (60mL) and 10% aq. Na_2CO_3 (60mL). After shaking, the layers were separated and the aqueous layer was washed with CH_2Cl_2 (2 x 60mL) and the pooled organic layers were dried (over MgSO_4), filtered, and evaporated to dryness. The residue was dissolved in a little CH_2Cl_2 , absorbed onto silica gel 60, and chromatographed on a dry-packed silica gel 60 column (3 x 36 cm) developed with EtOAc : hexanes (1 : 3). Fractions containing the required product were pooled and evaporated to dryness to give 2.15g (7.04mmol, 67% yield) of the title compound. Mass Spec. showed M^+ at m/e 304. Analysis calculated for $\text{C}_{14}\text{H}_{20}\text{N}_6\text{O}_2$ (304.35); C, 55.25; H, 6.62; N, 27.61. Found: C, 55.18; H, 6.58; N, 27.30

Step B:

8-(1-Piperazinyl)-1-(2,4-triazolo(1,5-a)pyrazine dihydrochloride

8-(1-(4-t-Butyloxycarbonyl)piperazinyl)-1-(2,4-triazolo(1,5-

a)pyrazine (1.18g, 3.86mmol), was dissolved in EtOH : EtOAc (1 : 1, 40mL) with warming and ethanolic HCl (10mL) was added.

Precipitation occurred immediately and the mixture was left at room temperature for 2 1/2 hr. The reaction mixture was blown down to dryness under a nitrogen stream and triturated under

$\text{EtOAc}/\text{Et}_2\text{O}$ and the white solid so obtained was filtered off and dissolved in $\text{CF}_3\text{CO}_2\text{H}$ (15mL) and then evaporated under a stream of nitrogen over a period of 1 1/2 hr. The residue so obtained was evaporated to dryness twice from H_2O and then dissolved in a little H_2O and passed down a Dowex 1x2 (OH-form) column (2 x 26 cm) packed and developed in H_2O . Fractions containing the required product were pooled and evaporated to dryness to give 0.78g (3.82mmol, 99% yield) of the title compound as the free base. This was dissolved in EtOH (15mL) with warming and ethanolic HCl was added. Immediate precipitation of the product occurred and this was filtered off after dilution with Et_2O to give

1.00g (3.61mmol, 94% yield overall) of the title compound. Analysis calculated for $\text{C}_{10}\text{H}_{14}\text{N}_6\text{Cl}_2\cdot 0.5\text{H}_2\text{O}$ (286.15): C, 37.77; H, 5.28; N, 29.37, Found: C, 37.63; H, 5.28; N, 29.23.

10 5 Step C: 1-(3-((S)-3,4-Dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(1,2,4-triazolo(1,5-a)pyrazin-8-yl)piperazine.

Reaction of 4-bromo-2-(S)-(3,4-dichlorophenyl)-1-(N-(3,5-dimethylbenzoyl)methylamino)butane with 8-(1-piperazinyl)-(1,2,4-triazolo(1,5-a)pyrazine dihydrochloride as described in example 17 gave the title compound. Mass Spectrum (Cl/NH_3) $\text{M}^+\text{H} = 566, 568$ (35,37Cl-isotope).

15 EXAMPLE 24

1-(3-((S)-3,4-Dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(5-methyl-pyrid-2-yl)piperazine.

The starting piperazine was prepared according to U.S. Patent # 4,876,256 (1989). Mass Spectrum (Cl/NH_3) $\text{M}^+\text{H} = 539, 541$ (35,37Cl-isotope).

EXAMPLE 25

1-(3-((S)-3,4-Dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(2-amino-pyrazin-4-yl)piperazine.

25 Step A: 2-Amino-4-(1-piperazinyl)pyrimidine dihydrochloride - 2-Amino-6-chloro-4-(1-piperazinyl)pyrimidine, prepared as described in *J. Med. Pharm. Chem.*, 5, 558 (1962), (1.07g, 5mmol) was suspended in EtOH (100mL) and heated and sonicated to effect maximum dissolution. MgO (0.75g) was added followed by 5% Pd on C (0.48g). The mixture was hydrogenated for 163/4 hr at room temperature and then was warmed and filtered while hot through a Celite pad, washing the pad well with hot EtOH . The filtrate was evaporated to a white solid residue (1.14g, quantitative yield). An analytical sample was

obtained by conversion to the dihydrochloride salt using ethanolic HCl in the usual fashion. Anal. Calc. for C₉H₁₅N₅Cl₂·0.1H₂O (253.94): C 37.84; H 6.03; N 27.58; Cl 27.92. Found: C 38.21; H 5.90; N 27.15; Cl 28.02.

5

Step B:

1-(3-((S)-3,4-Dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(2-amino-pyrazin-4-yl)piperazine

Reaction of 4-bromo-2-(S)-(3,4-dichlorophenyl)-1-(N-(3,5-dimethylbenzoyl)methylamino)butane with 2-amino-4-(1-piperazinyl)pyrimidine dihydrochloride according to the procedure given in Example 17 gave the title compound. Mass Spectrum (CI/NH₃) M+H = 541, 543 (35,37Cl-isotope).

15

EXAMPLE 26

1-(3-((S)-3,4-Dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(furo(2,3-c)pyrid-4-yl)piperazine

Step A:

1-(3-((S)-3,4-Dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(furo(2,3-c)pyrid-4-yl)piperazine

Step B: 1-(1-(4-t-Butyloxycarbonyl)piperazinyl)furo(2,3-c)pyridine

20 7-Chlorofuro(2,3-c)pyridine, prepared as described in *J. Heterocyclic Chem.*, **19**, 1207 (1982), (1.54g, 10mmol) and 1-(t-butylxycarbonyl)piperazine (7.45g, 40mmol) were mixed and heated at 180°C under nitrogen for 3hr, cooled, and the residue was partitioned between CHCl₃ (50mL) and 5% aqueous NaHCO₃ (30mL). The organic phase was dried and evaporated to dryness and the oil so obtained was dissolved in CHCl₃ and chromatographed on a column of silica gel, developed initially with CHCl₃ and then with hexanes : EtOAc (3 : 1). Fractions containing the required product were pooled and evaporated to dryness to give 1.90g of the title compound anal. Calc. for C₁₄H₂₂N₄O₃ (294.36): C 57.12; H 7.53; N 19.03

25

EXAMPLE 27

1-(3-((S)-3,4-Dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(2-amino-7,8-dihydro-6H-thiopyrano(3,2-c)pyrimid-4-yl)piperazine

The starting piperazine was prepared according to Kunch, Y., Iguchi, A., Gotch, M., Nomura, T., Shibata, M., Sakamoto, N. *Arch. Int. Pharmacodyn.* **1986**, 280, 302-313. Mass Spectrum (CI/NH₃) M+H = 613, 615 (35,37Cl-isotope).

15

EXAMPLE 28

1-(3-((S)-3,4-Dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(2-methyl-7,8-dihydro-6H-thiopyrano(3,2-c)pyrimid-4-yl)piperazine

The title compound was prepared by reaction of 4-bromo-2-(S)-(3,4-dichlorophenyl)-1-(N-(3,5-dimethylbenzoyl)methylamino)-butane (Example 15, Steps A and B) and 2-methyl-7,8-dihydro-4-piperazinyl-6H-thiopyrano(3,2-c)pyrimidine (prepared by analogy to the preparation of 2-amino-7,8-dihydro-4-piperazinyl-6H-thiopyrano(3,2-c)pyrimidine, as described in Ohno et al, UK Patent Application GB 2,119,368 A, 16 Nov.

30

EXAMPLE 29

1-(3-((S)-3,4-Dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(2-methyl-7,8-dihydro-4-piperazinyl-6H-thiopyrano(3,2-c)pyrimid-4-yl)piperazine

The title compound was prepared by deprotection of 7-1-(4-t-butyloxycarbonyl)piperazinyl)furo(2,3-c)pyridine with trifluoroacetic acid

in methylene chloride in the presence of anisole. The crude product was used immediately in Step C.

5

Step C: 1-(3-((S)-3,4-Dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(furo(2,3-c)pyrid-4-yl)piperazine

Reaction of 4-bromo-2-(S)-(3,4-dichlorophenyl)-1-(N-(3,5-dimethylbenzoyl)methylamino)butane with 7-(piperazinyl)furo(2,3-c)pyridine trifluoroacetate according to the procedure given in example 10 gave the title compound. Mass Spectrum (CI/NH₃) M+H = 565, 567 (35,37Cl-isotope).

in the reaction with ethyl 3-oxotetrahydrothiopyran-2-carboxylate according to the procedure given in Example 17. Mass Spectrum (Cl/NH_3) $M+H = 612, 614$ (35,37Cl-isotope).

EXAMPLE 29

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-bis(trifluoromethyl)benzoyl)-(methylamino)butyl)-4-(1,2,4-triazolo[1,5-a]pyrazin-8-yl)piperazine

The title compound was prepared by reaction of 4-bromo-2-(S)-3-(3,4-dichlorophenyl)-1-(N-(3,5-bis(trifluoromethyl)benzoyl)-methylamino)butane (prepared by analogy to 4-bromo-2-(S)-(3,4-dichlorophenyl)-1-(N-(3,5-dimethylbenzoyl)methylamino)butane in

Example 15, Steps A and B) and 8-(1-piperazinyl)-1-(2,4)-triazolo[1,5-a]pyrazine dihydrochloride (prepared in Example 23, Step B) according to the procedure given in Example 17. Mass Spectrum (Cl/NH_3) $M+H = 674$.

EXAMPLE 30

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-bis(trifluoromethyl)benzoyl)-(methylamino)butyl)-4-(1,2,4-triazolo[1,5-a]pyrazin-8-yl)piperazine

The title compound was prepared by reaction of 4-bromo-2-(S)-(4-chlorophenyl)-1-(N-(3,5-bis(trifluoromethyl)benzoyl)methylamino)butane (prepared by analogy to 4-bromo-2-(S)-(3,4-dichlorophenyl)-amino)butane in Example 15, Steps A and B) and 8-(1-piperazinyl)-1-(2,4)-triazolo[1,5-a]pyrazine dihydrochloride (prepared in Example 23, Step B) according to the procedure given in Example 17. Mass Spectrum (Cl/NH_3) $M+H = 640$.

EXAMPLE 31

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-bis(trifluoromethyl)benzoyl)-(methylamino)butyl)-4-(2-amino-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimid-4-yl)piperazine-5-oxide

EXAMPLE 32

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-bis(trifluoromethyl)benzoyl)-(methylamino)butyl)-4-(2-methyl-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimid-4-yl)piperazine-5-oxide

The title compound was prepared by following essentially the same procedure as in Example 31 but employing 1-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(2-methyl-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimid-4-yl)piperazine (from Example 28) as starting material. Mass Spectrum (Cl/NH_3) $M+H = 628$, 630 (35,37Cl-isotope).

EXAMPLE 33

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-bis(trifluoromethyl)benzoyl)-(methylamino)butyl)-4-(2-(tetrazolyl)methyl)phenyl)piperazine

30 Step A: 3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-bis(trifluoromethyl)benzoyl)methylamino)butanal

Following the procedure described in Example 1 step A, 3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-bis(trifluoromethyl)benzoyl)methylamino)butanal was prepared using 3,5-bis(trifluoromethyl)benzoic acid instead

A solution of 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(2-amino-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimid-4-yl)piperazine (13 mg; Example 27) in 5 mL of methanol at 0°C was treated with a solution of 17 mg of ozone in 0.5 mL of water. After three minutes the reaction was quenched with 10% aqueous sodium bisulfite and stirred for five minutes. The mixture was diluted with saturated sodium bicarbonate and extracted twice with dichloromethane. The combined organic layer was washed with brine, dried (Na_2SO_4) and evaporated to a clear oil. Purification on a 1000 um silica gel prep plate (9:1 $\text{CH}_2\text{Cl}_2:\text{MeOH}$) provided 4.6 mg of product as a white foam. Mass Spectrum (Cl/NH_3) $M+H = 629, 631$ (35,37Cl-isotope).

EXAMPLE 34

15 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-bis(trifluoromethyl)benzoyl)-(methylamino)butyl)-4-(2-methyl-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimid-4-yl)piperazine-5-oxide

The title compound was prepared by following essentially the same procedure as in Example 31 but employing 1-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(2-methyl-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimid-4-yl)piperazine (from Example 28) as starting material. Mass Spectrum (Cl/NH_3) $M+H = 628$, 630 (35,37Cl-isotope).

EXAMPLE 35

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-bis(trifluoromethyl)benzoyl)-(methylamino)butyl)-4-(2-(tetrazolyl)methyl)phenyl)piperazine

EXAMPLE 36

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-bis(trifluoromethyl)benzoyl)-(methylamino)butyl)-4-(2-(2-tetrazolyl)methyl)phenyl)piperazine

EXAMPLE 37

30 Step A: 3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-bis(trifluoromethyl)benzoyl)methylamino)butanal

Following the procedure described in Example 1 step A, 3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-bis(trifluoromethyl)benzoyl)methylamino)butanal was prepared using 3,5-bis(trifluoromethyl)benzoic acid instead

of 3,5-dimethylbenzoic acid. $^1\text{H-NMR}$ (500MHz CDCl_3) δ 2.5-4.0(8H, m), 6.7-8.0(6H, m), 9.78(1H, s).

Step B: 1-t-Butoxycarbonyl-4-(2-bromomethyl)phenyl)-piperazine

To 410mg (1.4mmol) of 1-t-butoxycarbonyl-4-(2-hydroxymethyl)phenyl)-piperazine (prepared in Example 9, Step B) in 12 mL of acetonitrile was added 625 mg (2.38mmol) of triphenylphosphine and 698mg (2.1mmol) of carbon tetrabromide with cooling in an ice-

water bath. After the mixture was stirred in a cold room (4°C) for 14hr, the solvent was removed under reduced pressure. The resulting oil was dissolved in EtOAc and water was then added. The phases were separated and the aqueous phase was extracted with two small portions of EtOAc. The combined organic phases were dried over anhydrous Na_2SO_4 , filtered, concentrated, and triturated with hexane. The triphenylphosphine oxide which precipitated was removed by filtration. The filtrate was concentrated to give the title compound, which was used in step C without further purification. $^1\text{H-NMR}$ (500MHz CDCl_3) δ 1.51(9H, s), 2.94(4H, m), 3.61(4H, s), 4.72(2H, s), 7.1-7.5(4H, m).

Step C: 1-t-Butoxycarbonyl-4-(2-(1'-tetrazolyl)methyl)phenyl)-piperazine and 1-t-Butoxycarbonyl-4-(2-(2-(tetrazolyl)methyl)phenyl)-piperazine

To a solution of 294mg (4.2mmol) of 1H-tetrazole in 9ml DMF was added 111mg (4.63mmol) sodium hydride at rt. After stirring for 10min, 9ml of the DMF solution of 1-t-butoxycarbonyl-4-(2-bromomethyl)phenyl)-piperazine prepared in step B was added, and the mixture was stirred in an oil bath at 70°C for 1.5hr. The DMF was then removed under reduced pressure. The resulting material was dissolved in EtOAc and sat. NH_4Cl aq. solution. The organic phase was separated and the aqueous phase was extracted twice with small portions of EtOAc. The combined organic phases were dried over anhydrous Na_2SO_4 , filtered, concentrated, and chromatographed on silica gel eluting with Hexane : EtOAc = 5 : 1 to 1 : 1 to give 144.3mg of 1-t-butoxycarbonyl-4-(2-(1'-tetrazolyl)methyl)phenyl)-piperazine (higher R_f), and 224.1mg of 1-t-

butoxycarbonyl-4-(2-(1'-tetrazolyl)methyl)-phenyl)-piperazine (lower R_f).

Step D: 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-bis(trifluoromethyl)benzoyl)-methyl)butyl)-4-(2-(2'-tetrazolyl)methyl)phenyl)-piperazine

$^1\text{H-NMR}$ (500MHz CDCl_3) δ 1.50(9H, s), 2.83(4H, s), 3.58(4H, s), 6.00(2H, s), 7.1-7.4(4H, m), 8.52(1H, s). Mass Spectrum (CI) 345 (M^++1). 1-t-

Butoxycarbonyl-4-(2-(1'-tetrazolyl)methyl)phenyl)-piperazine: $^1\text{H-NMR}$ (500MHz CDCl_3) δ 1.50(9H, s), 2.80(4H, s), 3.55(4H, s), 5.73(2H, s), 7.1-7.43(4H, m), 8.52(1H, s). Mass Spectrum (CI) 245($M^++\text{H-Boe}$)

Step D: 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-bis(trifluoromethyl)benzoyl)(methylamino))butyl)-4-(2-(2'-tetrazolyl)methyl)phenyl)-piperazine

was deprotected under the conditions given in Example 9, Step D, and the product was then reacted with 4-bromo-2-(S)-(3,4-dichlorophenyl)-4-(N-3,5-bis(trifluoromethyl)benzoyl)methyl-amino)butanal (prepared in step A) following the procedure described in Example 1 step E to give the title compound. MS(CI) 714($M^++\text{H}$)(35Cl_x2), 716(35Cl, 37Cl)

EXAMPLE 34

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-bis(trifluoromethyl)benzoyl)-methylamino)butyl)-4-(2-(1'-tetrazolyl)-methyl)phenyl)-piperazine

The title compound was prepared as following the procedure in Example 33, Step D using 1-t-butoxycarbonyl-4-(2-(1'-tetrazolyl)methyl)phenyl)-piperazine prepared in Example 33, Step C. MS(CI) 714($M^++\text{H}$)(35Cl_x2), 716(35Cl, 37Cl)

EXAMPLE 35

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-bis(trifluoromethyl)benzoyl)-(methylamino))butyl)-4-(2-(1', 2', 4-triazolyl)methyl)phenyl)-piperazine

Step A. 1-t-Butoxycarbonyl-4-(2-(1', 1', 2', 4'-triazoly)-methyl)-phenyl)-piperazine and 1-t-Butoxycarbonyl-4-(2-(4',1', 2', 4'-triazoly)-methyl)-phenyl)-piperazine

Following the procedure described in Example 33, Step C, the title compounds were prepared using 1,2,4-triazole instead of 1-H tetrazole. ⁵ 1-t-Butoxycarbonyl-4-(2-(1', 1', 2', 4'-triazoly)-methyl)-phenyl)-piperazine: ¹H-NMR(500MHz CDCl₃) δ 1.50(9H, s), 2.81(4H, s), 3.56(4H, s), 5.49(2H, s), 7.1-8.1(6H, m). Mass Spectrum (CI) 344(M⁺+H). 1-t-Butoxycarbonyl-4-(2-(4',1', 2', 4'-triazoly)-methyl)-phenyl)-piperazine: ¹H-NMR(500MHz CDCl₃) δ 1.50(9H, s), 2.79(4H, s), 3.56(4H, s), 5.29(2H, s), 7.1-7.42(4H, m), 8.21(2H, s). Mass Spectrum (CI) 344(M⁺+H).

Step B: 1-(3-((S)-3,4-Dichlorophenyl)-4-(N-3,5-bis-(trifluoromethyl)benzoyl)(methylamino)butyl)-4-(2-(1', 1', 2', 4'-triazoly)-methyl)-phenyl)-piperazine

According to the procedure described in Example 33, Step D, the title compound was prepared from 1-t-butoxycarbonyl-4-(2-(1', 1', 2', 4'-triazoly)-methyl)-phenyl)-piperazine. Mass Spectrum (CI) 713(M⁺+H, 35Clx2), 715(M⁺+H, 35Cl, 37Cl).

EXAMPLE 36

1-(3-((S)-3,4-Dichlorophenyl)-4-(N-3,5-bis-(trifluoromethyl)benzoyl)(methylamino)butyl)-4-(2-(4',1', 2', 4'-triazoly)-methyl)-phenyl)-piperazine

According to the procedure described in Example 33, Step D, the title compound was prepared from 1-t-butoxycarbonyl-4-(2-(4',1', 2', 4'-triazoly)-methyl)-phenyl)-piperazine prepared in Example 35, Step A. ²⁵ Mass Spectrum (CI) 713(M⁺+H, 35Clx2), 715(M⁺+H, 35Cl, 37Cl).

EXAMPLE 37

1-(3-((S)-3,4-Dichlorophenyl)-4-(N-3,5-bis-(trifluoromethyl)benzoyl)(methylamino)butyl)-4-(2-(1', 1', 2', 3'-triazoly)-methyl)-phenyl)-piperazine

Following the procedure described in Example 33, Step C, the title compound was prepared using 1,2,3-triazole instead of 1-H tetrazole. ⁵ 1-t-Butoxycarbonyl-4-(2-(1', 1', 2', 3'-triazoly)-methyl)-phenyl)-piperazine: ¹H-NMR(400MHz CDCl₃) δ 1.46(9H, s), 2.78(4H, s), 3.55(4H, s), 5.70(2H, s), 7.05-7.75(6H, s).

Step A. 1-t-Butoxycarbonyl-4-(2-(1', 2', 3'-triazoly)-methyl)-phenyl)-piperazine

The title compound was prepared according to the procedure described in Example 33, Step C using 1,2,3-triazole instead of 1-H tetrazole. ¹H-NMR(400MHz CDCl₃) δ 1.46(9H, s), 2.78(4H, s), 3.55(4H, s), 5.70(2H, s), 7.05-7.75(6H, s).

Step B: 1-(3-((S)-3,4-Dichlorophenyl)-4-(N-3,5-bis-(trifluoromethyl)benzoyl)(methylamino)butyl)-4-(2-(1', 1', 2', 3'-triazoly)-methyl)-phenyl)-piperazine

Following the procedure described in Example 33, Step D, the title compound was prepared using 1-t-butoxycarbonyl-4-(2-(1', 2', 3'-triazoly)-methyl)-phenyl)-piperazine. MS(CI) 713(M⁺+H, 35Clx2), 715(M⁺+H, 35Cl, 37Cl).

EXAMPLE 38

1-(3-((S)-3,4-Dichlorophenyl)-4-(N-3,5-bis-(trifluoromethyl)benzoyl)(methylamino)butyl)-4-(2-(methanesulfonylamino)methyl)-phenyl)-piperazine

Step A: 1-t-Butoxycarbonyl-4-(2-(methanesulfonylamino)methyl)-phenyl)-piperazine

The piperazine synthesized in Example 1, Step C was subjected to the condition described in Example 1 Step D using methanesulfonyl chloride instead of acetyl chloride. ²⁵

Step B: 1-(3-((S)-3,4-Dichlorophenyl)-4-(N-3,5-bis-(trifluoromethyl)benzoyl)(methylamino)butyl)-4-(2-(methanesulfonylamino)methyl)-phenyl)-piperazine

The piperazine obtained in Step A was reacted with the aldehyde prepared in Example 33, Step A following the conditions described in Example 1, Step E to give the title compound. MS(CI) 739(M⁺+H)(35Clx2), 741(M⁺+H)(35Cl, 37Cl).

EXAMPLE 39

5

1-(3-((S)-(4-Chlorophenyl))-4-(N-3,5-bis-(trifluoromethyl)benzoyl)-(methylamino)butyl)-4-(2-(1', 2', 3', 4'-tetrazolyl)-methyl)-phenyl)-piperazine

1-t-Butoxy-carbonyl-4-(2-(1', 2', 3', 4'-tetrazolyl)-methyl)-phenyl)-piperazine

1-(3-((S)-(4-Chlorophenyl))-4-(N-3,5-bis-(trifluoromethyl)-(methylamino)butyl)-4-(2-(4'-1', 2', 4'-triazolyl)methyl)-phenyl)-piperazine

MS(Cl) 679(M⁺⁺H)

EXAMPLE 42

5

1-(3-((S)-(4-Chlorophenyl))-4-(N-3,5-bis-(trifluoromethyl)benzoyl)-(methylamino)butyl)-4-(2-(4'-1', 2', 4'-triazolyl)methyl)-phenyl)-piperazine

MS(Cl) 679(M⁺⁺H)

EXAMPLE 43

10

1-(3-((S)-(4-Chlorophenyl))-4-(N-3,5-bis-(trifluoromethyl)-benzoyl)(methylamino)butyl)-4-(2-(1', 2', 3'-triazolyl)-methyl)-phenyl)-piperazine

MS(Cl) 679(M⁺⁺H)

EXAMPLE 44

15

1-(3-((S)-(4-Chlorophenyl))-4-(N-3,5-bis-(trifluoromethyl)benzoyl)-(methylamino)butyl)-4-(2-(methanesulfonylamino)methyl)-phenyl)-piperazine

MS(Cl) 705(M⁺⁺H)

EXAMPLE 45

20

1-(3-((S)-(4-Chlorophenyl))-4-(N-3-fluoro-5-(trifluoromethyl)-(methylamino)butyl)-4-(2-(1'-tetrazolyl)-methyl)-phenyl)-piperazine

MS(Cl) 680(M⁺⁺H)

EXAMPLE 46

25

1-(3-((S)-(4-Chlorophenyl))-4-(N-3-fluoro-5-(trifluoromethyl)-(methylamino)butyl)-4-(2-(1'-tetrazolyl)-methyl)-phenyl)-piperazine

MS(Cl) 680(M⁺⁺H)

EXAMPLE 47

30

3-((S)-(3,4-Dichlorophenyl))-4-(3-fluoro-5-(trifluoromethyl)-dimethylbenzoyl)methyl-amino-butanal

The title compound was prepared following the procedure described in Example 1, Step A using 3-fluoro-5-trifluoromethylbenzoic acid instead of 3,5-dimethylbenzoic acid.

Step B: 4-Bromo-2-((S)(3,4-Dichlorophenyl))-4-(N-3-fluoro-5-trifluoromethylbenzoyl)methylamino-butane

MS(Cl) 679(M⁺⁺H)

The aldehyde prepared in Step A was treated with the conditions described in Example 15, Steps A and B to give the title compound.

Step C: 1-(3-((S)-3,4-Dichlorophenyl)-4-(N-3-fluoro-5-(trifluoromethyl)-tetrazolyl)-methyl)benzoyl(methylamino))butyl)-4-(2-(1'-tetrazolyl)-methyl)phenyl)-piperazine

1-t-Butoxycarbonyl-4-(2-(1'-tetrazolyl)methyl)phenyl)-piperazine

(prepared in Example 33, Step C) was deprotected according to the conditions in Example 9, Step D and the product was carried on

according to Example 1, Step E using the aldehyde prepared in Step A above to give the title compound. MS(CI) 664(M⁺+H)(35Cl_x2),

666(M⁺+H)(35Cl, 37Cl)

EXAMPLE 46

15

1-(3-((S)-3,4-Dichlorophenyl)-4-(N-3-fluoro-5-(trifluoromethyl)-benzoyl(methylamino))butyl)-4-(2-(1'-tetrazolyl)-methyl)phenyl)-piperazine

10

20

1-t-Butoxycarbonyl-4-(2-(2-(1'-tetrazolyl)-methyl)phenyl)-piperazine (prepared in Example 33, Step C) was subjected to the conditions described in Example 45, Step C to give the title compound. MS(CI) 664(M⁺+H)(35Cl_x2), 666(M⁺+H)(35Cl, 37Cl)

EXAMPLE 47

15

1-(3-((S)-3,4-Dichlorophenyl)-4-(N-3-fluoro-5-(trifluoromethyl)-benzoyl(methylamino))butyl)-4-(2-(methanesulfonylamino)methyl)-phenyl)-piperazine

10

20

1-t-Butoxycarbonyl-4-(2-(methanesulfonylamino)methyl)phenyl)-piperazine prepared in Example 38, Step A was subjected to the conditions described in Example 45, Step C to give the title compound. MS(CI) 669(M⁺+H)(35Cl_x2), 691(M⁺+H)(35Cl, 37Cl)

Step B: 3-(R)-3,4-Dichlorophenyl)-hex-4-enoic acid

To a solution of the above diazoketone 4.55g (17.0mmol) in

25

340mL of tetrahydrofuran was added 170mL aqueous solution of silver nitrate 3.02g (17.8mmol). After stirring at rt overnight, tetrahydrofuran was removed under reduced pressure. The remaining aqueous layer was extracted with two 100mL portions of dichloromethane. The

30

combined organic phases were washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated. The resulting material was purified by silica gel column chromatography. Elution with dichloromethane : methanol = 10 : 1 gave 3.94g (90%) of 3-(R)-3,4-dichlorophenyl)-hex-4-enoic acid.

EXAMPLE 48

35

- 95 -

- 96 -

Step C: 3-(3(S)-[3,4-Dichlorophenyl]-2(S)-azido-1-oxo-5-hexenyl)-4(S)-benzyl-2-oxazolidinone

A solution of 3-(3(S)-[3,4-dichlorophenyl]-1-oxo-5-hexenyl)-4(S)-benzyl-2-oxazolidinone (190 mg, 0.45 mmol; prepared from 3-(R)-3,4-dichlorophenyl)-hex-4-enoic acid (from Step B above) and 4(S)-benzyl-2-oxazolidinone according to the procedure of Evans, D. A., et. al. *J. Am. Chem. Soc.* 1990, 112, 4011-4030) in THF (2.5 mL) was added to a solution of KHMDS (1.0 mL of 0.5 M in PhCH₃, 0.50 mmol), and THF (1.5 mL) at 78°C. The reaction was maintained at -78°C for 30 min whereupon a solution of trityl azide (177 mg, 0.57 mmol) and THF (1.5 mL) was added. The mixture was stirred for 2 min and HOAc (0.13 mL, 4.6 mmol) was added. The reaction mixture was stirred 1 h in a 30°C water bath, whereupon it was diluted with H₂O (60 mL) and extracted with CH₂Cl₂ (3 x 30 mL). The combined organic extracts were washed with sat. aq. NaHCO₃, brine, dried (MgSO₄) and concentrated in vacuo. The residue was purified by column chromatography (silica gel 60, 15-25% EtOAc/hexanes) to afford the title compound (169 mg, 81%) as a colorless oil. ¹H NMR (CDCl₃, 500 MHz) δ 7.44 (d, 1H, J = 8.2 Hz), 7.20-7.46 (m, 6H), 7.15 (d, 1H, J = 8.3 Hz), 5.58-5.65 (m, 1H), 5.45 (d, 1H, J = 8.4 Hz), 5.03-5.05 (m, 1H), 4.97-5.02 (m, 1H), 4.64-4.70 (m, 1H), 4.26-4.34 (m, 2H), 3.28-3.36 (m, 2H), 2.88 (dd, 1H, J = 9.1, 18.5 Hz), 2.47 (t, 2H, J = 7.3 Hz) ppm.

Step D: 2(S)-Azido-3(S)-[3,4-dichlorophenyl]-5-hexen-1-ol

To a solution of 3-(3(S)-[3,4-dichlorophenyl]-2(S)-azido-1-oxo-5-hexenyl)-4(S)-benzyl-2-oxazolidinone (890 mg, 1.94 mmol) and THF (25 mL) at 0°C was added MeOH (128 mL, 3.1 mmol), followed by LiBH₄ (68 mg, 3.1 mmol). The mixture was allowed to stir for 2 h, and was then quenched by addition of sat. aq. Rochelle salts (50 mL) and was allowed to warm to room temp and stirred vigorously for 2 h. The mixture was diluted with H₂O (150 mL) and extracted with CH₂Cl₂ (3 x 100 mL). The combined organic extracts were washed with brine, dried (Na₂SO₄) and concentrated in vacuo. The residue was purified by column chromatography (silica gel 60, 10-40% EtOAc/hexanes) to afford the alcohol (452 mg, 82%) as a colorless oil. ¹H NMR (CDCl₃, 500 MHz) δ 7.36-7.42 (m, 2H), 7.10 (dd, 1H, J = 2.1, 8.2 Hz), 5.59-5.69 (m, 1H), 5.09 (dd, 1H, J = 1.4, 17.1 Hz), 5.05 (dd, 1H, J = 0.9, 10.3 Hz), 3.77-3.85 (m, 1H), 3.65 (dd, 1H, J = 4.5, 11.2 Hz), 3.52 (dd, 1H, J = 7.6, 17.3 Hz), 2.88-2.95 (m, 1H), 2.55-2.64 (m, 1H), 2.43-2.52 (m, 1H), 1.28-1.34 (m, 1H) ppm. FTIR 3383, 2930, 2102, 1471, 1271, 1030, 930 cm⁻¹.

Step E: 2(S)-Amino-3(S)-[3,4-dichlorophenyl]-5-hexen-1-ol

A solution of 2(S)-azido-3(S)-[3,4-dichlorophenyl]-5-hexen-1-ol (620 mg, 2.17 mmol) and PPh₃ (682 mg, 2.60 mmol) in 4:1 THF/H₂O (20 mL) was stirred at room temp for 14 h and then heated to 65°C for 2 h. The reaction mixture was concentrated, and the residue diluted with H₂O (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with brine, dried (Na₂SO₄) and concentrated in vacuo. The residue was purified by column chromatography (silica gel 60, 2.5-8% MeOH/CH₂Cl₂) to afford the amino alcohol (260 mg, 46%) as a colorless oil. ¹H NMR (CDCl₃, 500 MHz) δ 7.40 (d, 1H, J = 8.3 Hz), 7.25-7.31 (m, 1H), 7.04 (dd, 1H, J = 1.9, 8.1 Hz), 5.51-5.61 (m, 1H), 4.92-5.03 (m, 2H), 3.68 (dd, 1H, J = 4.1, 10.7 Hz), 3.39 (dd, 1H, J = 7.4, 10.6 Hz), 3.01-3.08 (m, 1H), 2.68-2.75 (m, 1H), 2.49-2.56 (m, 1H), 2.32-2.41 (m, 1H) ppm.

Step F: 4(S)-1(S)-[3,4-Dichlorophenyl]-3-butenyl)-2-oxazolidinone

A solution of 2(S)-amino-3(S)-[3,4-dichlorophenyl]-5-hexen-1-ol (3.85 g, 14.8 mmol) and triphosgene (4.39 g, 14.8 mmol) in THF (100 mL) was stirred at room temp for 2 h. The reaction mixture was concentrated in vacuo and the residue was purified by column chromatography (silica gel 60, 1.5% MeOH/CH₂Cl₂) to afford the oxazolidinone (3.35 g, 79%) as a colorless solid. ¹H NMR (CDCl₃, 500 MHz) δ 7.45 (d, 1H, J = 8.2 Hz), 7.25-7.31 (m, 1H), 7.05 (dd, 1H, J = 2.1, 8.3 Hz), 5.50-5.62 (m, 1H), 4.99-5.16 (m, 2H), 4.56 (t, 1H, J = 8.7 Hz), 4.21 (dd, 1H, J = 6.4, 9.0 Hz), 4.00-4.08 (m, 1H), 2.73-2.80 (m, 1H), 2.30-2.43 (m, 2H) ppm.

Step G: 4(S)-1(S)-[3,4-Dichlorophenyl]-3-butene-1,2-oxazolidinone

chromatography (silica gel 60, 10-40% EtOAc/hexanes) to afford the alcohol (452 mg, 82%) as a colorless oil. ¹H NMR (CDCl₃, 500 MHz) δ 7.36-7.42 (m, 2H), 7.10 (dd, 1H, J = 2.1, 8.2 Hz), 5.59-5.69 (m, 1H), 5.09 (dd, 1H, J = 1.4, 17.1 Hz), 5.05 (dd, 1H, J = 0.9, 10.3 Hz), 3.77-3.85 (m, 1H), 3.65 (dd, 1H, J = 4.5, 11.2 Hz), 3.52 (dd, 1H, J = 7.6, 17.3 Hz), 2.88-2.95 (m, 1H), 2.55-2.64 (m, 1H), 2.43-2.52 (m, 1H), 1.28-1.34 (m, 1H) ppm. FTIR 3383, 2930, 2102, 1471, 1271, 1030, 930 cm⁻¹.

10 a solution of 4(S)-[1(S)-3,4-dichlorophenyl]-3-but enyl]-2-oxazolidinone (3.25 g, 11.4 mmol) in DMF (25 mL) at room temp was

5 added NaH (57.3 mg, 95%, 2.27 mmol). The mixture was stirred for 20 min whereupon MeI (3.54 mL, 57.0 mmol) freshly filtered through basic alumina was added and the resultant reaction mixture was stirred at

δ = 1.9, 8.1 Hz, 7.15-7.38 (m, 4H), 7.09 (dd, 1H, J = 2.1, 8.3 Hz), 5.66 (s, 2H), 4.26 (t, 1H, J = 8.9 Hz), 4.17 (dd, 1H, J = 6.2, 9.2 Hz), 3.82-3.90 (m, 1H), 3.07-3.14 (m, 1H), 2.80-2.92 (m, 4H), 2.73 (s, 3H), 2.50-2.61 (m, 2H), 2.38-2.50 (m, 2H), 2.20-2.33 (m, 2H), 1.65-1.90 (m, 3H) ppm.

70°C for 14 h. The cooled reaction mixture was diluted with H₂O (250 mL) and extracted with EtOAc (3 x 125 mL). The combined organic

extracts were washed with H_2O (3 x 100 mL), brine, dried (Na_2SO_4) and concentrated in vacuo. The residue was purified by column chromatography (silica gel 60, 1.5% $\text{MeOH}/(\text{CH}_2\text{Cl}_2)$) to afford the title compound (2.93 g, 86%) as a colorless solid and recovered starting material (382 mg, 11%). ^1H NMR (CDCl_3 , 500 MHz) δ 7.45 (d, 1H, J = 8.3 Hz), 7.25-7.31 (m, 1H), 7.06 (dd, 1H, J = 2.1, 8.2 Hz), 5.52-5.62 (m, 1H), 4.99-5.08 (m, 2H), 4.12-4.26 (m, 2H), 3.82-3.90 (m, 1H), 3.00-3.07 (m, 1H), 2.75 (s, 3H), 2.38-2.49 (m, 2H) ppm. FTIR 2922, 1747, 1472, 1433, 1405, 1122, 1030, 914, 733 cm^{-1} .

Step H: $4(S)\text{-}(1(S)\text{-}(3,4\text{-Dichlorophenyl)\text{-}3\text{-oxopropyl)\text{-}3\text{-methyl\text{-}2\text{-}}}$

111

dichlorophenyl)-3-butenyl]-3-methyl-2-oxazolidinone (prepared in Step G

above) as in Example 1, Step A to afford the aldehyde (98%). ¹H NMR (CDCl₃, 500 MHz) δ 9.76 (s, 1H), 7.45 (d, 1H, J = 8.4 Hz), 7.25-7.31 (m, 1H), 7.06 (dd, 1H, J = 2.0, 8.5 Hz), 4.15-4.20 (m, 1H), 4.10 (dd, 1H, J = 5.5 Hz, 9.2 Hz), 3.88-3.94 (m, 1H), 3.72-3.78 (m, 1H), 2.99 (ddd, 1H, J = 0.9, 9.8, 17.8 Hz), 2.84 (s, 3H), 2.79 (dd, 1H, J = 4.1, 17.9 Hz) ppm.

Step I:
4(S)-(1(S)-(3,4-Dichlorophenyl)-3-(4-(2-(1'-tetrazolyl)-methyl)phenyl)-1-piperazinyl)-propyl)-3-methyl-2-oxazolidinone

5 dichloropropenyl-3-oxopropyl)-3-methyl-2-oxazolidinone (prepared in Step H above) and 1-(2-(1'-*tert*-butyl-1-methyl)phenyl)piperazine (prepared according to the procedure in Example 34) as in Example 1, Step E. ¹H NMR (CDCl_3 , 500 MHz) δ 8.52 (s, 1H), 7.47 (d, 1H, J = 8.3 Hz), 7.42 (dt, 1H,

66

2.62 (m, 2H), 2.40-2.51 (m, 2H), 2.31 (s, 3H), 2.14-2.22 (m, 3H), 2.04-2.14 (m, 2H) ppm.

Step K: 1-(3-((S)-(3,4-Dichlorophenyl))-4-((S)-(N-3,5-bis-(trifluoro-

(tetrazolyl)-methylphenyl-piperazine

To a solution of 2(S)-amino-3(S)-[4,4-dichlorophenyl]-5-(4-(2-nitro-1-(tetrazolyl))-methylphenyl)-1-piperazinyl)-pentan-1-ol (24 mg, 0.048 mmol) and CH_2Cl_2 (1.5 mL) at 0°C was added Et_3N (13.3 mL, 0.096 mmol), and 3,5-bis(trifluoromethyl)benzoyl chloride (9.0 mL, 0.050 mmol). The resultant reaction mixture was stirred 30 min at 0°C whereupon it was purified directly, without concentration, by column

chromatography (silica gel 60, 25.8 % MeOH/CH₂Cl₂) to afford the title compound (26 mg) as a colorless solid. Mass spectrum (CI): m/z = 744 (35Cl + 35Cl isotope + H⁺), 746 (37Cl + 35Cl isotope + H⁺).

EXAMPLE 49

- 100 -

1-(3-((S)-(3,4-Dichlorophenyl))-4-((S)-(N-3,5-bis-(trifluoromethyl)-benzoyl)(methylamino))-5-hydroxy-pentyl)-4-(2-(1-(1',2',4'-triazolyl)-methyl)phenyl)-piperazine

5 **Step A:** 4(S)-1(S)-(3,4-Dichlorophenyl)-3-(4-(2-(1'-1',2',4'-triazolyl)-methyl)phenyl)-1-piperazinyl-propyl)-3-methyl-2-oxazolidinone

The title compound was prepared (98%) from 4(S)-1(S)-(3,4-dichlorophenyl)-3-oxopropyl)-3-methyl-2-oxazolidinone (prepared in Example 48, Step H) and 1-(2-(1'-1',2',4'-triazolyl)-methyl)phenyl-piperazine (prepared according to the procedure in Example 33, Step D) as in Example 1, Step E. ^1H NMR (CDCl_3 , 500 MHz) δ 8.08 (s, 1H), 7.94 (s, 1H), 7.68 (dd, 1H, J = 7.1, 12.1 Hz), 7.45-7.60 (m, 2H), 7.32-7.40 (m, 2H), 7.09 (dd, 1H, J = 2.1, 8.2 Hz), 5.44 (s, 2H), 4.27 (t, 1H, J = 9.0 Hz), 4.17 (dd, 1H, J = 6.1, 9.1 Hz), 3.82-3.88 (m, 1H), 3.08-3.16 (m, 1H), 2.82-2.94 (m, 4H), 2.73 (s, 3H), 2.52-2.63 (m, 2H), 2.42-2.51 (m, 2H), 2.20-2.34 (m, 2H), 1.71-1.93 (m, 3H) ppm.

20 **Step B:** 2(S)-Amino-3(S)-(3,4-dichlorophenyl)-5-(4-(2-(1'-1',2',4'-triazolyl)-methyl)phenyl)-pentan-1-ol

To a solution of 4(S)-1(S)-(3,4-dichlorophenyl)-3-(4-(2-(1'-1',2',4'-triazolyl)-methyl)phenyl)-1-piperazinyl-propyl)-3-methyl-2-oxazolidinone (78 mg, 0.147 mmol) and EtOH (2 mL) was added 1M aq KOH (2 mL). The resultant mixture was heated to 85°C for 14 h. The cooled mixture was then diluted with H_2O (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with brine, dried (Na_2SO_4), and concentrated *in vacuo* yielding the amino alcohol (71 mg, 96%) as a colorless solid. ^1H NMR (CDCl_3 , 500 MHz) δ 8.08 (s, 1H), 7.95 (s, 1H), 7.06-7.72 (m, 7H), 5.44 (s, 2H), 3.77 (dd, 1H, J = 3.7, 11.5 Hz), 3.60 (dd, 1H, J = 3.9, 11.2 Hz), 2.80-2.96 (m, 4H), 2.61-2.67 (m, 1H), 2.53-2.61 (m, 2H), 2.42-2.52 (m, 2H), 2.32 (s, 3H), 2.16-2.27 (m, 3H), 2.07-2.15 (m, 2H) ppm.

35 **Step C:** 1-(3-((S)-(3,4-Dichlorophenyl))-4-((S)-(N-3,5-bis-(trifluoromethyl)(methylamino))-5-hydroxy-

pentyl)-4-(2-(1'-1',2',4'-triazolyl)-methyl)phenyl)-piperazine

To a solution of 2(S)-amino-3(S)-(3,4-dichlorophenyl)-5-(4-(2-(1'-1',2',4'-triazolyl)-methyl)phenyl)-pentan-1-ol (22 mg, 0.044 mmol) and CH_2Cl_2 (1.5 mL) at 0°C was added Et_3N (12.0 mL, 0.088 mmol), and 3,5-bis(trifluoromethyl)benzoyl chloride (8.3 mmol). The resultant reaction mixture was stirred 30 min at 0°C whereupon it was purified directly, without concentration, by column chromatography (silica gel 60, 2.5-3 % $\text{MeOH}/\text{CH}_2\text{Cl}_2$) to afford the title compound (20 mg) as a colorless solid. Mass spectrum (CD): m/z = 743 ($35\text{Cl} + 35\text{Cl}$ isotope + H^+), 745 ($37\text{Cl} + 35\text{Cl}$ isotope + H^+).

EXAMPLE 50

15 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(2-(methylthiomethyl)phenyl)-piperazine

20 **Step A:** 1-t-Butoxycarbonyl-4-(2-(methylthiomethyl)phenyl)-piperazine

Potassium t-butoxide (159 mg, 1.42 mmol) in 15 mL of abs. EtOH was saturated with methyl mercaptan gas. To this mixture was added 1-t-butoxycarbonyl-4-(2-(methylthiomethyl)phenyl)-piperazine (0.94 mmol, which was generated according to the procedure described in Step C of Example 9). The resulting mixture was refluxed for 50 min and concentrated. The residue was purified by preparative TLC (20% EtOAc in Hex) to give the title compound (157 mg). ^1H NMR (200 MHz, CDCl_3) δ 1.47 (s, 9H), 2.05 (s, 3H), 2.87 (t, 4H), 3.55 (t, 4H), 3.80 (s, 2H), 7.08 (m, 2H), 7.20 (dd, 1H), 7.35 (dd, 1H).

30 **Step B:** 1-(2-(Methylthiomethyl)phenyl)-piperazine

The title compound was prepared from 1-t-butoxycarbonyl-4-(2-(methylthiomethyl)phenyl)-piperazine (from Step A above) according to the procedure given in Example 9, Step D, and was used below without further purification.

35

Step C: 1-(3-((S)-3,4-Dichlorophenyl)-4-(N-3,5-dimethylbenzoyl)-(methylthiomethylphenyl)-butyl)-piperazine

The title compound was prepared from 1-(2-(methylthiomethylphenyl)butyl)-piperazine (from Step B above) and 3-((S)-3,4-dichlorophenyl)-4-((3,5-dimethylbenzoyl)methylamino)-butanal (see Example 1, Step A) according to the procedure given in Example 1, Step E. ¹H NMR (400 MHz, CDCl₃) δ 2.02 (s, 3H), 2.26 (s, 6H), 3.76 (s, 2H). Mass Spectrum (CI) m/z 584, 586 (M⁺1, M⁺3).

10

EXAMPLE 51

1-(3-((S)-3,4-Dichlorophenyl)-4-(N-3,5-bis(trifluoromethylbenzoyl)-(methylamino)-butyl)-4-(2-(methylthiomethylphenyl)-butyl)-piperazine

15 The title compound was prepared by analogy to the procedure given in Example 50, Step C, using 3-((S)-3,4-dichlorophenyl)-4-((3,5-bis(trifluoromethylbenzoyl)methylamino)-butanal (from Example 33, Step A) instead of 3-((S)-3,4-dichlorophenyl)-4-((3,5-dimethylbenzoyl)methylamino)-butanal.

20 ¹H NMR (400 MHz, CDCl₃) δ 2.03 (s, 3H), 3.76 (s, 2H). Mass Spectrum (CI) m/z 692.1 (M⁺1).

EXAMPLE 52

25 1-(3-((S)-3,4-Dichlorophenyl)-4-(N-3-methylbenzoyl)-(methylthiomethylbutyl)-butyl)-4-(2-(methylthiomethylphenyl)-butyl)-piperazine

The title compound was prepared by analogy to the procedure given in Example 50, Step C, using 3-((S)-3,4-dichlorophenyl)-4-((3-methylbenzoyl)methylamino)-butanal instead of 3-((S)-3,4-dichlorophenyl)-4-((3,5-dimethylbenzoyl)methylamino)-butanal. Mass Spectrum (CI) m/z 570.3, 572.3 (M⁺1, M⁺3).

EXAMPLE 53

35

- 103 -

1-(3-((S)-3,4-Dichlorophenyl)-4-(N-3-methylbenzoyl)-(methylthiomethylbutyl)-4-(2-(methylthiomethylphenyl)-butyl)-piperazine, S-oxide

The title compound was prepared from 1 equiv. of 1-(3-((S)-3,4-dichlorophenyl)-4-(N-3,5-dimethylbenzoyl)-(methylamino)-butyl)-4-(2-(methylthiomethylphenyl)-butyl)-piperazine (from Example 50, Step C) and 1.5 equiv of ozone (potassium peroxymonosulfate) in MeOH/H₂O at 0 °C for 6 min. ¹H NMR (400 MHz, CDCl₃) δ 2.27 (s, 6H), 2.40 (s, 3H), 4.07 (d, 1H), 4.14 (d, 1H). Mass Spectrum (CI) m/z 600.2, 602.3 (M⁺1, M⁺3).

10

EXAMPLE 54

1-(3-((S)-3,4-Dichlorophenyl)-4-(N-3,5-bis(trifluoromethylbenzoyl)-(methylamino)-butyl)-4-(2-(methylthiomethylphenyl)-butyl)-piperazine, S-oxide

15 The title compound was prepared according to the procedure given in Example 53, using 1-(3-((S)-3,4-dichlorophenyl)-4-(N-3,5-bis(trifluoromethylbenzoyl)-(methylamino)-butyl)-4-(2-(methylthiomethylphenyl)-butyl)-piperazine (from Example 51) as starting material. ¹H NMR (400 MHz, CDCl₃) δ 2.40 (s, 3H), 4.06 (d, 1H), 4.15 (d, 1H). Mass Spectrum (CI) m/z 708.1 (M⁺1).

EXAMPLE 55

25 1-(3-((S)-3,4-Dichlorophenyl)-4-(N-3-methylbenzoyl)-(methylthiomethylbutyl)-4-(2-(methylthiomethylphenyl)-butyl)-piperazine, S-Oxide

The title compound was prepared according to the procedure given in Example 53, using 1-(3-((S)-3,4-dichlorophenyl)-4-(N-3-methylbenzoyl)-(methylamino)-butyl)-4-(2-(methylthiomethylphenyl)-butyl)-piperazine (from Example 52) as starting material. ¹H NMR (400 MHz, CDCl₃) δ 2.31 (s, 3H), 2.40 (s, 3H), 4.07 (d, 1H), 4.13 (d, 1H). Mass Spectrum (CI) m/z 586.2, 588.2 (M⁺1, M⁺3).

EXAMPLE 56

- 104 -

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(2-(methylthiomethyl)phenyl)-piperazine, S-S-dioxide

The title compound was prepared from 1-(3-((S)-(3,4-dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(2-(methylthiomethyl)phenyl)-piperazine, S-oxide and 3 equiv of oxone in MeOH/H₂O at room temperature for 1 h. ¹H NMR (400 MHz, CDCl₃) δ 2.27 (s, 6H), 2.67 (s, 3H), 4.39 (s, 2H). Mass Spectrum (Cl) m/z 616.2 (M⁺⁺¹).

EXAMPLE 57

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-bistrifluoromethylbenzoyl)-(methylamino)butyl)-4-(2-(methylthiomethyl)phenyl)-piperazine, S-S-dioxide

The title compound was prepared from 1-(3-((S)-(3,4-dichlorophenyl))-4-(N-3,5-bistrifluoromethylbenzoyl)-(methylamino)butyl)-4-(2-(methylthiomethyl)phenyl)-piperazine, S-oxide and 3 equiv of oxone in MeOH/H₂O at room temperature for 1 h. ¹H NMR (400 MHz, CDCl₃) δ 2.68 (s, 6H), 4.39 (s, 2H). Mass Spectrum (Cl) m/z 724.1 (M⁺⁺¹).

EXAMPLE 58

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3-methylbenzoyl)-(methylamino)butyl)-4-(2-(methylthiomethyl)phenyl)-piperazine, S-S-dioxide

The title compound was prepared from 1-(3-((S)-(3,4-dichlorophenyl))-4-(N-3-methylbenzoyl)-(methylamino)butyl)-4-(2-(methylthiomethyl)phenyl)-piperazine, S-oxide and 3 equiv of oxone in MeOH/H₂O at room temperature for 1 h. ¹H NMR (400 MHz, CDCl₃) δ 2.31 (s, 3H), 2.68 (s, 6H), 4.39 (s, 2H). Mass Spectrum (Cl) m/z 602, 604.3 (M⁺⁺¹, M⁺⁺³).

Additional compounds for Formula I can be prepared from the piperazine starting materials given in the following Examples 59 or Example 60 or from the sources listed below by using the methods given in Example 1, Step E, Example 15, Step C or Example 17:

EXAMPLE

Z-(1-Piperazinyl)triazolo[2,3-c]pyrimidine dihydrochloride

Step A: 7-(1-(4-t-Butyloxycarbonyl)piperazinyl)triazolo[2,3-c]pyrimidine

7-Chloro-triazolo[2,3-c]pyrimidine (Chem. Pharm. Bull., 1959, 7, 907) 1.01g, 6.54mmol, was suspended in isoamyl alcohol (25mL) and 1-(t-butyloxycarbonyl)piperazine (4.86g, 26.13mmol) was added.

This solution (dissolution occurred readily upon warming) was heated under reflux, under nitrogen for 1hr and then the reaction mixture was cooled, evaporated to dryness and the residue was dissolved in CH₂Cl₂ (100mL) and 10% aqu. Na₂CO₃ (100mL). After shaking, the layers were separated and the organic layer was washed with 10% aqu. Na₂CO₃ (2x 100mL) and the pooled organic layers were dried (over MgSO₄), filtered, and evaporated to dryness. This oily residue was dissolved in a little CH₂Cl₂, absorbed onto silica gel 60, and applied to a silica gel 60 column (3.5 x 22.0 cm), packed and developed in CH₂Cl₂. Fractions containing the required product were pooled and evaporated to dryness to give a white solid which was crystallized from CH₂Cl₂/Et₂O to give 1.47g of the title compound as a white crystalline solid. Yield 1.71g (5.63mmol, 86% yield) in two crops. Analysis calculated for C₁₄H₂₀N₆O₂ (304): C, 55.17; H, 6.62; N, 27.61, Found: C, 55.17; H, 6.32; N, 27.75.

Step B: Z-(1-Piperazinyl)triazolo[2,3-c]pyrimidine dihydrochloride

7-(1-(4-t-Butyloxycarbonyl)piperazinyl)triazolo[2,3-c]pyrimidine prepared as described in step A (0.301g, 0.99mmol), was dissolved in anhydrous HCO₂H (10mL) and allowed to stand at room temperature for 1 1/2hr and then was evaporated to dryness *in vacuo*. This residue was dissolved in a little H₂O and applied to a Dowex 1 x 2 (OH⁻ form) column (2 x 23cm). The column was developed with H₂O and fractions containing the required product were pooled and evaporated to dryness to give 0.21g. TLC indicated a small amount of starting

material remaining and the residue was then dissolved in $\text{CF}_3\text{CO}_2\text{H}$ (10 mL) and allowed to stand at room temperature for 1 h .

reaction was then evaporated to dryness slowly under a nitrogen stream and the residue was evaporated to dryness once from H_2O before being dissolved in a little H_2O and passed down a Dowex 1 \times 2 (OH -form)

10 column (2 x 25cm) as before. Fractions containing the required product were pooled and evaporated to dryness to give the title compound as a white solid (0.21g, quantitative yield) in the free base form. Analysis calculated for C₉H₁₂N₆•1.7 H₂O (234.86) C, 46.02; H, 6.61; N, 35.78. Found: C, 46.31; H, 6.01; N, 35.64.

A portion of this material (0.10g) was dissolved in EtOH (3.5mL) and 3.49M HCl in MeOH (1mL) was added. A white precipitate formed immediately which was removed by centrifugation after

x 5mL, and Et₂O (5mL) to give 0.11g (0.407mmol) of the title compound as the dihydrochloride salt. Analysis calculated for C₉H₁₄N₆Cl₂·0.7H₂O (289.76), C, 37.30; H, 5.36; N, 29.00, Found: C, 37.52; H, 5.17; N, 28.92.

EXAMPLE 60

1-(2,3-dihydro-1,3-dihydro-2H-1,2,4,5-tetrahydropyrimidin-2-yl)-4-phenyl-1,3-dihydro-2H-1,2,4,5-tetrahydropyrimidine dihydrochloride

Step A: 7-Chloro-triazolo(2,3- α)pyrimidine

Pharm. Bull. 7:907 (1959).

Step B: $7\cdot(1\cdot(4\cdot t\text{-Butyl}\text{oxycarbonyl})\text{piperazinyl})\text{triazole}(3\cdot 3\cdot 2\text{-})\text{-} \cdot \text{H}_2\text{O}$

7-Chloro-triazo[2,3-a]pyrimidine: prepared as described in

Step A above (1.01 g, 6.34 mmol), was suspended in isoamyl alcohol (25

This solution (dissolution of 1 g in 6 mL water) was

mixture was cooled, evaporated to dryness and the residue was dissolved in CH_2Cl_2 (100 mL) and 10% aq. Na_2CO_3 (100 mL). After shaking the

- 107 -

-108-

5 layers were separated and the organic layer was washed with 10% aqu. Na₂CO₃ (2 x 100 mL) and the pooled organic layers were dried (over MgSO₄), filtered, and evaporated to dryness. This oily residue was dissolved in a little CH₂Cl₂, absorbed onto silica gel 60, and applied to a silica gel 60 column (3.5 x 22.0 cm), packed and developed in CH₂Cl₂. Fractions containing the required product were pooled and evaporated to dryness to give a white solid which was crystallized from CH₂Cl₂/Et₂O to give 1.47 g of the title compound as a white crystalline solid. Yield 1.71 g (5.63 mmol, 86% yield) in two crops. Anal. Calcd. for C₁₄H₂₀N₆O₂ (304): C, 55.25; H, 6.62; N, 27.61. Found: C, 55.17; H, 6.32; N, 27.75.

10 Step C: Z-(4-Piperazinyltriazolo[2,3-c]pyrimidine dihydrochloride

15 a) piperazine, prepared as described in Step B above (0.301 g, 0.99 mmol), was dissolved in anhydrous HCO₂H (10 mL) and allowed to stand at room temperature for 1 1/2 hr and then was evaporated to dryness *in vacuo*. This residue was dissolved in a little H₂O and applied to a Dowex 1 x 2 (OH- form) column (2 x 23 cm). The column was developed with H₂O and fractions containing the required product were pooled and evaporated to dryness to give 0.21 g. TLC indicated a small amount of starting material remaining and the residue was then dissolved in CF₃CO₂H (10 mL) and allowed to stand at room temperature for 45 min. The reaction was then evaporated to dryness slowly under a nitrogen stream and the residue was evaporated to dryness once from H₂O before being dissolved in a little H₂O and passed down a Dowex 1 x 2 (OH- form) column (2 x 25 cm) as before. Fractions containing the required product were pooled and evaporated to dryness to give the title compound as a white solid (0.21 g, quantitative yield) in the free base form. Anal. Calcd. for C₉H₁₂N₆•1.7H₂O (234.86): C, 46.02; H, 6.61; N, 35.78. Found: C, 46.31; H, 6.01; N, 35.64.

30 A portion of this material (0.10 g) was dissolved in EtOH (3.5 mL) and 3.49 M HCl in MeOH (1 mL) was added. A white precipitate formed immediately which was removed by centrifugation after standing at room temperature for 4 hr and was washed with cold EtOH (2 x 5 mL) and Et₂O (5 mL) to give 0.11 g (0.407 mmol) of the title

compound as the dihydrochloride salt. Anal. Calc. for C₉H₁₄N₆Cl₂·0.7H₂O (289.76): C, 37.30; H, 5.36; N, 29.00. Found: C, 37.52; H, 5.17; N, 28.92.

5 Additional starting materials may be prepared as described in US Patent 5,057,517:

6-(1-piperazinyl)-8-methylpurine dihydrochloride, 6-(1-piperazinyl)-8,9-dimethylpurine dihydrochloride,

6-(1-piperazinyl)-9-methyl-3-deazapurine dihydrochloride, (i.e. 1-methyl-4-(1-piperazinyl)-1H-imidazo(4,5-c)pyridine dihydrochloride),

8-bromo-6-(1-piperazinyl)purine dihydrochloride,

8-bromo-9-methyl-6-(1-piperazinyl)purine dihydrochloride,

2,9-dimethyl-8-methylamino-6-(1-piperazinyl)purine dihydrochloride,

2,9-dimethyl-8-dimethylamino-6-(1-piperazinyl)purine dihydrochloride,

2,9-dimethyl-6-(1-piperazinyl)-8-(1-pyrrolidinyl)purine dihydrochloride,

8-methoxy-9-methyl-6-(1-piperazinyl)purine dihydrochloride,

9-methyl-6-(1-piperazinyl)-8-(1-pyrrolidinyl)purine dihydrochloride,

8-dimethylamino-9-methyl-6-(1-piperazinyl)purine dihydrochloride,

6-(1-piperazinyl)-2,8,9-trimethylpurine dihydrochloride,

2-chloro-9-methyl-6-(1-piperazinyl)purine dihydrochloride,

9-methyl-2-morpholino-6-(1-piperazinyl)purine dihydrochloride,

9-methyl-6-(1-piperazinyl)-2-(1-pyrrolidinyl)purine dihydrochloride,

2-methyl-2-methylamino-6-(1-piperazinyl)purine dihydrochloride,

2-dimethylamino-9-methyl-6-(1-piperazinyl)purine dihydrochloride,

2,8-bis(dimethylamino)-9-methyl-6-(1-piperazinyl)purine dihydrochloride,

2-methoxy-9-methyl-6-(1-piperazinyl)purine dihydrochloride,

2,8-dimethyl-6-(1-piperazinyl)purine dihydrochloride,

2,8-dimethyl-6-(1-piperazinyl)purine dihydrochloride,

9-ethoxymethyl-2-methoxy-6-(1-piperazinyl)purine maleate, 9-cyclopropylmethyl-2-ethoxy-6-(1-piperazinyl)purine dihydrochloride, 2-methoxy-9-methoxyethyl-6-(1-piperazinyl)purine dihydrochloride, 2-methoxy-6-(1-piperazinyl)-9-(1-(2-propynyl)purine dihydrochloride, 9-(1-allenyl)-2-methoxy-6-(1-piperazinyl)purine dihydrochloride, 2-methoxy-6-(1-piperazinyl)-9-(1-(2-propenyl)purine dihydrochloride, 9-cyclopropyl-2-ethyl-6-(1-piperazinyl)purine, 2-ethyl-9-methyl-6-(1-piperazinyl)purine dihydrochloride, 2-ethyl-9-(1-(2,2,2-trifluoroethylamino)-6-(1-piperazinyl)purine, 2-methoxy-9-(1-piperazinyl)-9-(2-propyl)purine dihydrochloride, 2-methoxy-9-(1-(2-oxopropyl))-6-(1-piperazinyl)purine dihydrochloride, 9-(1-(2,2-difluoropropyl))-2-methoxy-6-(1-piperazinyl)purine, 2-ethyl-9-(2-fluoroethyl)-6-(1-piperazinyl)purine dihydrochloride, 2-methoxy-6-(1-piperazinyl)-9-(2-furanylmethyl)purine, 9-((1S,2R)-2-fluoro-1-methylpropyl)-2-methoxy-6-(1-piperazinyl)purine, 9-((1S,2S)-2-fluoro-1-methylpropyl)-2-methoxy-6-(1-piperazinyl)purine, 9-((1R,2R)-2-fluoro-1-methylpropyl)-2-methoxy-6-(1-piperazinyl)purine.

5 Additional starting materials may be prepared as described in US Patent 4,980,350:

4,5-dimethyl-2-(1-piperazinyl)pyrimidine dihydrochloride, 4,6-dimethyl-2-(1-piperazinyl)pyrimidine dihydrochloride,

4,5,6-trimethyl-2-(1-piperazinyl)pyrimidine dihydrochloride, 6-(1-butyl)-4-methyl-2-(1-piperazinyl)pyrimidine dihydrochloride, 4-(2-butyl)-2-(1-piperazinyl)pyrimidine dihydrochloride,

4-methyl-5-methoxy-4-(1-piperazinyl)pyrimidine dihydrochloride, 2-methyl-4-(1-piperazinyl)-S-triazine dihydrochloride,

Additional starting materials may be prepared as described in US Patent No. 4,876,256:

6-methyl-2-(1-piperazinyl)pyridine dihydrochloride, 2-(1-piperazinyl)pyridine dihydrochloride,

30 Additional starting materials may be prepared as described in US Patent No. 4,876,256:

- 109 -


- 110 -

Additional starting materials may be prepared as described in *J. Heterocyclic Chem.*, 27, 1559 (1990).

8,9-dihydro-1-methyl-5-(1-piperazinyl)-7*H*-thiopyrano(2,3-*e*)triazolo(4,3-*a*)pyrimidine,
e)(1,2,4)triazolo(4,3-*a*)pyrimidine,
5 8,9-dihydro-5-(1-piperazinyl)-7*H*-thiopyrano(2,3-*e*)(1,2,4)triazolo(4,3-*a*)pyrimidine,
a)pyrimidine,
8,9-dihydro-5-(1-piperazinyl)-7*H*-tetrazolo(1,5-*a*)thiopyrano(2,3-*e*)pyrimidine,
c)pyrimidine,
5,6-dihydro-7*H*-9-(1-piperazinyl)thiopyrano(3,2-*d*)(1,2,4)triazolo(2,3-*e*)pyrimidine,
10 a)pyrimidine.


EXAMPLE 61

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-bis(trifluoromethyl)-benzoyl(methylamino)butyl)-4-(2-(1-(R)-(methanesulfonyl)-amino)ethyl)phenyl)-piperazine and 1-3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-bis-(trifluoromethyl)benzoyl-(methylamino)butyl)-4-(2-(1-(S)-(methanesulfonyl)ethyl)phenyl)-piperazine



10

Step A: 1-t-butoxycarbonyl-4-(2-(1-(RS)-hydroxyethyl)phenyl)-piperazine




15

To a solution of 1g of 1-t-butoxycarbonyl-4-(2-formylphenyl)-piperazine (3.44mmol) (prepared as described in example 9 step A) in THF 30ml was added methylmagnesium bromide (3M THF solution) 1.26ml (3.78mmol) with cooling in an ice-water bath. The cooling bath was then removed and the reaction mixture was stirred at rt for 1hr. The reaction was quenched by the addition of saturated NH4Cl solution. After removal of THF under reduced pressure, the reaction mixture was diluted with ethyl acetate and water. Organic phase was separated. The aqueous phase was extracted twice with ethyl acetate, and the combined

org. phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash chromatography on silica gel eluting with a hexanes/ethyl acetate mixture to give 9.9mg (87%) of the desired alcohol. $^1\text{H-NMR}$ (500MHz, CDCl_3): d1.51(s, 9H),

5 1.55(d, $J=6.5\text{Hz}$, 3H), 2.91-2.97(m, 4H), 3.4-3.8(br s, 4H), 5.1(br s, 1H),
5.8(br s, 1H). Mass spectrum (Cl) m/z 307 ($M^{+}+1$).

Step B
1-t-butoxycarbonyl-4-(2-(1-(RS)-aminoethyl)phenyl)-
piperazine



To a solution of 1g of the alcohol obtained in step A

(3.26mmol) in THF 10mL was added 1.03g (3.93mmol) of

15 triphenylphosphine and 62.4mg (4.24mmol) of phthalimide, and finally 0.565mL (3.44mmol) of diethylazodicarboxylate with cooling in an ice-water bath. The cooling bath was then removed and the reaction mixture was stirred at rt overnight. THF was removed under reduced pressure. The remaining material was diluted with ethyl acetate and water, and the organic phase was separated. The aqueous phase was extracted twice with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was purified by flash chromatography on silica gel eluting with 10:1 to 3:1 hexanes/ethyl acetate to give 1.13g (79%) of the desired compound. $^1\text{H-NMR}$ (500MHz, CDCl_3): d1.5 & 1.55 (s, 9H), 1.82(d, 3H), 2.7-2.82(br s, 4H), 3.2-4.0(br s, 4H), 6.1(m, 1H), 7.1-7.8(m, 8H).

To a solution of 1.13g (2.6mmol) of the compound obtained above dissolved in 25 mL of absolute ethanol was added 0.8mL (26mmol) of hydrazine hydrate and the reaction mixture was heated to reflux for 1.5hr. The voluminous precipitate of phthalimide was removed by filtration through a pad of celite. The filtrate was concentrated to give

750mg (95%) of the desired amine. This material was pure enough to be used in the next step. $^1\text{H-NMR}$ (500MHz, CDCl_3): d1.41(d, $J=6.7\text{Hz}$, 3H), 1.51(s, 9H), 2.85-2.87(br s, 4H), 4.6(q, $J=6.7\text{Hz}$, 1H), 7.1-7.5(m, 4H), 1.54(d, $J=7\text{Hz}$, 3H), 2.75(s, 3H), 2.8-3.0(br s, 4H), 3.3-3.9(br s, 4H), 5.05(m, 1H), 5.85(br s, 1H), 7.2-7.4(m, 4H). Mass spectrum (Cl) m/z 284 ($M^{+}+1$).

15 **Step D:** 1-(3-(S)-(3,4-Dichlorophenyl)-4-(N-3,5-bis-(trifluoromethyl)benzoyl)(methylamino)butyl)-4-(2-(1-(R)-(methanesulfonylamino)ethyl)phenyl)-piperazine and 1-(3-(S)-(3,4-Dichlorophenyl)-4-(N-3,5-bis-(trifluoromethyl)benzoyl)(methylamino)butyl)-4-(2-(1-(S)-(methanesulfonylamino)ethyl)phenyl)-piperazine

20 The title compounds were prepared as an inseparable mixture following the procedure described in example 33 step D. Mass spectrum: (Cl) m/z 755(37Cl+35Cl), 753 (35Clx2).

25 The compounds in example 62-70 were prepared by reacting the requisite piperazine with either 3-((S)-3,4-dichlorophenyl))-4-((3,5-bis(trifluoromethyl)benzoyl)methylamino)butanal (Example 33 step A) or 3-((S)-3,4-dichlorophenyl))-4-((3-fluoro-5-trifluoromethylbenzoyl)methylamino)butanal (Example 45 step A) or 3-((S)-4-chlorophenyl))-4-((3,5-bis(trifluoromethyl)benzoyl)methylamino)butanal (example 30) according to the procedure of Example 1, step E. The piperazine


substrates were synthesized by the method of example 61 step C by substituting the appropriate acylation agent. In each case diastereomeric mixtures were obtained.

5

EXAMPLE 62

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-bis-(trifluoromethyl)-benzoyl(methylamino))butyl)-4-(2-(1-(R)-(dimethylamino-carbonylaminoethyl)phenyl)-piperazine and 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-bis-(trifluoromethyl)benzoyl(methylamino))butyl)-4-(2-(1-(S)-(dimethylamino carbonylaminoethyl)phenyl)-piperazine

15



Mass spectrum: (Cl) m/z 748 (37Cl+35Cl), 746(35Clx2).


5

EXAMPLE 64

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-bis-(trifluoromethyl)benzoyl(methylamino))butyl)-4-(2-(1-(R)-(dimethylamino carbonyl)(N-methyl)amino)butyl)-4-(2-(1-(S)-(methylamino carbonyl)(N-methyl)amino)butyl)-piperazine

10 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-bis-(trifluoromethyl)benzoyl(methylamino))butyl)-4-(2-(1-(R)-(dimethylamino-carbonylaminoethyl)phenyl)-piperazine and 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-bis-(trifluoromethyl)benzoyl(methylamino))butyl)-4-(2-(1-(S)-(dimethylamino carbonylaminoethyl)phenyl)-piperazine


15 Mass spectrum: (Cl) m/z 791 (37Cl+35Cl), 789(35Clx2).

EXAMPLE 63**EXAMPLE 65**

- 115 -

- 116 -

1-(3-((S)-4-Chlorophenyl))-4-(N-3,5-bis-(trifluoromethyl)-benzoyl(methylamino)butyl)-4-(2-(1-R)-(methanesulfonylamino)-ethyl)phenyl)-piperazine and 1-(3-((S)-4-Chlorophenyl))-4-(N-3,5-bis-(trifluoromethyl)benzoyl(methylamino)butyl)-4-(2-(1-S)-(methanesulfonylamino)ethyl)phenyl)-piperazine




Mass spectrum: (Cl) m/z 721(37Cl), 719(35Cl).

10

EXAMPLE 66

1-(3-((S)-4-Chlorophenyl))-4-(N-3,5-bis-(trifluoromethyl)-benzoyl(methylamino)butyl)-4-(2-(1-R)-(dimethylaminocarbonyl)-aminoethyl)phenyl)-piperazine and 1-(3-((S)-4-Chlorophenyl))-4-(N-3,5-bis-(trifluoromethyl)benzoyl(methylamino)butyl)-4-(2-(1-S)-(dimethylaminocarbonyl)aminoethyl)phenyl)-piperazine



Mass spectrum: (Cl) m/z 714(37Cl), 712(35Cl).

10

EXAMPLE 67


1-(3-((S)-4-Chlorophenyl))-4-(N-3,5-bis-(trifluoromethyl)-benzoyl(methylamino)butyl)-4-(2-(1-R)-(methylaminocarbonyl)-aminoethyl)phenyl)-piperazine and 1-(3-((S)-4-Chlorophenyl))-4-(N-3,5-bis-(trifluoromethyl)benzoyl(methylamino)butyl)-4-(2-(1-S)-(methylaminocarbonyl)aminoethyl)phenyl)-piperazine

Mass spectrum: (Cl) m/z 701(37Cl), 699(35Cl).

EXAMPLE 68

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3-fluoro-5-(trifluoromethyl)-benzoyl(methylamino)butyl)-4-(2-(1-(R)-(methanesulfonylamino)-ethyl)phenyl)-piperazine and 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3-fluoro-5-(trifluoromethyl)benzoyl(methylamino)butyl)-4-(2-(1-(S)-methanesulfonylaminoethyl)phenyl)-piperazine.

5 (methanesulfonylaminoethyl)phenyl)-piperazine




Mass spectrum: (Cl) m/z 705(37Cl+35Cl), 703(35Clx2).

10

EXAMPLE 69

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3-fluoro-5-(trifluoromethyl)-benzoyl(methylamino)butyl)-4-(2-(1-(R)-(dimethylaminocarbonyl)-amino)ethyl)phenyl)-piperazine and 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3-fluoro-5-(trifluoromethyl)benzoyl(methylamino)butyl)-4-(2-(1-(S)-(dimethylaminocarbonyl)aminoethyl)phenyl)-piperazine

15 3-fluoro-5-(trifluoromethyl)benzoyl(methylamino)butyl)-4-(2-(1-(S)-(dimethylaminocarbonyl)aminoethyl)phenyl)-piperazine



Mass spectrum: (Cl) m/z 684(37Cl+35Cl), 682(35Clx2).

15

EXAMPLE 70

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(2-acetylaminophenyl)-piperazine

Step A: t-Butoxycarbonyl-4-(2-acetylaminophenyl)-piperazine

20 To a 30 ml DMF solution of t-butoxypiperazine carboxylate 10g (53.7mmol) and o-fluoronitrobenzene 8.35g (59.2mmol) were added potassium carbonate 14.9 g (107.4 mmol). The reaction mixture was stirred at 150 °C in an oil bath overnight. After cooling to rt, the reaction mixture was concentrated under reduced pressure. The residual material was suspended in Et₂O and filtered through a pad of celite.

25 The filtrate was washed with sat NH₄Cl aq. solution, dried over anhydrous Na₂SO₄, filtered, concentrated, and chromatographed

(silica, Hexanes : EtOAc = 10:1 to 7:1) to give 17.7 g of the title compound. ¹H-NMR (500MHz CDCl₃) δ 1.49 (s, 9H), 3.02 (bs, 4H), 3.59 (bt, 4H, J = 4.8 Hz), 7.10 (t, 1H, J = 7.1 Hz), 7.15 (d, 1H, J = 7.1 Hz), 7.50 (t, 1H, J = 6.6 Hz), 7.79 (d, 1H, J = 8.2 Hz).

5

Step B:**1-t-Butoxycarbonyl-4-(2-amino)phenyl-piperazine**

To a solution of 1-t-Butoxycarbonyl-4-(2-nitrophenyl-

piperazine (3.38g, 11 mmol) in 40 mL of methanol was added 0.2 g of (10% Pd on carbon). The reaction mixture was shaken under 50 psi of hydrogen for 18 h. The solution was then filtered through a plug of celite, concentrated, chromatographed on silica gel column eluting with Hexanes : EtOAc = 4:1 to give 2.61 g (86%) of the title compound. ¹H-NMR (500MHz CDCl₃) δ 1.51 (s, 9H), 2.87 (bs, 4H), 3.58 (bs, 4H), 4.00 (bs, 2H), 6.75-6.77 (m, 2H), 6.95-6.99 (m, 2H).

15

Step C:**4-(2-(Acetylaminobutyl)-piperazine**

A solution of 8.6 g (30.7 mmol) of 4-(2-amino)-phenyl-1-t-

butyloxycarbonylpiperazine (from Step B above) in 150 mL of CH₂Cl₂ was

treated with 8.7 mL (90 mmol) of acetyl chloride and 7.5 mL (90 mmol) of

pyridine. After stirring for 12 hr the reaction mixture was diluted with 200 mL CH₂Cl₂ and washed with water, saturated NaHCO₃, brine and dried over MgSO₄. After the filtrate was concentrated, the residue was

dissolved in 150 mL of THF and to it was added 50 mL of concentrated HCl and the reaction was stirred at rt. After 30 min., the reaction mixture

was diluted with 200 mL of water and it was washed with EtOAc. The

aqueous fraction was brought to pH = 12 by careful addition of solid KOH and extracted with EtOAc. The organic fractions were washed with dilute NaOH and dried over MgSO₄. The filtrate was concentrated and chromatographed on a silica gel column eluting with CHCl₃ : CH₃OH =

4:1 to furnish 4.2 g (63%) of the title compound. ¹H-NMR (500MHz CDCl₃) δ 2.22 (s, 3H, Ac), 2.86 (m, 4H, NCH₂), 3.08 (m, 4H, NCH₂), 6.76 - 7.18 (m, 4H, ar-H), 8.35 (d, 1H, 8.52 (br, 1H).

4H, NCH₂).

5

Step D:**1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methyl-amino))butyl)-4-(2-(acetylaminomethyl)phenyl)-piperazine**

To a solution of 0.895 g (2.57 mmol) of 3-((S)-(3,4-

dichlorophenyl))-4-((3,5-dichlorobenzoyl)methylamino)butanal (from Example 2, Step A) in 40 mL of dichloroethane were added 0.676 g (3.1 mmol) of 4-(2-acetylaminophenyl)-piperazine (Step C), and 0.818 g (3.85 mmol) of NaB(OAc)₃H and the reaction mixture was stirred at rt. After 2 hr, the reaction was diluted with 100 mL of CH₂Cl₂ and washed with saturated NaHCO₃, brine and dried over MgSO₄. After filtration, the filtrate was concentrated and the residue was purified by HPLC (RCM SepPak, silica 25x100, 4.5% CH₃CN, 0.1% diisopropylamine in tBuOC₂H₃) to give 1.15 gm of the title compound. ¹H NMR (CD₃CN, ppm ranges are given because of amide rotamers and line broadening) δ 2.09 (s, 3H, Ac), 2.79 (s, 3H, NMe), 6.62-7.53 (m, 9H, ar-H), 8.16 (m, 1H, ar-H), 8.40 (br, 1H, N-H); Mass Spectrum (ESI): m/e 621, 623, 625, 627 (M⁺+1 / 35Cl/37Cl-isotope pattern).

EXAMPLE 72

1-(3-((R)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methyl-amino))butyl)-4-(2-(acetylaminophenyl)-piperazine

The title compound was prepared according to procedures described in Example 71. In this example (R)-(3,4-dichlorophenyl)-4-

25 methylamino-1-pentene was employed in place of (S)-(3,4-dichlorophenyl)-4-methylamino-1-pentene (Example 71, Step A) to prepare the requisite 3-((S)-(3,4-dichlorophenyl))-4-((3,5-dichlorobenzoyl)methylamino)butanal. ¹H NMR (CD₃CN, ppm ranges are given because of amide rotamers and line broadening) δ 2.09 (s, 3H, Ac), 2.79 (s, 3H, NMe), 6.62-7.53 (m, 9H, ar-H), 8.16 (m, 1H, ar-H), 8.40 (br, 1H, N-H); Mass Spectrum (ESI): m/e 621, 623, 625, 627 (M⁺+1 / 35Cl/37Cl-isotope pattern).

EXAMPLE 73

35

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(2-nitrophenyl)-piperazine

Step A:
4-(2-nitrophenyl)-piperazine

To a solution of 2.2 gm (7.16 mmol) of t-butoxycarbonyl-4-(2-nitro)phenyl-piperazine in 10 ml of CH_2Cl_2 was added 5 ml of trifluoroacetic acid and the reaction mixture was stirred for 2 hr. The reaction mixture was concentrated and the residue was redissolved in CH_2Cl_2 , washed with brine and saturated NaHCO_3 . The organic fractions were dried over Na_2SO_4 , filtered and the filtrate was concentrated to give 1.16 gm of the title compound as a red oil. The material was used in Step B below without further purification.

Step B:
1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(2-nitrophenyl)-piperazine

To a solution of 0.102 g (0.49 mmol) of 4-(2-nitrophenyl)-piperazine (Step A) in 1 ml of 1,2-dichloroethane were added 0.101 g (0.24 mmol) of 3-((S)-3,4-dichlorophenyl)-4-(3,5-dichlorobenzoyl)methyl-amino)butanal (from Example 2, Step A) in 4 mL of 1,2-dichloroethane.

After stirring the mixture for 5 min, a solution of 0.103 g (0.49 mmol) of NaCNBH_3 was added. Some gas evolution was observed. After 3 h when the reaction was complete by TLC the mixture was filtered through a pad of celite, the reaction flask and the pad were rinsed with MeOH . The filtrate was concentrated to approximately 2 mL and the residue was diluted with $\text{Et}_2\text{O}:\text{EtOAc}$. The $\text{Et}_2\text{O}:\text{EtOAc}$ solution was washed with water, brine and dried over Na_2SO_4 . The filtrate was concentrated and the residue was purified by chromatography (silica, 1:2 acetone:hexanes) to isolate 0.148 g (100%) of the title compound as a white solid. ^1H NMR (CDCl_3 , ppm ranges are given because of amide rotamers and line broadening). ^1H -NMR (500MHz CDCl_3) δ 1.60-3.83 (m, 18H), 6.81-7.44 (m, 8H), 7.48 (t, 1H, J = 8.0 Hz), 7.75 (d, 1H, J = 8.1 Hz). Mass Spectrum (CD)609, 611, 613, 615 ($M^{+}+1$ / $^{35}\text{Cl}/^{37}\text{Cl}$ -isotope pattern).

EXAMPLE 74

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(2-aminophenyl)-piperazine

Step A:
A mixture of 0.195 gm (0.32 mmol) of 1-(3-((S)-3,4-dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(2-nitrophenyl)-piperazine and 0.296 6 gm (1.315 mmol) of $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$

was placed under vacuum for 1.5h. To this mixture in a nitrogen atmosphere was added 3 ml of EtOH and the reaction mixture was heated at reflux for 90 min. The reaction mixture was diluted with 10 ml of EtOAc . The solution was washed with water, brine and dried over Na_2SO_4 . The filtrate was refiltered through a pad of celite and concentrated to give the title compound as an oil. This material was used in the examples below without further purification. ^1H NMR (CDCl_3 , ppm ranges are given because of amide rotamers and line broadening) δ 1.62-3.95 (20 H), 6.72-7.46 (m, 10 H).

EXAMPLE 75

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(2-formylaminophenyl)-piperazine

To a solution of 0.133 gm (0.59 mmol) of 1-(3-

dimethylaminopropyl)-3-ethylcarbodiimide (EDC) and 0.159 gm of dimethylaminopyridine (DMAP) in 2 mL of CH_2Cl_2 at 0°C was added 0.0164 ml (0.43 mmol) of formic acid. After stirring for 5 min. the solution was added to a solution of 0.051 gm (0.088 mmol) of 1-(3-((S)-3,4-dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(2-aminophenyl)-piperazine in 2 mL of CH_2Cl_2 and the reaction mixture was stirred at rt for 4 hr. The reaction mixture was further diluted with CH_2Cl_2 , washed with brine, dried over Na_2SO_4 , filtered through a pad of silica and concentrated. The residue was purified by chromatography (silica, 1:3 acetone: hexanes) to give 0.017 gm of the title compound. ^1H NMR (600MHz CDCl_3) δ 1.61-3.87 (18H), 6.83-7.46 (m, 10H), 8.11-8.87 (m, 2H). Mass Spectrum (CI) 607, 609, 611, 613 ($M^{+}+1$ / $^{35}\text{Cl}/^{37}\text{Cl}$ -isotope pattern).

The compounds in Examples 76 to 81 were prepared according to the procedure described in Example 75. The corresponding carboxylic acids are commercially available.

EXAMPLE 76

1-(3-(S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(2-nbutylaminolaminophenyl)-piperazine

Mass Spectrum (CI) 649, 651, 653 ($M^{+}+1 / 35Cl/37Cl$ -isotope pattern).

EXAMPLE 77

1-(3-(S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(2-n-propionylaminolaminophenyl)-piperazine

Mass Spectrum (CI) 635, 637, 639 ($M^{+}+1 / 35Cl/37Cl$ -isotope pattern).

EXAMPLE 78

1-(3-(S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(2-(3-methoxycarbonylaminolaminophenyl)-piperazine

Mass Spectrum (CI) 661, 663, 665 ($M^{+}+1 / 35Cl/37Cl$ -isotope pattern).

EXAMPLE 79

1-(3-(S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(2-(3-methoxycarbonylaminolaminophenyl)-piperazine

Mass Spectrum (CI) 637, 639, 641 ($M^{+}+1 / 35Cl/37Cl$ -isotope pattern).

EXAMPLE 80

1-(3-(S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(2-ethoxycarbonylaminolaminophenyl)-piperazine

The title compound was prepared according to procedures described in Example 75, but utilizing methylchloroformate. Mass Spectrum (CI) 637, 639, 641 ($M^{+}+1 / 35Cl/37Cl$ -isotope pattern).

EXAMPLE 81

1-(3-(S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(2-methansulfonylaminolaminophenyl)-piperazine

Mass Spectrum (CI) 651, 653, 655 ($M^{+}+1 / 35Cl/37Cl$ -isotope pattern).

EXAMPLE 82

1-(3-(S)-(3,4-Dichlorophenyl))-4-(N-4-methoxybenzoyl)-(methylamino)butyl)-4-(2-acetylaminolaminophenyl)-piperazine

Step A: 3-(S)-(3,4-Dichlorophenyl)-4-(t-butoxycarbonyl)methylamino-1-pentene

To a solution of 8.89 g (36.4 mmol) of 3-(S)-3,4-dichlorophenyl)-4-methylaminol-1-pentene (prepared as described by J. Halász et al., *Bioorganic and Medicinal Chemistry Letters*, 1993, 3, 319-322) in 80 mL of CH_2Cl_2 was added 40 mL of 15% NaOH solution. With vigorous stirring, 11.9 gm of Boc_2O was slowly added over 30 min. After stirring for 30 min, the layers were separated and the organic layer was washed with saturated $NaHCO_3$ and brine. The solution was dried over Na_2SO_4 and concentrated to give 17 g of the title compound as an oil.

Step B: 3-(S)-(3,4-Dichlorophenyl)-4-(t-butoxycarbonyl)methylamino-butanal

The title compound 1.96 gm was prepared from 2 gm (5.81 mmol) of 3-(S)-(3,4-dichlorophenyl)-4-(t-butoxycarbonyl)methylamino-1-pentene (Example 82, Step A) according to procedures described in Example 2, Step A. The reaction mixture was filtered through a thin pad of silica gel and the filtrate was concentrated. The residue was used in the next step without purification.

Step C:**1-3-((S)-3,4-Dichlorophenyl)-4-(N-t-butoxycarbonyl)-**

methyl-amino)butyl)-4-((2-acetylaminophenyl)-piperazine

The title compound (2.61 gm) was prepared from 2 gm (5.8 mmol) of 3-((S)-3,4-dichlorophenyl)-4-((2-acetylaminophenyl)-butyl) (Example 82, Step B) and 1.53 gm (7 mmol) of 4-(2-amino)-butanal (Example 82, Step B) and 1.53 gm (7 mmol) of 4-(2-acetylaminophenyl)-piperazine (Example 71, Step C) according to procedures described in Example 71, Step D). ¹H NMR (CD₃CN, ppm ranges are given because of amide rotamers and line broadening) δ 1.32 (s, 9H, OBu), 2.10 (s, 3H, Ac), 2.69 (s, 3H, NMe), 7.03-7.10 (m, 2H, ar-H), 7.18-7.22 (m, 2H, ar-H), 7.44-7.48 (m, 2H, ar-H), 8.17 (m, 1H, ar-H), 8.41 (br, 1H, N-H); Mass Spectrum (ESI): m/e 549, 551, 553 (M⁺+1 / 35Cl/37Cl-isotope pattern).

15 Step D: **1-3-((S)-3,4-Dichlorophenyl)-4-(methylaminobutyl)-4-((2-acetylaminophenyl)-piperazine**

To a solution of 0.85 gm (1.55 mmol) of 1-3-((S)-3,4-dichlorophenyl)-4-((N-t-butoxycarbonyl)methyl-amino)butyl)-4-((2-

acetylaminophenyl)-piperazine in 50 mL of EtOAc was added 50 mL of

20 70% HCl and the reaction was stirred 45 min at rt. The layers were separated and the aqueous fraction was brought to pH = 12 by careful addition of solid KOH and extracted with EtOAc. The organic fractions

were washed with brine, dried over MgSO₄, filtered and concentrated. The residue was purified by chromatography (silica, CH₃OH: CH₂Cl₂, 1:5) to give 0.76 gm of the title compound. ¹H NMR (CD₃CN, ppm ranges are given because of amide rotamers and line broadening) δ 2.12 (s, 3H, Ac), 2.71 (s, 3H, NMe), 7.03-7.10 (m, 2H, ar-H), 7.18-7.22 (m, 2H, ar-H), 6.64 - 7.58 (m, 6H, ar-H), 8.14 (m, 1H, ar-H), 8.41 (br, 1H, N-H); Mass Spectrum (ESI): m/e 449, 451, 453 (M⁺+1 / 35Cl/37Cl-isotope pattern).

30 Step E: **1-3-((S)-3,4-Dichlorophenyl)-4-(N-4-methoxybenzoyl)-(methylaminobutyl)-4-((2-acetylaminophenyl)-piperazine**

To a solution of 0.1 gm (0.22 mmol) of 1-3-((S)-3,4-dichlorophenyl)-4-(methylaminobutyl)-4-((2-acetylaminophenyl)-piperazine in 2.5 mL of CH₂Cl₂ was added 0.05 mL (0.62 mmol) of

pyridine and 0.076 gm (0.44 mmol) of p-anisoylchloride and the reaction mixture was stirred at rt. After 24 hr, 50 mL of EtOAc was added and the solution was washed with saturated NaHCO₃ and brine. The organic fraction was dried over MgSO₄, filtered and concentrated. The residue was purified by chromatography (silica, 2% CH₃OH in CH₂Cl₂) to give 0.096 gm of the title compound. ¹H NMR (CHCl₃, ppm ranges are given because of amide rotamers and line broadening) δ 2.20 (s, 3H, Ac), 2.89 (s, 3H, NMe), 3.84 (s, 3H, OMe), 6.69-7.53 (m, 10H, ar-H), 8.34 (m, 1H, ar-H), 8.43 (br, 1H, N-H); Mass Spectrum (ESI): m/e 583, 585, 587 (M⁺+1 / 35Cl/37Cl-isotope pattern).

The compounds in Examples 83-111 were prepared by reacting 1-3-((S)-3,4-dichlorophenyl)-4-(methyl-amino)butyl)-4-((2-acetylaminophenyl)-piperazine with the requisite acid chlorides as described in Example 79.

EXAMPLE 83**1-3-((S)-3,4-Dichlorophenyl)-4-(N-3,4-dichlorobenzoyl)-(methyl-****amino)butyl)-4-((2-acetylaminophenyl)-piperazine**

Mass Spectrum (ESI): m/e 621, 623, 625, 627 (M⁺+1 / 35Cl/37Cl-isotope pattern).

EXAMPLE 84**1-3-((S)-3,4-Dichlorophenyl)-4-(N-benzoyl)-(methyl-amino)butyl)-4-((2-****acetylaminophenyl)-piperazine**

Mass Spectrum (ESI): m/e 553, 555, 557 (M⁺+1 / 35Cl/37Cl-isotope pattern). EXAMPLE 85

30 1-3-((S)-3,4-Dichlorophenyl)-4-(N-4-chlorobenzoyl)-(methyl-**amino)butyl)-4-((2-acetylaminophenyl)-piperazine**

Mass Spectrum (ESI): m/e 587, 589, 591, 593 (M⁺+1 / 35Cl/37Cl-isotope pattern).

35 EXAMPLE 86

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3-chlorobenzyl)-(methyl-
amino)butyl)-4-((2-acetylaminophenyl)-piperazine
Mass Spectrum (ESI): m/e 587, 589, 591, 593 (M⁺+1 / 35Cl/37Cl-isotope
pattern).

EXAMPLE 87

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-2-chlorobenzoyl)-(methyl-
amino)butyl)-4-((2-acetylaminophenyl)-piperazine

10

Mass Spectrum (ESI): m/e 587, 589, 591, 593 (M⁺+1 / 35Cl/37Cl-isotope
pattern).

EXAMPLE 88

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-4-methylbenzoyl)-(methyl-
amino)butyl)-4-((2-acetylaminophenyl)-piperazine

15

Mass Spectrum (ESI): m/e 587, 589, 591, 593 (M⁺+1 / 35Cl/37Cl-isotope
pattern).

EXAMPLE 89

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dimethoxybenzoyl)-(methyl-
amino)butyl)-4-((2-acetylaminophenyl)-piperazine

20

Mass Spectrum (ESI): m/e 611, 613, 615 (M⁺+1 / 35Cl/37Cl-isotope
pattern).

EXAMPLE 90

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3-trifluoromethylbenzoyl)-(methyl-
amino)butyl)-4-((2-acetylaminophenyl)-piperazine

25

Mass Spectrum (ESI): m/e 611, 613, 615 (M⁺+1 / 35Cl/37Cl-isotope
pattern).

EXAMPLE 91

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-4-i-propoxybenzoyl)-(methyl-
amino)butyl)-4-((2-acetylaminophenyl)-piperazine

30

Mass Spectrum (ESI): m/e 621, 623, 625 (M⁺+1 / 35Cl/37Cl-isotope
pattern).

EXAMPLE 92

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,6-dichlorobenzoyl)-(methyl-
amino)butyl)-4-((2-acetylaminophenyl)-piperazine
Mass Spectrum (ESI): m/e 611, 613, 615 (M⁺+1 / 35Cl/37Cl-isotope
pattern).

EXAMPLE 93

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3-trifluoromethyl-4-fluorobenzoyl)-
(methylamino)butyl)-4-((2-acetylaminophenyl)-piperazine

10

Mass Spectrum (ESI): m/e 601, 603, 605, 607 (M⁺+19 / 35Cl/37Cl-isotope
pattern).

EXAMPLE 94

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dimethoxybenzoyl)-(methyl-
amino)butyl)-4-((2-acetylaminophenyl)-piperazine

15

Mass Spectrum (ESI): m/e 611, 613, 615 (M⁺+1 / 35Cl/37Cl-isotope
pattern).

EXAMPLE 95

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3-trifluoromethylbenzoyl)-(methyl-
amino)butyl)-4-((2-acetylaminophenyl)-piperazine

20

Mass Spectrum (ESI): m/e 611, 613, 615 (M⁺+1 / 35Cl/37Cl-isotope
pattern).

EXAMPLE 96

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-2,5-dichlorobenzoyl)-(methyl-
amino)butyl)-4-((2-acetylaminophenyl)-piperazine

25

Mass Spectrum (ESI): m/e 621, 623, 625 (M⁺+1 / 35Cl/37Cl-isotope
pattern). EXAMPLE 97

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-2,3-dichlorobenzoyl)-(methyl-amino)butyl)-4-((2-acetylaminophenyl)phenyl)-piperazine
 5 Mass Spectrum (ESI): m/e 621, 623, 625, 627 (M⁺+1 / 35Cl/37Cl-isotope pattern). EXAMPLE 98

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-2-trifluoromethylbenzoyl)-(methyl-amino)butyl)-4-((2-acetylaminophenyl)phenyl)-piperazine
 10 Mass Spectrum (ESI): m/e 621, 623, 625 (M⁺+1 / 35Cl/37Cl-isotope pattern). EXAMPLE 99

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-bis-trifluoromethylbenzoyl)-(methyl-amino)butyl)-4-((2-acetylaminophenyl)phenyl)-piperazine
 15 Mass Spectrum (ESI): m/e 603, 605, 609 (M⁺+1 / 35Cl/37Cl-isotope pattern). EXAMPLE 100

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-naphth-1-oyl)(methyl-amino)butyl)-4-((2-acetylaminophenyl)phenyl)-piperazine
 20 Mass Spectrum (ESI): m/e 603, 605, 609 (M⁺+1 / 35Cl/37Cl-isotope pattern). EXAMPLE 101

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-naphth-2-oyl)(methyl-amino)butyl)-4-((2-acetylaminophenyl)phenyl)-piperazine
 25 Mass Spectrum (ESI): m/e 603, 605, 609 (M⁺+1 / 35Cl/37Cl-isotope pattern). EXAMPLE 102

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-4-trifluoromethylbenzoyl)-(methyl-amino)butyl)-4-((2-acetylaminophenyl)phenyl)-piperazine
 30 Mass Spectrum (ESI): m/e 621, 623, 625 (M⁺+1 / 35Cl/37Cl-isotope pattern). EXAMPLE 103

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3-nitrobenzoyl)-(methyl-amino)butyl)-4-((2-acetylaminophenyl)phenyl)-piperazine
 5 Mass Spectrum (ESI): m/e 598, 599, 592 (M⁺+1 / 35Cl/37Cl-isotope pattern). EXAMPLE 104

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3-cyanobenzoyl)-(methyl-amino)butyl)-4-((2-acetylaminophenyl)phenyl)-piperazine
 10 Mass Spectrum (ESI): m/e 578 (M⁺+1). EXAMPLE 105

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3-nitrobenzoyl)-(methyl-amino)butyl)-4-((2-acetylaminophenyl)phenyl)-piperazine
 15 Mass Spectrum (ESI): m/e 598, 599, 592 (M⁺+1 / 35Cl/37Cl-isotope pattern). EXAMPLE 106

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3-dimethyl-4-fluorobenzoyl)-(methyl-amino)butyl)-4-((2-acetylaminophenyl)phenyl)-piperazine
 20 Mass Spectrum (ESI): m/e 599, 601, 603 (M⁺+1 / 35Cl/37Cl-isotope pattern). EXAMPLE 107

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-4-fluorobenzoyl)-(methyl-amino)butyl)-4-((2-acetylaminophenyl)phenyl)-piperazine
 25 Mass Spectrum (ESI): m/e 679, 681, 683 (M⁺+1 / 35Cl/37Cl-isotope pattern). EXAMPLE 108

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3-iodobenzoyl)-(methyl-amino)butyl)-4-((2-acetylaminophenyl)phenyl)-piperazine
 30 Mass Spectrum (ESI): m/e 583, 585, 587 (M⁺+1 / 35Cl/37Cl-isotope pattern). EXAMPLE 109

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dibromobenzoyl)-(methylamino)butyl)-4-(2-acetylaminobenzyl)-piperazine

Mass Spectrum (ESI): m/e 709, 711, 713, 715 (M⁺+1 / 35Cl/37Cl, 79Br/81Br-isotope pattern).

EXAMPLE 110
5
1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(2-acetylaminobenzyl)-piperazine

10 Mass Spectrum (ESI): m/e 581, 583, 585 (M⁺+1 / 35Cl/37Cl-isotope pattern).

EXAMPLE 111
15 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methylamino)butyl)-4-(2-acetylaminophenyl)-piperazine

Mass Spectrum (ESI): m/e 491, 493, 495 (M⁺+1 / 35Cl/37Cl-isotope pattern).

The compounds in Examples 112-120 were prepared by reacting the requisite piperazine with 3-((S)-(3,4-dichlorophenyl))-4-(3,5-dichlorobenzoyl)methylamino butanal (from Example 2, Step A) according to the procedure of Example 71, Step D. The piperazine substrates were purchased or synthesized by the indicated procedures.

EXAMPLE 112
20

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(4-fluorophenyl)-piperazine

Mass Spectrum (CI) 582, 584, 586 (M⁺+1 / 35Cl/37Cl-isotope pattern).

EXAMPLE 113
25 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(3-nitrophenyl)-piperazine

Mass Spectrum (CI) 609, 611, 613 (M⁺+1 / 35Cl/37Cl-isotope pattern).

EXAMPLE 114
30

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(4-acetylphenyl)-piperazine

Mass Spectrum (CI) 606, 608, 610 (M⁺+1 / 35Cl/37Cl-isotope pattern).

EXAMPLE 114
35

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(4-methoxyphenyl)-piperazine

Mass Spectrum (CI) 578, 580, 582 (M⁺+1 / 35Cl/37Cl-isotope pattern).

EXAMPLE 115
5
1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(4-chlorophenyl)-piperazine

Mass Spectrum (CI) 598, 600, 602 (M⁺+1 / 35Cl/37Cl-isotope pattern).

EXAMPLE 116
10 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(3,4-dichlorobenzoyl)-piperazine

Mass Spectrum (CI) 582, 584, 586 (M⁺+1 / 35Cl/37Cl-isotope pattern).

EXAMPLE 117
15 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(4-nitrophenyl)-piperazine

Mass Spectrum (CI) 609, 611, 613 (M⁺+1 / 35Cl/37Cl-isotope pattern).

EXAMPLE 118
20

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(3-trifluoromethylphenyl)-piperazine

Mass Spectrum (CI) 632, 634, 636 (M⁺+1 / 35Cl/37Cl-isotope pattern).

EXAMPLE 119
25

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(3-methoxyphenyl)-piperazine

Mass Spectrum (CI) 578, 580, 582 (M⁺+1 / 35Cl/37Cl-isotope pattern).

EXAMPLE 120
30

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino)butyl)-4-(2-cyanophenyl)-piperazine

Mass Spectrum (CI) 588, 590, 592 (M⁺+1 / 35Cl/37Cl-isotope pattern).

EXAMPLE 121
35

1-(3-((S)-3-Chlorophenyl))-4-(N-(phenylsulfonyl)(methylamino)butyl)-4-phenylpiperazine.

EXAMPLE 124

5 A mixture of 3-((S)-3-chlorophenyl))-4-(N-(phenylsulfonyl)(methylamino)butyl)-4-phenylpiperazine according to the procedure of Hale, J.J.; Finke, P.E.; MacCoss, M.

Bioorganic & Medicinal Chemistry Letters 1993, 3, 319-322 and Example 1 except using phenylsulfonyl chloride in place of the benzoyl chloride in the acylation.

10 1-phenylpiperazine (22 mg, 0.135 mmol), 4A molecular sieves (25 mg) and acetic acid (0.008 mL, 0.136 mmol) in THF (1 mL) was stirred at rt for 20 min. Sodium triacetoxyborohydride (19 mg, 0.090 mmol) was then added and the reaction was stirred at rt for 16 h. The mixture was poured into a water containing excess sodium carbonate and was extracted twice with ethyl acetate. The organic layers were

15 washed with brine, dried, combined and concentrated in vacuo. The residue was purified by prep TLC using 2% triethylamine in 85% ethyl acetate/hexanes as eluent to afforded the title compound (17 mg). Mass Spectrum (ESI) M+H = 498, 450

20 Using essentially the same procedure as Example 121 but employing the corresponding substituted piperazine, the following Examples were prepared.

EXAMPLE 122

25 1-(3-((S)-3-Chlorophenyl))-4-(N-(phenylsulfonyl)(methylamino)butyl)-4-(2-methylphenyl)piperazine.

Mass Spectrum (ESI) M+H = 512, 514

EXAMPLE 123

30 1-(3-((S)-3-Chlorophenyl))-4-(N-(phenylsulfonyl)(methylamino)butyl)-4-(3-hydroxouinoxalin-2-yl)piperazine.

35

5 1-(3-((S)-3-Chlorophenyl))-4-(N-(phenylsulfonyl)(methylamino)butyl)-4-(4-pyridyl)piperazine

10 Mass Spectrum (NH₃/Cl) M+H = 499, 501

EXAMPLE 125

15 1-(3-((S)-3-Chlorophenyl))-4-(N-(phenylsulfonyl)(methylamino)butyl)-4-benzylpiperazine

20 Mass Spectrum (NH₃/Cl) M+H = 512, 514

EXAMPLE 126

25 1-(3-((S)-3-Chlorophenyl))-4-(N-(phenylsulfonyl)(methylamino)butyl)-4-(2-methoxyphenyl)piperazine

Mass Spectrum (NH₃/Cl) M+H = 528, 530

EXAMPLE 127

30 1-(3-(R,S)-Phenyl)-4-(N-(phenylsulfonyl)(methylamino)butyl)-4-(pyrimidin-2-yl)piperazine


Mass Spectrum (ESI) M+H = 466

While the invention has been described and illustrated with

reference to certain particular embodiments thereof, those skilled in the art will appreciate that various adaptations, changes, modifications,

5 substitutions, deletions, or additions of procedures and protocols may be made without departing from the spirit and scope of the invention. For

5. A method for modulation of chemokine receptor activity in a
mammal comprising the administration of an effective amount of a
compound of formula I:



15 there are present pharmaceutical carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. It is intended, therefore, that the invention be defined by the scope of the claims which follow and that such claims be interpreted as broadly as is reasonable.

wherein the nitrogen attached to R₁ shown above is optionally

R₁ is selected from a group consisting of: quaternized with C₁-alkyl or phenylC₁-alkyl or is optionally present as the N-Oxide (N+O⁻), and wherein:

15 α_1 is selected from a group consisting of:
linear or branched C1-8 alkyl, linear or branched C2-8
alkenyl, wherein the C1-8 alkyl or C2-8 alkenyl is optionally

mono, di, tri or tetra substituted, the substituents independently selected from:

(a) hydroxy,
(b) oxo,

20 (c) cyano,

(a) halogen which is defined to include Br, Cl, I, and F,
 (e) trifluoromethyl,
 (f) phenyl or mono, di or tri-substituted phenyl, the
 substituents independently selected from

(1') phenyl,
; ; ;

- (2') hydroxy,
- (3') C1-3alkyl,
- (4') cyano,
- (5') halogen,

•137•

10 (6') trifluoromethyl,
 (7') -NR₆COR₇,
 (8') -NR₆CO₂R₇,
 (9') -NR₆CONHR₇,
 (10') -NR₆SO_jR₇, wherein j is 1 or 2,
 (11') -CONR₆R₇,
 (12') -COR₆,
 (13') -CO₂R₆,
 (14') -OR₆,
 (15') -S(O)_kR₆, wherein k is 0, 1 or 2,
 (g) -NR₆RR₇,
 (h) -NR₆COR₇,
 (i) -NR₆CO₂R₇,
 (j) -NR₆CONH₇,
 (k) -NR₆S(O)_jR₇,
 (l) -CONR₆R₇,
 (m) -COR₆,
 (n) -CO₂R₆,
 (o) -OR₆,
 (p) -S(O)_kR₆,
 (q) -NR₆CO-heteraryl,
 (r) -NR₆S(O)_j-heteraryl, and
 (s) heteraryl, wherein heteraryl is selected from the
 group consisting of:
 (1') benzimidazolyl,
 (2') benzofuranyl,
 (3') benzoxazolyl,
 (4') furanyl,
 (5') imidazolyl,
 (6') indolyl,
 (7') isooxazolyl,
 (8') isothiazolyl,
 (9') oxadiazolyl,
 (10') oxazolyl,
 (11') pyrazinyl,
 10 (12') pyrazolyl,
 (13') pyridyl,
 (14') pyrimidyl,
 (15') pyrrolyl,
 (16') quinolyl,
 (17') tetrazolyl,
 (18') thiadiazolyl,
 (19') thiazolyl,
 (20') thiienyl, and
 (21') triazolyl,
 10 wherein the heteraryl is unsubstituted or mono di or
 tri-substituted, the substituents independently selected
 from:
 15 (a'') phenyl,
 (b'') hydroxy,
 (c'') oxo,
 (d'') cyano,
 (e'') halogen, and
 (f'') trifluoromethyl;

20 Ar is selected from the group consisting of:
 (1) phenyl,
 (2) pyridyl,
 (3) pyrimidyl,
 (4) naphthyl,
 (5) furyl,
 (6) pyrryl,
 (7) thiaryl,
 (8) isothiazolyl,
 30 (9) imidazolyl,
 (10) benzimidazolyl,
 (11) tetrazolyl,
 (12) pyrazinyl,
 (13) quinolyl,
 (14) isoquinolyl,

(15) benzofuryl,
(16) isobenzofuryl,
(17) benzothienyl,
(18) pyrazolyl,
5 (19) indolyl,
(20) isoindolyl,
(21) purinyl,
(22) isoxazolyl,
(23) thiazolyl,
10 (24) oxazolyl,
(25) triazinyl, and
(26) benzthiazolyl,
(27) benzoxazolyl,
(28) imidazopyrazinyl,
15 (29) triazolopyrazinyl,
(30) naphthypyridinyl,
(31) furopyridinyl,
(32) thiopyranopyrimidyl and the 5-oxide and 5-dioxide thereof,
(33) pyridazinyl,
20 (34) quinazolinyl,
(35) pteridinyl,
(36) triazolopyrimidyl,
(37) triazolopyrazinyl,
(38) thiapurinyl,
25 (39) oxapurinyl, and
(40) deazapurinyl,

wherein Ar items (1) to (40) are optionally mono or di-substituted, said substituents being independently selected from:

(a) C₁-3 alkyl, unsubstituted or substituted with
30 (1') oxo,
(2') hydroxy,
(3') OR₆,
(4') halogen,
(5') trifluoromethyl,

(6') phenyl or mono, di or tri-substituted phenyl,
the substituents independently selected from
hydroxy, cyano, halogen, and trifluoromethyl,

(b) -(CH₂)_nS(O)j-NH(C₁-6 alkyl), wherein n is 0, 1 or 2,
(c) -(CH₂)_nS(O)j-NH₂,
(d) -(CH₂)_nS(O)j-NHR₆,
(e) -(CH₂)_nS(O)j-NHR₆,
5 (f) -(CH₂)_nS(O)j-NR₆(C₁-6 alkyl),
(g) -(CH₂)_nCONH₂,
(h) -(CH₂)_nCONH(C₁-6 alkyl),
(i) -(CH₂)_nCONHR₆,
(j) -(CH₂)_nCONR₆(C₁-6 alkyl),
10 (k) -(CH₂)_nCO₂H,
(l) -(CH₂)_nCO₂(C₁-6 alkyl),
(m) -(CH₂)_nNR₆R₇,
(n) -(CH₂)_nCO₂H, and
15 (o) -(CH₂)_nNH-C(O)NH₂,
(p) -(CH₂)_nNH-C(O)NH₂,
(q) -(CH₂)_nNH-C(O)N(dC₁-6 alkyl),
(r) -(CH₂)_nNH-S(O)j-C₁-6 alkyl,
20 (s) -(CH₂)_nN(C₁-3alkyl)-C(O)N(dC₁-6 alkyl),
(t) -(CH₂)_n-heteroaryl, -C(O)-heteroaryl or
-(CH₂)_n-O-heteroaryl, wherein the heteroaryl is
25 selected from the group consisting of:
(1') benzimidazolyl,
(2') benzofuranyl,
(3') benzoxazolyl,
(4') furanyl,
(5') imidazolyl,

(6') indolyl,
(7') isooxazolyl,
(8') isothiazolyl,
(9') oxadiazolyl,
(10') oxazolyl,
30 (11') pyrazinyl,

- (12') pyrazolyl,
- (13') pyridyl or oxypyridyl,
- (14') pyrimidyl,
- (15') pyrrolyl,
- 5 (16') quinolyl,
- (17') tetrazolyl,
- (18') thiadiazolyl,
- (19') thiazolyl,
- (20') thiaryl, and
- (21') triazolyl,

wherein the heteroaryl group of items (1') to (21') is unsubstituted, mono, di or tri substituted, the substituents selected from:

- (a') hydrogen,
- (b') C₁-6 alkyl, branched or unbranched, unsubstituted or mono or di-substituted, the substituents being selected from
- hydrogen and hydroxy,
- (c') hydroxy,
- (d') oxo,
- (e') -OR₆,
- (f') halogen,
- (g') trifluoromethyl,
- (h') nitro,
- (i') cyano,
- (j') -NHR₆,
- (k') -NR₆R₇,
- (l') -NHCOR₆,
- 25 (m') -NR₆COR₇,
- (n') -NHO₂R₆,
- (o') -NR₆CO₂R₇,
- (p') -NHS(O)R₆,
- (q') -NR₆SO₂R₇,
- (r') -CONR₆R₇,
- 30 (s') -COR₆,

- (t') -CO₂R₆, and
- (u') -S(O)jR₆;

R₆ is selected from:

- 5 (1) hydrogen,
- (2) C₁-6 alkyl, or mono or di-substituted C₁-6 alkyl, the substituents independently selected from:
 - (a) phenyl,
 - (b) hydroxy,
 - (c) oxo,
 - (d) cyano,
 - (e) halogen,
 - (f) trifluoromethyl, and
- 10 (3) phenyl or mono di or tri-substituted phenyl, the substituents independently selected from:
 - (a) hydroxy,
 - (b) C₁-3alkyl,
 - (c) cyano,
 - (d) halogen,
 - (e) trifluoromethyl;
- 15 (3) phenyl or mono di or tri-substituted phenyl, the substituents independently selected from:
 - (a) hydroxy,
 - (b) C₁-3alkyl,
 - (c) cyano,
 - (d) halogen,
 - (e) trifluoromethyl;
- 20 R₇ is selected from:
 - (1) hydrogen,
 - (2) C₁-6 alkyl, or mono or di-substituted C₁-6 alkyl, the substituents independently selected from:
 - (a) phenyl unsubstituted or substituted with
 - (1') hydroxy,
 - (2') C₁-3alkyl,
 - (3') cyano,
 - (4') halogen,
 - (5') trifluoromethyl,
 - (6') C₁-3alkyloxy,
 - (b) hydroxy,
 - (c) oxo,

5 (d) cyano,
 (e) halogen,
 (f) trifluoromethyl,
 phenyl or mono di or tri-substituted phenyl, the substituents
 independently selected from:
 (a) hydroxy,
 (b) C1-3alkyl,
 (c) cyano,
 (d) halogen,
 (e) trifluoromethyl,


10 (4) naphthyl or mono di or tri-substituted naphthyl, the
 substituents independently selected from:
 (a) hydroxy,
 (b) C1-3alkyl,
 (c) cyano,
 (d) halogen,
 (e) trifluoromethyl,

20 or R6 and R7 are joined together to form a 5-, 6-, or 7-
 membered monocyclic saturated ring containing 1 or 2
 heteroatoms independently selected from nitrogen, oxygen,
 and sulfur, and in which the ring is unsubstituted or mono
 or di-substituted, the substituents independently selected
 from:
 (1) hydroxy,
 (2) oxo,
 (3) cyano,
 (4) halogen,
 (5) trifluoromethyl,

25 (3) cyano,
 (4) halogen,
 (5) trifluoromethyl,
 (6) C1-3alkyloxy,

5 provided that when Ar is phenyl, pyridyl or pyrimidyl, then Ar is mono
 di or tri-substituted;
 and further provided that when Ar is mono substituted phenyl, then the
 substituent is other than halo, hydroxy, -OC1-4alkyl, CF3 or C1-alkyl;
 and further provided that when Ar is di- or tri-substituted, at least one of
 the substituents is other than halo, hydroxy, -OC1-4alkyl, CF3 or
 C1-4alkyl;
 and pharmaceutically acceptable salts thereof.

15 2. The method of Claim 1 wherein the compound
 is of Formula Ia:



20 wherein:

R1 is selected from a group consisting of:
 C3, C4, C5, C6, C7, C8 linear or branched alkyl, unsubstituted or
 mono, di or tri-substituted, the substituents independently
 selected from:

25 (a) hydroxy,
 (b) Cl or F,
 (c) phenyl or mono, di or tri-substituted phenyl, the
 substituents independently selected from:
 (1') phenyl,

35 (1) hydroxy,
 (2) hydrogen,

(2') hydroxy,
(3') C1-3alkyl,

(4') cyano,

(5') halogen,

(6') trifluoromethyl,

(d) -NR6CO-R7, wherein R6 is hydrogen or C1-3 alkyl and R7 is phenyl optionally substituted with Cl, F, CF3 or C1-3alkyl,

(e) -COR6,

(f) -OR6,

(g) -NR6S(O)j-R7, where j is 1 or 2,

(h) -NR6S(O)j-heteroaryl, wherein heteroaryl is selected from the group consisting of:

(1') benzimidazolyl,

(2') benzofuranyl,

(3') benzoxazolyl,

(4') furanyl,

(5') imidazolyl,

(6') indolyl,

(7') isoaxazolyl,

(8') isothiazolyl,

(9') oxadiazolyl,

(10') oxazolyl,

(11') pyrazinyl,

(12') pyrazolyl,

(13') pyridyl,

(14') pyrimidyl,

(15') pyrrolyl,

(16') quinolyl,

(17') tetrazolyl,

(18') thiadiazolyl,

(19') thiazolyl,

(20') thietyl, and

(21') triazolyl,
wherein the heteroaryl is unsubstituted or mono di or

35

wherein the heteroaryl is unsubstituted or mono di or

-147-

35 wherein the heteroaryl is unsubstituted or mono di or

tri-substituted, the substituents independently selected

from:

(a') phenyl,

(b') hydroxy,

(c') oxo,

(d') cyano,

(e') halogen, and

(f') trifluoromethyl;

10

10 Ar is selected from the group consisting of:

(1) phenyl,

(2) pyrazinyl,

(3) pyrazolyl,

(4) pyridyl,

(5) pyrimidyl, and

(6) thieryl,

wherein the Ar is unsubstituted or mono or di-substituted, and substituents are independently selected from:

(a) C1-3 alkyl, unsubstituted or substituted with

(1') oxo,

(2') hydroxy,

(3') OR6,

(4') halogen, and

(5') trifluoromethyl,

(b) CONR6-C1-2alkyl,

(c) CO2H,

(d) CO2(C1-2 alkyl),

(e) CH2NR6-C1-2alkyl,

(f) CH2NH-C(O)-C1-3alkyl,

(g) CH2NH-C(=O)NH-C1-3alkyl,

(h) CH2NH-C(=O)NH2,

(i) CH2NH-C(=O)NHC1-3alkyl,

(j) CH2NH-S(O)j-C1-3alkyl,

(k) CH2-heteroaryl, with the heteroaryl is selected from

5

5 wherein the heteroaryl is unsubstituted or mono di or

-148-

- (1') imidazolyl,
- (2') oxazolyl,
- (3') pyridyl,
- (4') tetrazolyl,
- (5') triazolyl,

and the heteroaryl is unsubstituted, mono, di or tri-substituted, where the substituents selected from:

- (a') hydrogen,
- (b') C1-6 alkyl, branched or unbranched, unsubstituted or mono or di-substituted,

the substituents being selected from hydrogen and hydroxy;

and pharmaceutically acceptable salts thereof.

15

R1 is selected from a group consisting of: C4, C5, C6, C7 or C8 linear or branched alkyl, which is mono, di- or tri-substituted, where the substituents are independently selected from:

- (a) hydroxy,
- (b) Cl or F,
- (c) phenyl or mono or di-substituted phenyl, where the substituents are independently selected from:

(1') hydroxy,

(2') methyl or ethyl,

(3') Cl or F,

(4') trifluoromethyl,

(d) -NR6COR7, wherein R6 is methyl and R7 is phenyl optionally substituted with halo, CF3, C1-3alkyl or C1-3alkoxy, and

(e) -NR6S(O)j-R7, where j is 1 or 2;

and pharmaceutically acceptable salts thereof.

35

4. The method of Claim 1 wherein the compound Ar is mono substituted or di-substituted, wherein the substituents are selected from the group consisting of:

- (a) C1-3 alkyl, unsubstituted or substituted with (1') oxo,
- (2') hydroxy, or
- (3') OR6, wherein R6 is hydrogen or C1-3 alkyl,
- (b) -CH2NR6-(C1-2 alkyl),
- (c) -CH2NH-C(O)-C1-3alkyl,
- (d) -CH2NH-C(O)NH2,
- (i) -CH2NH-C(O)NH-C1-3alkyl,
- (j) -CH2NH-C(ONHC1-3alkyl),
- (k) -CH2NH-S(O)j-C1-3alkyl,
- (l) -CH2-heteroaryl, where heteroaryl is selected from the group consisting of:

- (1') imidazolyl,
- (2') oxazolyl,

(3') pyridyl,

(4') tetrazolyl,

(5') triazolyl,

and where heteroaryl is unsubstituted, mono, di or tri-substituted, where the substituents are independently selected from:

25 (a') hydrogen,


(b') C1-6 alkyl, branched or unbranched,

unsubstituted or mono or di-substituted, where the substituents are selected from: hydrogen and hydroxy;

30 and pharmaceutically acceptable salts thereof.


5. The method of Claim 1 wherein the compound

is of Formula Ia:




Ia

5 R1 is
wherein:



, or



;

where B is selected from:

(a) phenyl, naphthyl, mono, di or tri-substituted phenyl, and

10 mono, di or tri-substituted naphthyl wherein the
substituents on phenyl or naphthyl are independently
selected from: chloro, methyl, phenyl, C1-3alkoxy, and CF3;(b) -CH2phenyl, and mono or di-substituted -CH2phenyl
wherein the substituents on phenyl are independently
selected from: chloro, methyl, phenyl, C1-3alkoxy and CF3;15 (c) pyridyl, and mono di or tri-substituted pyridyl wherein the
substituents on pyridyl are independently selected from:
chloro, methyl, phenyl, C1-3alkoxy and CF3; and

(d) thiophene, and mono or disubstituted thiophene wherein
the substituents on thiophene are independently selected
from: chloro, methyl, phenyl, C1-3alkoxy and CF3;

5 Ar is mono substituted phenyl wherein the substituent is selected from
the group consisting of:

- (a) -CH2-tetrazolyl,
- (b) -CH2-triazolyl,
- (c) -CH2-imidazolyl,
- (d) -CH2-N(HC(=O)NCH3)2,
- (e) -CH2-N(HC(=O)NHC(=O)CH3),
- (f) -CH2-N(HS(=O)2CH3),
- (g) -CH2-pyridyl,
- (h) -CH2-oxopyridyl,
- (i) -CH2-N(HC(=O)CH3),
- (j) -CH2-O-pyridyl, and
- (k) mono or di-substituted purine wherein the substituents are
selected from:

- (1') C1-3alkyl,
- (2') C1-3alkoxy,
- (3') fluoro,
- (4') hydrogen, and
- (5') fluoroC1-3alkyl;


25 R10 is selected from: hydrogen, C1-3alkyl, and phenyl;

R11 and R12 are independently selected from:
hydrogen, halogen, methyl, phenyl or CF3;




30 and pharmaceutically acceptable salts thereof.

6. The method of Claim 5 wherein the compound of
Formula Ia B is unsubstituted phenyl or unsubstituted thiophene.

7. The method of Claim 1 wherein the compound of Formula I Ar is selected from




5




8. The method of Claim 1 wherein the compound of Formula I Ar is selected from the group consisting of:

5



-153-



-154-

9. The method of Claim 1 wherein the compound is selected from the group consisting of:

- (a) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl-(methylamino))butyl)-4-(2-acetylaminomethyl)-piperazine;
- (b) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl-(methylamino))butyl)-4-(2-(3-pyridyloxy)methylphenyl)-piperazine;
- (c) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl-(methylamino))butyl)-4-((2-methylaminocarbonylamino-methyl)phenyl)-piperazine;
- (d) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl (methylamino)butyl)-4-((2-dimethylaminocarbonylamino-methyl) phenyl)-piperazine;
- (e) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl-(methylamino)butyl)-4-(2-methylsulfonylamino-methyl-phenyl)-piperazine;
- (f) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl-(methylamino))butyl)-4-((2-methylaminocarbonylamino-methyl)phenyl)-piperazine;
- (g) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl-(methylamino))butyl)-4-((2-dimethylaminocarbonylamino-methyl) phenyl)-piperazine;
- (h) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl-(methylamino))butyl)-4-(2-methylsulfonylamino-methyl-phenyl)-piperazine;
- (i) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl-(methylamino))butyl)-4-(2-(1-imidazolyl)methylphenyl)-piperazine;
- (j) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl-(methylamino))butyl)-4-(2-(1,2,4-triazolyl)methyl-phenyl)-piperazine;
- (k) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl-(methylamino))butyl)-4-(2-(1',2',4-triazolyl)methyl-phenyl)-piperazine;
- (l) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl-(methylamino))butyl)-4-(1,2,4-triazolo(1,5-a)pyrazin-8-yl)piperazine;
- (m) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl-(methylamino))butyl)-4-(2-(3-pyridyloxy)methylphenyl)-piperazine;
- (n) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl-(methylamino))butyl)-4-(2-(1'-2(1'H)-pyridone)methyl-phenyl)-piperazine;
- (o) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl-(methylamino))butyl)-4-(2-(1'-2(1'H)-pyridone)methyl-phenyl)-piperazine;
- (p) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-4-(2-pyridine-5-oxide);
- (q) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-4-(2-pyrimid-4-yl)piperazine-5-oxide;
- (r) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl-(methylamino))butyl)-4-(9-(2-fluoroethyl)-2-methoxy-purin-6-yl)piperazine;
- (s) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl-(methylamino))butyl)-4-(9-methyl-purin-6-yl)piperazine;
- (t) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl-(methylamino))butyl)-4-(9-methyl-purin-6-yl)piperazine;
- (u) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl-(methylamino))butyl)-4-(6-methyl-imidazo(1,2-a)pyrazin-1-yl)piperazine;
- (v) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl-(methylamino))butyl)-4-(1,7-naphthyridin-8-yl)piperazine;
- (w) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl-(methylamino))butyl)-4-(1,2,4-triazolo(1,5-a)pyrazin-8-yl)piperazine;
- (x) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl-(methylamino))butyl)-4-(5-methyl-pyrid-2-yl)piperazine;


(y) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)-(methylamino)butyl)-4-(2-amino-pyrazin-4-yl)piperazine;
 (z) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)-(methylamino)butyl)-4-(furo(2,3-c)pyrid-4-yl)piperazine;

5 (aa) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)-(methylamino)butyl)-4-(2-amino-7,8-dihydro-6H-thiopyrano-(3,2-d)pyrimid-4-yl)piperazine;

(ab) 1-(3-((S)-3,4-Dichlorophenyl))-4-(2-amino-7,8-dihydro-6H-thiopyrano-(3,2-d)pyrimid-4-yl)piperazine;

10 (ac) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)-(methylamino)butyl)-4-(2-methyl-7,8-dihydro-6H-thiopyrano-(3,2-d)pyrimid-4-yl)piperazine;

5



I

bis(trifluoromethyl)benzoyl)-(methylamino)butyl)-4-(1,2,4-triazolo(1,5-

a)pyrazin-8-yl)piperazine; and
 (ad) 1-(3-((S)-4-Chlorophenyl))-4-(N-(3,5-

15 bis(trifluoromethyl)benzoyl)-(methylamino)butyl)-4-(1,2,4-triazolo(1,5-

a)pyrazin-8-yl)piperazine;

and pharmaceutically acceptable salts thereof.

R₁ is selected from a group consisting of:

15 linear or branched C₁-8 alkyl, linear or branched C₂-8 alkenyl, wherein the C₁-8 alkyl or C₂-8 alkenyl is optionally mono, di, tri or tetra substituted, the substituents independently selected from:

(a) hydroxy,
 (b) oxo,

(c) cyano,

20 (d) halogen which is defined to include Br, Cl, I, and F,
 (e) trifluoromethyl,
 (f) phenyl or mono, di or tri-substituted phenyl, the substituents independently selected from:

(1') phenyl,
 (2') hydroxy,
 (3') C₁-3alkyl,
 (4') cyano,
 (5') halogen,
 (6') trifluoromethyl,

10. A method for preventing infection by HIV, treating infection by HIV, delaying of the onset of AIDS, or treating AIDS comprising the administration to a patient of an effective amount of a compound of the formula:

5 (7') -NR₆COR₇,
 (8') -NR₆CO₂R₇,
 (9') -NR₆CONHR₇,
 (10') -NR₆SO_jR₇, wherein j is 1 or 2,
 (11') -CONR₆R₇,
 5 (12') -COR₆,
 (13') -CO₂R₆,
 (14') -OR₆,
 (15') -S(O)_kR₆, wherein k is 0, 1 or 2,
 10 (g) -NR₆R₇,
 (h) -NR₆COR₇,
 (i) -NR₆CO₂R₇,
 (j) -NR₆CONHR₇,
 (k) -NR₆S(O)_jR₇,
 15 (l) -CONR₆R₇,
 (m) -COR₆,
 (n) -CO₂R₆,
 (o) -OR₆,
 (p) -S(O)_kR₆,
 (q) -NR₆CO-heteraryl,
 (r) -NR₆S(O)_j-heteraryl, and
 (s) heteraryl, wherein heteraryl is selected from the
 group consisting of:
 (1') benzimidazolyl,
 (2') benzofuranyl,
 (3') benzoxazolyl,
 (4') furanyl,
 (5') imidazolyl,
 (6') indolyl,
 20 (7') isoindazolyl,
 (8') isothiazolyl,
 (9') oxadiazolyl,
 (10') oxazolyl,
 (11') pyrazinyl,
 30 (9) imidazolyl,
 (10) benzimidazolyl,
 (11) tetrazolyl,
 (12) pyrazinyl,
 (13) quinolyl,
 35 (14) isoquinolyl,

wherein the heteraryl is unsubstituted or mono di or tri-substituted, the substituents independently selected from:
 15 (a") phenyl,
 (b") hydroxy,
 (c") oxo,
 (d") cyano,
 (e") halogen, and
 (f") trifluoromethyl;

20 Ar is selected from the group consisting of:
 (1) phenyl,
 (2) pyridyl,
 (3) pyrimidyl,
 (4) naphthyl,
 (5) furyl,
 (6) pyrrolyl,
 (7) thiényl,
 (8) isothiazolyl,

30 (9) imidazolyl,
 (10) benzimidazolyl,
 (11) tetrazolyl,
 (12) pyrazinyl,
 (13) quinolyl,
 35 (14) isoquinolyl,

(15) benzofuryl,
 (16) isobenzoturyl,
 (17) benzothiaryl,
 (18) pyrazolyl,
 5 (19) indolyl,
 (20) isoindolyl,
 (21) purinyl,
 (22) isoxazolyl,
 (23) thiazolyl,
 (24) oxazolyl,
 10 (25) triazinyl, and
 (26) benzthiazolyl,
 (27) benzoxazolyl,
 (28) imidazopyrazinyl,
 (29) triazolopyrazinyl,
 (30) naphthyridinyl,
 (31) furopyridinyl,
 (32) thiopyranopyrimidyl and the 5-oxide and 5-dioxide thereof,
 (33) pyridazinyl,
 20 (34) quinazolinyl,
 (35) pteridinyl,
 (36) triazolopyrimidyl,
 (37) triazoloprazinyl,
 (38) thiapurinyl,
 25 (39) oxapurinyl, and
 (40) deazapurinyl,
 wherein Ar items (1) to (40) are optionally mono or di-substituted, said
 substituents being independently selected from:
 (a) C1-3 alkyl, unsubstituted or substituted with
 30 (1') oxo,
 (2') hydroxy,
 (3') OR₆,
 (4') halogen,
 (5') trifluoromethyl,
 35 (6') phenyl or mono, di or tri-substituted phenyl,
 the substituents independently selected from
 (b) hydroxy, cyano, halogen, and trifluoromethyl,
 (c) -(CH₂)_nS(O)(C₁₋₆ alkyl), wherein n is 0, 1 or 2,
 (d) -(CH₂)_nS(O)(C₁₋₆ alkyl),
 (e) -(CH₂)_nS(O)(NH)R₆,
 (f) -(CH₂)_nS(O)(NR₆)(C₁₋₆ alkyl),
 (g) -(CH₂)_nCONH₂,
 (h) -(CH₂)_nCONH(C₁₋₆ alkyl),
 (i) -(CH₂)_nCONHR₆,
 (j) -(CH₂)_nCONR₆R₇,
 (k) -(CH₂)_nCO₂,
 (l) -(CH₂)_nCO₂(C₁₋₆ alkyl),
 (m) -(CH₂)_nNR₆R₇,
 (n) -(CH₂)_nNH-C(O)-C₁₋₆ alkyl,
 (o) -(CH₂)_nNH-C(O)NH₂,
 (p) -(CH₂)_nNH-C(O)NHCl-C₁₋₆ alkyl,
 (q) -(CH₂)_nNH-C(O)-N(C₁₋₃ alkyl)-C(O)-N(C₁₋₆ alkyl),
 (r) -(CH₂)_nNH-SO₂-C₁₋₆ alkyl,
 (s) -(CH₂)_nN(C₁₋₃ alkyl)-C(O)-N(C₁₋₆ alkyl),
 (t) -(CH₂)_n-heteroaryl, -C(O)-heteroaryl or
 -(CH₂)_n-O-heteroaryl, wherein the heteroaryl is
 selected from the group consisting of:
 (1') benzimidazolyl,
 (2) benzofuranyl,
 (3) benzoxazolyl,
 (4) furanyl,
 (5) imidazolyl,
 (6) indolyl,
 (7) isooxazolyl,
 (8) isothiazolyl,
 (9) oxadiazolyl,
 (10) oxazolyl,
 (11) pyrazinyl,

- (12') pyrazolyl,
- (13') pyridyl or oxopyridyl,
- (14') pyrimidyl,
- (15') pyrrolyl,
- (16') quinolyl,
- (17') tetrazolyl,
- (18') thiadiazolyl,
- (19') thiazolyl,
- (20') thionyl, and
- (21') triazolyl,

wherein the heteroaryl group of items (1') to (21') is unsubstituted, mono, di or tri substituted, the

substituents selected from:

- (a') hydrogen,
- (b') C1-6 alkyl, branched or unbranched, unsubstituted or mono or di-substituted, the substituents being selected from hydrogen and hydroxy,
- (c') hydroxy,
- (d') oxo,
- (e') -OR₆,
- (f') halogen,
- (g') trifluoromethyl,
- (h') nitro,
- (i') cyano,
- (j') -NHR₆,
- (k') -NR₆R₇,
- (l') -NHCOR₆,
- (m') -NR₆COR₇,
- (n') -NHCOR₆R₇,
- (o') -NR₆CO₂R₇,
- (p') -NHS(O)R₆,
- (q') -NR₆S(O)R₇,
- (r') -CONR₆R₇,
- (s') -COR₆,

-163-

5

- (17') tetrazolyl,
- (18') thiadiazolyl,
- (19') thiazolyl,
- (20') thionyl, and
- (21') triazolyl,

10

15

- (21') triazolyl,

wherein the heteroaryl group of items (1') to (21') is

unsubstituted, mono, di or tri substituted, the

substituents selected from:

- (a) phenyl,
- (b) hydroxy,
- (c) oxo,
- (d) cyano,
- (e) halogen,
- (f) trifluoromethyl, and

wherein the substituents are independently selected from:

the substituents being selected from

- (a) hydrogen,
- (b) C1-3alkyl,
- (c) cyano,
- (d) halogen,
- (e) trifluoromethyl,

15

- (3) phenyl or mono di or tri-substituted phenyl, the substituents

independently selected from:

- (a) hydroxy,
- (b) C1-3alkyl,
- (c) cyano,
- (d) halogen,
- (e) trifluoromethyl,

20

R7 is selected from:

- (1) hydrogen,
- (2) C1-6 alkyl, or mono or di-substituted C1-6 alkyl, the

substituents independently selected from:

the substituents independently selected from:

- (a) phenyl unsubstituted or substituted with
- (1') hydroxy,
- (2') C1-3alkyl,

25

- (3') cyano,

the substituents independently selected from:

- (4') halogen,
- (5') trifluoromethyl,
- (6') C1-3alkyloxy,
- (b) hydroxy,
- (c) oxo,

30

-164-

5 (d) cyano,
 (e) halogen,
 (f) trifluoromethyl,
 phenyl or mono di or tri-substituted phenyl, the substituents
 independently selected from:
 (a) hydroxy,
 (b) C1-3alkyl,
 (c) cyano,
 (d) halogen,
 (e) trifluoromethyl,
 naphthyl or mono di or tri-substituted naphthyl, the

10 substituents independently selected from:
 (a) hydroxy,
 (b) C1-3alkyl,
 (c) cyano,
 (d) halogen,
 (e) trifluoromethyl,

15 naphthyl or mono di or tri-substituted naphthyl, the

substituents independently selected from:
 (a) hydroxy,
 (b) C1-3alkyl,
 (c) cyano,
 (d) halogen,
 (e) trifluoromethyl,

20 or R6 and R7 are joined together to form a 5-, 6-, or 7- membered monocyclic saturated ring containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and in which the ring is unsubstituted or mono or di-substituted, the substituents independently selected from:
 (1) hydroxy,
 (2) oxo,
 (3) cyano,
 (4) halogen,
 (5) trifluoromethyl,

25 R1 is selected from a group consisting of:
 C3, C4, C5, C6, C7, C8 linear or branched alkyl, unsubstituted or mono, di or tri-substituted, the substituents independently selected from:
 (a) hydroxy,
 (b) Cl or F,
 (c) phenyl or mono, di or tri-substituted phenyl, the

30 substituents independently selected from:
 (1') phenyl,

R8 and R9 are each independently hydrogen or substituted C1-4alkyl wherein the substituent is selected from the group consisting of

35 (1) hydroxy,
 (2) hydrogen,

(2') hydroxy,
(3') C1-3alkyl,

(4') cyano,

(5') halogen,

(6') trifluoromethyl,

(d) -NR6CO-R7, wherein R6 is hydrogen or C1-3 alkyl and R7 is phenyl optionally substituted with Cl, F, CF3 or C1-3alkyl,

(e) -COR6,

(f) -OR6,

(g) -NR6S(O)j-R7, where j is 1 or 2,

(h) -NR6S(O)j-heteraryl, wherein heteraryl is selected from the group consisting of:

(1') benzimidazolyl,

(2') benzofuranyl,

(3') benzoxazolyl,

(4') furanyl,

(5') imidazolyl,

(6') indolyl,

(7') isooxazolyl,

(8') isothiazolyl,

(9') oxadiazolyl,

(10') oxazolyl,

(11') pyrazinyl,

(12') pyrazolyl,

(13') pyridyl,

(14') pyrimidyl,

(15') pyrrolyl,

(16') quinolyl,

(17') tetrazolyl,

(18') thiadiazolyl,

(19') thiazolyl,

(20') thiophenyl, and

(21') triazolyl,

wherein the heteraryl is unsubstituted or mono di or

10

(a) phenyl,

(b') hydroxy,

(c') oxo,

(d') cyano,

(e') halogen, and

(f') trifluoromethyl;

5

(a') phenyl,

(b') hydroxy,

(c') oxo,

(d') cyano,

(e') halogen, and

(f') trifluoromethyl;

10

Ar is selected from the group consisting of:

(1) phenyl,

(2) pyrazinyl,

(3) pyridyl,

(4) pyrimidyl, and

(5) thiienyl,

wherein the Ar is unsubstituted or mono or di-substituted, and substituents are independently selected from:

(a) C1-3 alkyl, unsubstituted or substituted with

(1') oxo,

(2') hydroxy,

(3') OR6,

(4') halogen, and

(5') trifluoromethyl,

(b) CONR6-(C1-2 alkyl),

(c) CO2H,

(d) CO2(C1-2 alkyl),

(e) CH2NR6-(C1-2 alkyl),

(f) CH2NH-C(=O)-C1-3alkyl,

(g) CH2NH-C(=O)NH2,

(h) CH2NH-C(=O)NHCH2,

(i) CH2NH-C(=O)NHC1-3alkyl,

(j) CH2NH-C(=O)N-d(C1-3 alkyl),

(k) CH2NH-S(O)j-C1-3alkyl,

the group consisting of:

35

- (1') imidazolyl,
- (2') oxazolyl,
- (3') pyridyl,
- (4') tetrazolyl,
- (5') triazolyl,

and the heteraryl is unsubstituted, mono, di or tri-substituted, where the substituents selected from:

- (a') hydrogen,
- (b') C1-6 alkyl, branched or unbranched, unsubstituted or mono or di-substituted, the substituents being selected from hydrogen and hydroxy;

and pharmaceutically acceptable salts thereof.

12. The method of Claim 10 wherein the compound R1 is selected from a group consisting of:

- C4, C5, C6, C7 or C8 linear or branched alkyl, which is mono, di- or tri-substituted, where the substituents are independently selected from:

- (a) hydroxy,

- (b) Cl or F,

- (c) phenyl or mono or di-substituted phenyl, where the substituents are independently selected from:

- (1') hydroxy,

- (2') methyl or ethyl,

- (3') Cl or F,

- (4') trifluoromethyl,

- (d) -NR6COR7, wherein R6 is methyl and R7 is phenyl optionally substituted with halo, CF3, C1-3alkyl or C1-3alkoxy, and

- (e) -NR6S(O)j-R7, where j is 1 or 2;

and pharmaceutically acceptable salts thereof.

35

13. The method of Claim 10 wherein the compound Ar is mono substituted or di-substituted heteraryl, wherein the substituents are selected from the group consisting of:

- (1') oxo,
- (2') hydroxy, or
- (3') OR6, wherein R6 is hydrogen or C1-3 alkyl,
- (b) -CH2NR6(C1-2 alkyl),
- (c) -CH2NH-C(O)C1-3alkyl,
- (d) -CH2NH-C(O)NH2,
- (i) -CH2NH-C(O)NHC1-3alkyl,
- (j) -CH2NH-C(O)N-diC1-3 alkyl,
- (k) -CH2NH-S(O)j-C1-3alkyl,
- (l) -CH2-heteraryl, where heteraryl is selected from the group consisting of:

- (1') imidazolyl,
- (2') oxazolyl,
- (3') pyridyl,
- (4') tetrazolyl,
- (5') triazolyl,


and where heteraryl is unsubstituted, mono, di or tri-substituted, where the substituents are independently selected from:

- (a') hydrogen,
- (b') C1-6 alkyl, branched or unbranched, unsubstituted or mono or di-substituted, where the substituents are selected from: hydrogen

- and hydroxy;


- 30 and pharmaceutically acceptable salts thereof.

14. The method of Claim 10 wherein the compound is of Formula Ia:




Ia

5 wherein:
6 R1 is



, or



;

wherein B is selected from:

(a) phenyl, naphthyl, mono, di or tri-substituted phenyl, and

mono, di or tri-substituted naphthyl wherein the

substituents on phenyl or naphthyl are independently

selected from: chloro, methyl, phenyl, C1-3alkoxy, and CF3;

(b) -CH2phenyl, and mono or di-substituted -CH2phenyl

wherein the substituents on phenyl are independently

selected from: chloro, methyl, phenyl, C1-3alkoxy and CF3;

(c) pyridyl, and mono di or tri-substituted pyridyl wherein the

substituents on pyridyl are independently selected from:

chloro, methyl, phenyl, C1-3alkoxy and CF3; and

10

25 R10 is selected from: hydrogen, C1-3alkyl, and phenyl;

R11 and R12 are independently selected from:

hydrogen, halogen, methyl, phenyl or CF3;

30 and pharmaceutically acceptable salts thereof.

15 The method of Claim 4 wherein the compound of

Formula Ia B is unsubstituted phenyl or unsubstituted thiophene.





(d) thiophene, and mono or disubstituted thiophene wherein the substituents on thiophene are independently selected from: chloro, methyl, phenyl, C1-3alkoxy and CF3;

5 Ar is mono substituted phenyl wherein the substituent is selected from the group consisting of:

- CH2-tetrazolyl,
- CH2-triazolyl,
- CH2-imidazolyl,
- CH2-N(HC(O)N(CH3)2,
- CH2-N(HC(O)NH)CH3,
- CH2-N(HC(O)O)CH3,
- CH2-NHS(O)2CH3,
- CH2-pyridyl,
- CH2-oxopyridyl,
- CH2-O-pyridyl, and
- mono or di-substituted purine wherein the substituents are selected from:



- C1-3alkyl,
- C1-3alkoxy,
- fluoro,
- hydrogen, and
- fluoroC1-3alkyl;

16. The method of Claim 10 wherein the compound of Formula I Ar is selected from



17. The method of Claim 10 wherein the compound of Formula I Ar is selected from the group consisting of:

5



18. The method of Claim 10 wherein the compound is selected from the group consisting of:

- (a) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl-(methylamino))butyl)-4-(2-acetylaminomethyl)-piperazine;
- (b) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl-(methylamino))butyl)-4-(2-acetylaminomethylphenyl)-piperazine;
- (c) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl-(methylamino))butyl)-4-(2-methylaminocarbonylamino-methyl);
- (d) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl-(methylamino))butyl)-4-((2-dimethylaminocarbonylamino-phenyl)-piperazine;
- (e) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl-(methylamino))butyl)-4-(2-methylsulfonylamino-methyl-phenyl);
- (f) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl-(methylamino))butyl)-4-(2-methylaminocarbonylamino-methyl-phenyl)-piperazine;
- (g) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl-(methylamino))butyl)-4-(2-dimethylaminocarbonylamino-methyl-phenyl)-piperazine;
- (h) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl-(methylamino))butyl)-4-(2-methylsulfonylamino-methyl-phenyl)-piperazine;
- (i) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl-(methylamino))butyl)-4-(2-(1-imidazolyl)methyl-phenyl)-piperazine;
- (j) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl-(methylamino))butyl)-4-(2-(1'-1',2',4'-triazolyl)methyl-phenyl)-piperazine;
- (k) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl-(methylamino))butyl)-4-(2-(1'-1',2',4'-triazolyl)methyl-phenyl)-piperazine;
- (l) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl-(methylamino))butyl)-4-(2-(1'-1',2',4'-triazolyl)methyl-phenyl)-piperazine;
- (m) 1-(3-((S)-3,4-Dichlorophenyl))-4-(2-(3'-pyridyloxy)methylphenyl)-piperazine;
- (n) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl-(methylamino))butyl)-4-(2-(1-(2(1H)-pyridone)methyl-phenyl)-piperazine;
- (o) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethyl-benzoyl-(methylamino))butyl)-4-(2-dimethylaminocarbonylphenyl)-piperazine;
- (p) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methyl-amino))butyl)-4-(2-amino-7,8-dihydro-6H-thiopyranof[3,2-d]pyrimid-4-yl)piperazine-5-oxide;
- (q) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethylthiopyranof[3,2-d]pyrimid-4-yl)piperazine-5-oxide;
- (r) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methylamino))butyl)-4-(9-(2-fluoroethyl)-2-methoxy-purin-6-yl)piperazine;
- (s) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methylamino))butyl)-4-(9-(2-methoxymethyl)-2-methoxy-purin-6-yl)piperazine;
- (t) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methylamino))butyl)-4-(9-methyl-purin-6-yl)piperazine;
- (u) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methylamino))butyl)-4-(6-methyl-imidazo(1,2-a)pyrazin-1-yl)piperazine;
- (v) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methylamino))butyl)-4-(1,7-naphthyridin-8-yl)piperazine;
- (w) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methylamino))butyl)-4-(1,2,4-triazolo(1,5-a)pyrazin-8-yl)piperazine;
- (x) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methylamino))butyl)-4-(5-methyl-pyridi-2-yl)piperazine;
- (y) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methylamino))butyl)-4-(6-methyl-imidazo(1,2-a)pyrazin-8-yl)piperazine;

- 30 (z) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methylamino))butyl)-4-(1,2,4-triazolo(1,5-a)pyrazin-8-yl)piperazine;
- 35 (aa) 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methylamino))butyl)-4-(5-methyl-pyridi-2-yl)piperazine;

(y) 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)-(methylamino))butyl)-4-(2-amino-pyrazin-4-yl)piperazine;

(z) 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)-(methylamino))butyl)-4-(furo(2,3-c)pyrid-4-yl)piperazine;

5 (aa) 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)-(methylamino))butyl)-4-(2-amino-7,8-dihydro-6H-thiopyrano-(3,2-d)pyrimid-4-yl)piperazine;

(ab) 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethyl-benzoyl)-(methylamino))butyl)-4-(2-methyl-7,8-dihydro-6H-thiopyrano(3,2-d)pyrimid-4-yl)piperazine;

10 (ac) 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-bis(trifluoromethyl)benzoyl)-(methylamino))butyl)-4-(1,2,4-triazolo(1,5-a)pyrazin-8-yl)piperazine; and

(ad) 1-(3-((S)-(4-Chlorophenyl))-4-(N-(3,5-bis(trifluoromethyl)benzoyl)-(methylamino))butyl)-4-(1,2,4-triazolo(1,5-a)pyrazin-8-yl)piperazine;

15 and pharmaceutically acceptable salts thereof.

19. A compound which is selected from the group consisting of:

20

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino))butyl)-4-((2-ethoxycarbonylamino)phenyl)piperazine;

15 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino))butyl)-4-((2-methansulfonylamino)phenyl)piperazine;

20 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-4-methoxybenzoyl)-(methylamino))butyl)-4-((2-acetylaminophenyl)piperazine;

25 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,4-dichlorobenzoyl)-(methylamino))butyl)-4-((2-acetylaminophenyl)piperazine;

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino))butyl)-4-((2-nitrophenyl)piperazine;

30 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino))butyl)-4-((2-acetylaminophenyl)piperazine;

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino))butyl)-4-((2-formylamino)phenyl)piperazine;

35 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methylamino))butyl)-4-((2-acetylaminophenyl)piperazine;

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-4-methylbenzoyl)-(methyl-amino))butyl)-4-((2-acetylaminophenoxy)phenyl)-piperazine;

1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-4-ethylbenzoyl)-(methyl-amino))butyl)-4-((2-acetylaminophenoxy)phenyl)-piperazine;

5 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3-trifluoromethylbenzoyl)-(methyl-amino))butyl)-4-((2-acetylaminophenoxy)phenyl)-piperazine;

10 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-4-propoxybenzoyl)-(methyl-amino))butyl)-4-((2-acetylaminophenoxy)phenyl)-piperazine;

15 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3-methyl-4-chlorobenzoyl)-(methyl-amino))butyl)-4-((2-acetylaminophenoxy)phenyl)-piperazine;

20 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dimethoxybenzoyl)-(methyl-amino))butyl)-4-((2-acetylaminophenoxy)phenyl)-piperazine;

25 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3-cyanoenzoxy)-(methyl-amino))butyl)-4-((2-acetylaminophenoxy)phenyl)-piperazine;

30 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-2,6-dichlorobenzoyl)-(methyl-amino))butyl)-4-((2-acetylaminophenoxy)phenyl)-piperazine;

35 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3-trifluoromethylbenzoyl)-(methyl-amino))butyl)-4-((2-acetylaminophenoxy)phenyl)-piperazine;

40 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methyl-amino))butyl)-4-((2-acetylaminophenoxy)phenyl)-piperazine;

45 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3-iodobenzoyl)-(methyl-amino))butyl)-4-((2-acetylaminophenoxy)phenyl)-piperazine;

50 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dibromobenzoyl)-(methyl-amino))butyl)-4-((2-acetylaminophenoxy)phenyl)-piperazine;

55 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methyl-amino))butyl)-4-((2-acetylaminophenoxy)phenyl)-piperazine;

60 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dibromobenzoyl)-(methyl-amino))butyl)-4-((2-acetylaminophenoxy)phenyl)-piperazine;

65 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methyl-amino))butyl)-4-((2-acetylaminophenoxy)phenyl)-piperazine;

70 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methyl-amino))butyl)-4-((2-acetylaminophenoxy)phenyl)-piperazine;

75 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methyl-amino))butyl)-4-((2-acetylaminophenoxy)phenyl)-piperazine;

80 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methyl-amino))butyl)-4-((2-acetylaminophenoxy)phenyl)-piperazine;

85 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methyl-amino))butyl)-4-((2-acetylaminophenoxy)phenyl)-piperazine;

90 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methyl-amino))butyl)-4-((2-acetylaminophenoxy)phenyl)-piperazine;

95 1-(3-((S)-(3,4-Dichlorophenyl))-4-(N-3,5-dimethylbenzoyl)-(methyl-amino))butyl)-4-((2-acetylaminophenoxy)phenyl)-piperazine;

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-acetyl)-(methyl-amino))butyl)-4-((2-acetyl-amino)phenyl)-piperazine;

1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methyl-amino))butyl)-4-(4-trifluoromethyl-phenyl)-piperazine;

5 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methyl-amino))butyl)-4-(4-acetyl-phenyl)-piperazine;

10 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methyl-amino))butyl)-4-(4-methyl-phenyl)-piperazine;

15 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methyl-amino))butyl)-4-(4-ethyl-phenyl)-piperazine;

20 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methyl-amino))butyl)-4-(4-fluorophenyl)-piperazine;

25 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methyl-amino))butyl)-4-(3-trifluoromethyl-phenyl)-piperazine;

30 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methyl-amino))butyl)-4-(3-methyl-phenyl)-piperazine;

35 1-(3-((S)-3,4-Dichlorophenyl))-4-(N-3,5-dichlorobenzoyl)-(methyl-amino))butyl)-4-(2-cyano-phenyl)-piperazine;

1-(3-((S)-3-Chlorophenyl))-4-(N-(phenylsulfonyl)(methylamino))butyl)-4-(3-hydroxyquinoxalin-2-yl)piperazine;

5 1-(3-((S)-3-Chlorophenyl))-4-(N-(phenylsulfonyl)(methylamino))butyl)-4-(4-pyridyl)piperazine;

10 1-(3-((S)-3-Chlorophenyl))-4-(N-(phenylsulfonyl)(methylamino))butyl)-4-(2-methoxyphenyl)piperazine;

15 1-(3-((S)-3-Chlorophenyl))-4-(N-(phenylsulfonyl)(methylamino))butyl)-4-(pyrimidin-2-yl)piperazine;

20 and pharmaceutically acceptable salts thereof.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/22769

A. CLASSIFICATION OF SUBJECT MATTER

IPC6 : A61K 31/495; 31/350

US CL : 514/255, 252, 253

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/255, 252, 253

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
STN: COMPOUNDS AND METHODS OF USE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.

A	GB 2 076 395 A (NISSHIN FLOUR MILLING CO.) 02 December 1981, see entire document.	1-4 1-19
Y	JP 03/082 A (AJINOMOTO KK), 09 March 1977, see entire document.	1-4 1-4 1-4 5-19
X		1-4 1-4 1-4
Y		1-4 1-4
A		5-9, 12-19

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'B' document not published on or after the international filing date
- 'C' document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (a specification)
- 'D' document referring to an oral disclosure, use, exhibition or other means
- 'E' document published prior to the international filing date but later than the priority date claimed

Date of the actual completion of the international search **12 MARCH 1998** Date of mailing of the international search report **16 APR 1998**Name and mailing address of the IAS/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20531
Post Office No. (703) 308-1230Authorized officer
RUSSELL TRAVERS

Telephone No. (703) 308-1230

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

OTHER: Side text

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.